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1.1 Lysosomal storage diseases
Pompe’s disease or Glycogen Storage Disease type II (Pompe’s, disease OMIM 232300) is a 
lysosomal storage disorder with an autosomal recessive mode of inheritance. The disease is 
caused by the defi ciency of the lysosomal enzyme acid α-glucosidase (acid maltase). 
Lysosomes are cytoplasmic organelles with an acidic interior containing a great variety of 
enzymes capable of hydrolysing most biologic materials (1, 2). Primary lysosomes pinch 
off from the Golgi apparatus and fuse with other membrane bound vesicles containing the 
lysosomal substrates, to form secondary lysosomes. These substrates are either derived from 
the extra cellular space through endocytosis or from within the cell through autophagy. A 
major function of the lysosome is degradation of intra- and extra cellular macromolecules 
in the process of normal cellular recycling and tissue remodeling. Other functions of the 
lysosome are more cell type specifi c. For instance, lysosomes play a special role in erythrocyte 
maturation, in macrophage activity and in bone resorption by osteoclasts (3). At present, 
approximately 40 lysosomal enzymes have been identifi ed (3, 4). They are glycoproteins 
that are synthesised in the endoplasmic reticulum in a precursor form. The initial protein 
undergoes extensive modifi cation including proteolytic cleavage, glycosylation and addition of 
recognition markers for compartmentalisation into the primary lysosomes. 
The concept of lysosomal storage diseases arose from studies of glycogen storage disease 
type II. The demonstration of lysosomal accumulation of glycogen as a result of acid α-
glucosidase defi ciency led Hers et al. to defi ne a lysosomal storage disease as an inborn error 
of metabolism in which a single lysosomal enzyme defi cit causes abnormal deposition of a 
substrate in vacuoles (lysosomes) (2). In time this defi nition was expanded to encompass 
diseases related to defi ciencies of other proteins necessary for lysosomal function such as 
activator proteins and lysosomal membrane proteins.
The spectrum of lysosomal storage disorders includes mucopolysaccharidosis, lipidosis, 
oligo-saccharidosis and others. Most diseases are inherited in an autosomal recessive mode, 
with the exception of Fabry’s disease (OMIM 301500) and mucopolysaccharidosis II (MPS II, 
Hunters disease, OMIM 309900), which are X-linked recessive (5). 
In the years following the introduction of the lysosomal concept, the primary enzyme 
defi ciencies of many of the lysosomal disorders were gradually discovered (fi g.1). Later, 
genes were cloned and mutations were identifi ed. When the disease loci became known 
and the knowledge of the human genome increased, some lysosomal disorders were fi rst 
identifi ed by their gene rather than by their protein defect, as for instance in juvenile Ceroïd 
lipofuscinosis (CLN3, OMIM 204200) (6).
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In lysosomal storage disorders, the affected cell type usually plays a major role in the 
degradation of the (accumulated) substrate. For example, cerebral white matter is affected 
in patients with defects in the degradation of sphingolipids. Connective tissue is involved 
in mucopolysaccharide storage disorders. The symptoms are obviously related to the site 
of accumulated undegradable materials, but the exact cause of cell death or dysfunction 
is often unclear. All the disorders are progressive and can be fatal. Defi nitive diagnosis is 
accomplished by measuring specifi c enzyme activities or function in leukocytes or cultured 
skin fi broblasts or other tissue specimens, selected on the basis of clinical symptoms. Light 
or electron microscopy, and DNA analysis can confi rm the diagnosis. There is extensive 
heterogeneity within each of the disorders, exemplifi ed by infantile, juvenile or adult onset 
of symptoms, mostly related to residual (enzyme) function. The different types of mutations 
within the same gene totally eliminating or partially reducing the enzyme activity or lysosomal 
protein function explain this. In addition, expression of modifying genes also infl uences the 
phenotype (7, 8).
1.2 Cell biology of lysosomes
Processing of lysosomal enzymes
The nucleotide sequence of the DNA contains all the information necessary for protein 
synthesis, modifi cation, transport, and function. There are signals for routing to the various 
organelles of the eukaryotic cell, post-translational modifi cation, and folding instructions for 
proper function (Fig. 2).
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Glycoproteins, such as lysosomal enzymes undergo several modifying steps before transport 
to their functional location. An amino-terminal signal peptide (signal recognition sequence) 
leads to co-translational segregation into the lumen of the Endoplasmic Reticulum (ER). 
There are other peptide sequences that guide newly synthesised proteins to the nucleus, 
the peroxisomes, or the mitochondria. Proteins without a signal sequence remain in the 
cytoplasm (9-11). The glycoproteins receive their carbohydrate moieties co-translationally 
in the ER and are further modifi ed en route to the Golgi complex, the Trans Golgi Reticulum, 
and from there to either the lysosome, the plasma membrane, or the extracellular space 
(secretory proteins).
As soon as the signal sequence extends from the ribosome it is recognised by a protein 
complex known as the signal recognition particle (SRP), and translation is transiently arrested 
(9-11). The protein complex targets to the ER where it is attached to the SRP-receptor at the 
ER membrane. By docking at this translocation site at the ER membrane the SRP is released 
and ribosomal activity is restored.
In the rough ER, co-translational modifi cations occur. An oligosaccharide complex of N-acetyl 
glucosamine, mannose and glucose is transferred from a lipid carrier to the NH2 group of an 
asparagine residue of the protein in the context of Asp-Xxx-Asn (12). This process is called N-
linked glycosylation (13, 14). In contrast to N-linked glycosylation, oligosaccharides can also 
be linked to the hydroxyl-group of a serine or threonine residue (O-linked glycosylation). No 
lipid intermediate is required. All post-translational modifi cations have an effect on the three-
dimensional structure of the protein and thereby on the stability, function and interaction with 
other proteins. The process of protein folding is controlled by a group of proteins functioning 
as chaperones, whereby incomplete or miss-folded proteins are detected and eliminated (15). 
When glycoproteins have the correct glycosylation and three-dimensional structure, they are 
allowed to leave the rough ER and enter the cis-Golgi cisternae of the Golgi complex.
Lysosomal enzymes contain Asparagine-linked oligosaccharide chains that can be divided into 
three groups: high mannose, hybrid and complex. All three have a common core structure. 
The outer branches determine the differences. 
The common carbohydrate precursor contains three outer glucose residues linked to 
dolichol pyrophosphate, and is transferred en bloc to an asparagine residue of the protein. 
Subsequently, the fi rst glucose is removed by glucosidase I. Glucosidase II removes the 
remaining other two glucose molecules. A high mannose type of chain remains when 
processing stops at this point.
A complex type of chain is formed when four mannose residues are cleaved off by 
mannosidase I (12) and N-acetylglucosamine is added by N-acetylglucosamine-transferase 
(16). Mannosidase II then cleaves off two other mannose residues, and a second N-
acetylglucosamine is transferred to the mannose residues. Sequential addition of galactose, 
fucose, and sialic acid completes the synthesis of these complex types of oligosaccharide 
side chains. When an N-acetylglucosamine is transferred to the β-linked mannose residue, 
the two outer mannose residues cannot be removed by mannosidase II, and a hybrid type of 
oligosaccharide chain is created after linkage of galactose and sialic acid residues. 
Most lysosomal glycoproteins have at least one phosphorylated high mannose type of 
carbohydrate chain. The phosphorylation is a two-step process. First, N-acetyl- glucosamine 
1-phosphate is transferred from UDP-N-acetyl glucosamine. Second, the N-acetyl glucosamine 
residue is cleaved off exposing the so-called mannose 6-phosphate recognition marker (17). 
Routing of lysosomal enzymes to the lysosome
Newly formed lysosomal proteins with the M6P marker are bound by the mannose 6-
phosphate receptor and gather as complexes in vesicles that pinch off from the Trans Golgi 
Network. These vesicles have clathrin as their major structural membrane protein and 
are therefore called Clathrin Coated Vesicles (CCV’s). There are different types of CCV’s, 
distinguishable by their assembly proteins (AP’s). The ones that pinch off from the Trans Golgi 
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Network are associated with AP-1 complex assembly proteins. The ones that are involved 
in transport from the cell surface to the lysosomes are associated with AP-2 (18, 19). The 
mannose 6-phosphate receptor involved in the further routing of the lysosomal enzymes is a 
major constituent of the CCV’s (20).
In mammalian cells, mannose 6-phosphate receptors (MPR) are involved in transport of 
lysosomal enzymes (21). Two distinct MPR’s have been isolated and characterized: (i) the 
46 kD cation dependent MPR (CD-MPR) and the 300 kD cation independent MPR (CI-MPR), 
Which is also the receptor for insulin-like growth factor II (IGFII) (17). The two MPR’s recycle 
constitutively between the Trans Golgi Network and the endosomal compartment as well 
as between the endosomal compartment and the cell surface. Only the CI-MPR binds and 
mediates endocytosis of extra cellular ligands (22). The CD-MPR is known to contain binding 
sites for AP’s and plays a role in the formation of a lysosomal enzyme specifi c CCV (20). The 
role of MPR’s in lysosomal targeting of newly synthesised lysosomal enzymes is illustrated in 
cells from patients with I-cell disease. These patients lack the phosphotransferase needed for 
the transfer of the N-acetylglucosamine 1-phosphate to the high mannose carbohydrate chain 
of the lysosomal enzyme. As a consequence, the phosphotransferase defi cient cells secrete the 
non-phosphorylated lysosomal enzymes excessively and lack them inside so that undigested 
materials accumulate in the lysosomal system. However, in some tissues from I-cell patients, 
lysosomal storage is absent and lysosomal activities are normal (23). Further insight in the 
MPR system was provided by studies in CI-MPR (300 kD) defi cient cells containing normal 
levels of CD-MPR’s (46 kD). These transfection studies show that re-expression of the CI-
MPR can fully restore lysosomal routing while over-expression of the CD-MPR only partially 
compensates for the loss of the CI-MPR (24-27). Experiments with cells defi cient for both 
receptors show that sorting can be partially restored by expressing the CD-MPR while it can 
be fully restored by expressing the CI-MPR. 
Receptor mediated endocytosis
Receptor mediated endocytosis is defi ned as the uptake of material into a cell by invagination 
of the plasma membrane, containing ligand-specifi c receptors, followed by the intra-cellular 
formation of a membrane-bound vesicle. The internalised material is delivered to the 
lysosomes for breakdown or transported to another destination. The mechanism of receptor 
mediated endocytosis was nicely demonstrated by Goldstein & Brown in their studies on the 
cause of atherosclerosis  in humans with a strong genetic predisposition. It was shown that 
cholesterol, needed for membrane synthesis, was internalised via the Low-Density Lipoprotein 
receptor (28). At present more than 25 receptors are known to be involved in receptor 
mediated endocytosis, and they all apparently use the same clathrin coated pit pathway. 
Endocytosis of glycoproteins
Several glycoprotein receptors have been identifi ed as mediators of glycoprotein endocytosis 
(note all lysosomal enzymes are glycoproteins). Glycoprotein receptors involved in endocytosis 
are shown in Table 1. Most of these receptors do not have an intracellular function as the M6P/ 
IGFII receptor. 
Circulating glycoproteins have a complex type of oligosaccharide chain ending with sialic acid 
residues. These molecules remain in the circulation for a rather long time. When the sialic acid 
is removed, the exposed galactose is available for the asialoglycoprotein receptor, and these 
glycoproteins are cleared from the circulation by the hepatocytes.
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Table 1.  Glycoprotein receptors involved in endocytosis   
Receptor specifi city Cell type REF
Mannose 6-Phosphate Fibroblasts (21)
Macrophages (29)
Hepatocytes (30)
Smooth Muscle (31)
Skeletal muscle (32)
Heart muscle (33)
Endothelium (31)
Lymfocytes (34)
Fucose Hepatocytes (35, 36)
Mannose/N-acetyl glucosamine Macrophages (37, 38)
Galactose/ N-acetyl galactosamine Hepatocyte (39)
Mannose 6-phosphate receptor mediated endocytosis
The mannose 6-phosphate receptor was fi rst recognised as a mediator for the uptake of 
secreted phosphorylated lysosomal enzymes (40, 41). Several cell types carry this receptor 
on their surface, often in areas where Clathrin Coated Pits are formed after binding of ligands 
to the receptor. The mannose 6-phosphate receptor is currently considered as a useful target 
for enzyme replacement therapy after the successful application of this therapy for Gauchers 
disease type I using the mannose receptor (42). 
1.3 Therapy for lysosomal storage disorders
There are basically two therapeutic approaches for the treatment of lysosomal storage 
disorders. One is to reduce the substrate intake by a specifi c diet or interference with 
metabolic pathways. The other is increasing the lysosomal enzyme activity or function by 
providing the missing protein. Tailor made solutions may be found in cases such as the 
treatment of Cystinosis (OMIM 219900) with cysteamine
Bone marrow transplantation and stem cell therapy
The success for bone marrow transplantation for the treatment of lysosomal storage 
disorders in general depends on the transfer of the corrective lysosomal enzyme from the 
transplanted cells to the defi cient tissues. The therapy seems most successful in patients with 
Mucopolysaccharidosis type I (Hurler disease OMIM 607014) Metachromatic leucodystrophy 
(OMIM 250100) and Krabbe’s (OMIM 245200) disease. Long-term follow up studies report a 
stabilisation of the neurological symptoms in the patients who were treated before the age of 
two years (43, 44).
Stem cell therapy can be seen as a modern variant of bone marrow transplantation. The 
advantage is that the stem cells home to the different tissues to replace the affected cells and 
repair the damaged tissue (45). 
In the case of Gauchers disease type 1 (OMIM 230800) the progenitor cells can be a 
permanent source of enzyme profi cient macrophages. Stem cell therapy is rarely applied in 
Gauchers disease type 2 (OMIM 230900) as it does not rescue the neuronal storage in these 
patients form of this disease. However the therapy is too risky for patients with a fair life 
expectancy even without therapeutic intervention.
Gene therapy
A permanent enzyme source is created by introducing the gene encoding the missing enzyme 
into the somatic cells. The transfection of the somatic cells can either be direct, in vivo, or 
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the indirect approach can be taken, that is to transfect the cells ex vivo and transplant them 
back into the body. These are the theoretical options. The widespread practical application is 
hampered by the lack of versatile vectors and problems encountered in clinical studies. For 
instance, the recent treatment of patients with the X-linked form of SCID (OMIM 300400) was 
successful for some patients but others developed leukemia (46). A patient with Ornithine 
transcarbamylase (OTC, OMIM 311250) defi ciency succumbed by exposure to an overdose of 
adeno virus. The ideal vector for gene therapy has not yet been found. All viral vectors have 
their limitations. Some elicit a restrictive immunologic response when they are used for the 
second time. Others are potentially harmful when they incorporate into the host-cell DNA. For 
these reasons non-viral vectors are also developed for the delivery of genes, and transfection 
effi ciency enhancers are studied. But, this is still in an experimental stage. The HIV-1 TAT 
protein regulating the transcriptional activation of HIV-1 has been shown to function as a 
protein transduction domain, penetrating the cell membrane in a manner different from the 
classical endocytotic route. The TAT peptide presents a nuclear localisation signal, which 
enables nuclear targeting (47).
Enzyme replacement therapy
The idea to treat lysosomal storage disorders with intravenous enzyme administration was 
brought up by de Duve shortly after the historic discovery of acid α-glucosidase defi ciency 
in Pompe’s disease. He suggested that the therapeutic enzyme could possibly reach the 
lysosome through heterophagy. The fi rst clinical attempt dates from 1964 and was performed 
in a case of infantile Pompe’s disease with acid α-glucosidase from the fungus Apergilles Niger 
(48, 49). The longest study by Hug et al. lasted 116 days (50). Initially there was an increase 
in acid α-glucosidase activity in the liver of the patients but not in the skeletal muscle. The 
patient then developed an immune nephritis as reaction to the foreign enzyme and eventually 
died. Several studies followed whereby acid α-glucosidases of different sources were used. 
Similar pioneering studies were also undertaken in other lysosomal storage disorders in the 
years 1965-1980 (51-54) but none was successful enough to proof the feasibility of enzyme 
replacement therapy. On the contrary it became clear that the therapy could not be used in 
lysosomal storage disorders involving the brain as the corrective enzyme did not cross the 
blood brain barrier (53). But, new insights in the role of cell surface receptors as effective 
mediators of endocytosis kept the concept of enzyme replacement therapy alive. Especially the 
discovery of the mannose and the mannose 6-phosphate receptors (21, 55) and the exchange 
of lysosomal enzymes between cells in culture were important events (41, 56, 57). In 1989 
a patient with Gauchers disease type I was the fi rst to benefi t from enzyme replacement 
therapy. The therapeutic enzyme (glucocerebrosidase) was extracted from human placenta 
and modifi ed so as to expose mannose residues (58, 59). They could serve as a ligand for the 
mannose receptor to target the enzyme to the Kupfer cells and tissue macrophages that are 
the major sites of storage in Gaucher’s disease.
In the same period, enzyme replacement for Fabry disease was developed. Single dose 
studies proved that intravenously infused enzyme could decrease the level of accumulated 
plasma Globotraiosylceramide. Phase I and II clinical trials proved the safety and effi cacy of 
enzyme replacement therapy for both Gauchers and Fabry disease but further research has to 
be conducted to optimize the therapy. In collaboration with the pharmaceutical industry both 
medicines are now registered for the treatment of these two lysosomal storage disorders. 
The development of ERT for other LSD’s like Niemann-Pick, Mucopolysaccharidosis type I and 
Pompe’s disease is well on its way (60, 61).
1.4 Pompe’s disease
Pompe’s disease or Glycogen storage disease type II (GSDII, OMIM 232300) is an autosomal 
recessive myopathy caused by mutations in the acid α-glucosidase gene. The resulting 
total or partial defi ciency of lysosomal acid α-glucosidase causes glycogen to accumulate in 
lysosomes (62). In 1932 the most severe phenotype was described by the Dutch pathologist, 
Dr. J. C. Pompe, who reported about a girl of 7 months old with idiopathic hypertrophy of the 
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heart (63). Massive vacuolar glycogen accumulation was histologically demonstrated in many 
organs and tissues. Later, milder phenotypes were also described, and early infantile, and late 
onset (juvenile and adult) forms were distinguished (64-68).
Infantile Pompe’s disease
Patients with infantile Pompe’s disease are the most severely affected. They have a rapidly 
progressive generalised hypotonia with severe muscle weakness and wasting resulting in a poor 
motor development. Symptoms develop within the fi rst months of life. Cardiac enlargement is 
characteristically manifested on an X-ray of the thorax, and hepatomegaly and macroglossia 
are often found on further physical examination. Echocardiography reveals a hypertrophy 
of both the ventricular (posterior) walls as well as the intra-ventricular septum. In addition, 
a left ventricular outfl ow tract obstruction may be present (69-72). Electrocardiographic 
fi ndings confi rm the ventricular hypertrophy (large QRS-complexes), and a shortening of the 
PR intervals is often found (73) Cardio-respiratory problems are common and the usual cause 
of death in the fi rst year of life.
Patients with the infantile form of Pompe’s disease have virtually no acid α-glucosidase 
activity. Glycogen accumulation is found in skeletal muscle, heart, liver, spleen, kidneys, 
vascular smooth muscle, skin, endothelium, and Schwann-cells surrounding the peripheral 
nerves (62, 74-81). In addition, glycogen storage was found in post-mortem brain (74, 80). 
Lysosomal glycogen storage was most prominently present in the anterior horns, the motor 
nuclei of the brainstem and the spinal ganglia. Some thalamic nuclei were more involved in 
the disease process than others and contained balloon shaped neurones while others were 
spared. Cortical neurones showed very slight to no storage at all, and myelinisation appeared 
to be normal.
Late onset Pompe’s disease
Patients with late onset Pompe’s disease develop a proximal myopathy. Children with the 
disease usually present a delayed motor development or Gower’s sign. Older patients typically 
complain of diffi culties in climbing stairs and rising from a chair (82, 83). Some patients have 
respiratory diffi culties as initial symptom. There are no clinical signs of cardiac involvement. 
The symptoms may resemble those of a limb girdle muscular dystrophy or polymyositis, 
which may lead to misdiagnosis (82, 84). The age of onset of late onset Pompe disease varies 
greatly. In general, patients with an early onset of disease are more severely affected and 
decline more rapidly than patients with a later manifestation.
When the disease progresses, patients may become wheelchair dependent and require 
artifi cial ventilation. Respiratory failure is the major cause of death. 
The acid α-glucosidase defi ciency in late onset Pompe’s disease is usually less profound than 
in infants. Nevertheless, glycogen storage has been reported in many organs. Histological 
examination revealed vacuolisation of cardiac muscle cells, (not leading to clinical symptoms), 
nerve bundles (Schwann cells and perineurium), endothelial cells and smooth muscle cells. 
Lysosomal accumulation in the latter cell types may attribute to the occurrence of aneurysms 
of the basilar artery, as was described by Matsui and co-workers (85-89). Enlargement of the 
tongue has been reported in some cases of late onset Pompe’s disease (67, 90).
The heterogeneous course of late onset Pompe’s disease has led to a further sub-typing of 
adult, juvenile, childhood, and non-classical infantile forms of Pompe’s disease (91). The 
latter classifi cation is somewhat arbitrary as Pompe’s disease encompasses in fact a clinical 
spectrum of subtypes with the classic infantile form on the one side and the adult phenotype 
at the other. 
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Diagnosis
Clinical Diagnosis
A thorough clinical examination may raise the suspicion of Pompe’s disease, but is not 
suffi cient to establish the diagnosis. Additional laboratory tests, such as the measurement of 
serum CK, ALAT, ASAT and LDH, which levels are usually increased, may be helpful in setting 
the diagnosis (82, 92, 93). An EMG may reveal abnormal patterns with repetitive discharges 
and positive waves as a sign of muscle pathology (94-96).
Microscopic sections of the muscle show “purple” membrane bound deposits of glycogen 
within the muscle fi bres if the material is properly processed, fi xed with glutaraldehyde and 
stained with Periodic Acid Schiff (PAS). The glycogen is washed out if microscopic sections are 
not properly handled and a lacework pattern appears (97, 98). 
Glycogen storage is more pronounced in infantile than in the late onset forms of the disease, 
as is the rate of progression. In particular, in patients with an adult onset of disease the 
glycogen accumulation may vary between fi bers and muscle groups. Some muscle biopsies of 
mildly affected patients may show no microscopical abnormalities, and the diagnosis can be 
missed. A defi nite diagnosis for Pompe’s disease can be made by demonstrating a defi ciency 
of α-glucosidase activity or occurrence of a pathogenic mutation in each of the two acid a-
glucosidase alleles.
 
Enzyme diagnosis
Acid α-glucosidase hydrolyses the α-1,4 and α-1,6 glycosidic linkages of glycogen to release 
glucose. The activity of the enzyme can be measured with the natural substrate glycogen or 
the synthetic substrate 4-Methylumbelliferyl-α-D-glucopyranoside. For diagnostic purposes 
the enzyme activity is preferably measured in fi broblasts or muscle tissue.
Determination of acid α-glucosidase activity in leukocytes is not recommended because 
neutral α-glucosidases interfere with the measurement causing an overlap
of the enzyme activity levels between patients and controls (99, 100). Patients with infantile 
Pompe’s disease have a complete enzyme defi ciency whereas patients with the late onset form 
of the disease have residual activities up to 25% of normal. In general the clinical subtype 
correlates well with the level of residual enzyme activity, but unusually low acid α-glucosidase 
activities have been reported in a few cases of adult onset disease. Also non-classical infantile 
and childhood Pompe’s disease cannot always be distinguished from the classic infantile type 
of disease on the basis of enzyme activity. In addition, there are mutations which affect the 
activity for the natural substrate more than for the artifi cial substrate (62, 101). Carrier 
detection is unreliable via enzyme activity measurement.
DNA diagnosis
The acid α-glucosidase gene (GAA) was mapped on chromosome 17, region q25.3 (102). It is 
approximately 20 kb long and contains 20 exons. The gene is transcribed and spliced into an 
m-RNA of 3.6 kb with 2856 bp of coding sequence (103). The acid α-glucosidase polypeptide 
contains 952 amino acids (104, 105). The mutations are equally distributed over all the 
coding exons (2-20). Deletions, insertions, missense and splice site mutations were found. 
More than 100 mutations are presently known in the public domain (www.Pompecenter.nl).
The most common mutation world-wide is IVS1(-13T−>G). It causes aberrant splicing of the 
fi rst coding exon (exon 2) in 80-90% of the splicing events. 
Some mutations specifi cally occur in certain ethnic groups. For example, the deletion of 
exon 18 is quite common in the Caucasian Dutch sub-population and in the southern part of 
Italy, while the delT525 mutation in exon 2 is common in Western Europe and in the French-
Canadian population (106). Both mutations lead to a total defi ciency of acid α-glucosidase. 
The C1935A (exon 14) transition is a frequent mutation in Taiwanese and Chinese populations 
and also leads to a total defi ciency of enzyme activity (107). 
Different strategies can be taken for mutation analysis. Certain subgroups of patients can be 
screened fi rst for the presence of frequent mutations, but otherwise it is quicker to sequence 
the whole gene. The fi nding of a known mutation is immediately informative, but new 
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mutations have to be judged for their effect. Non-sense and frame-shift mutations have a 
predictable fully deleterious effect. Missense mutations can be introduced in the normal c-DNA 
construct and expressed in vitro to estimate their effect. It is most informative to measure 
not only the enzyme activity of the acid α-glucosidase that is generated by the transfection 
of the cDNA construct but also to analyse the biosynthesis of the enzyme by Western blotting 
or pulse-chase labeling. 
The more than 100 mutations were seen in a variety of allelic combinations in the clinically 
heterogeneous group of patients with Pompe’ s disease. Combining all information, there 
appears to be a correlation between the genotype and the phenotype, which makes DNA 
analysis useful for diagnositic and prognostic purposes. For instance, patients who are 
heterozygous for the common IVS1 (-13T->G) mutation have late onset Pompe’s disease and 
a slowly progressive myopathy. Only patients with two fully deleterious mutations have the 
classic infantile phenotype.
DNA analysis is usually not necessary to confi rm the diagnosis, but is mandatory for carrier 
detection and genetic counseling of family members. If diagnostic material of a deceased 
patient is unavailable, DNA analysis in the parents may be required for setting a diagnosis in 
retrospect.
1.5 Animal models
There are several animal models of Pompe’s disease. They were used to study pathological 
features and therapeutic options. Lysosomal glycogen storage was found in Lapland dogs, 
Corriedale sheep, Nicholas turkey, cat, Japanese Quail and Brahman and Shorthorn cattle 
(108-119). Not all natural animal models parallel the human condition with respect to the 
clinical parameters. Cardiac enlargement for example was reported in a sub-population of 
Shorthorn cattle, dogs and turkeys but not in cats, sheep and quails. The Japanese quail and 
the artifi cially made mouse models were used most extensively. The quail model, mimicking 
the late onset form of Pompe’s disease, has a residual activity of approximately 10-16 % and 
manifests overt clinical symptoms at 6-12 weeks after hatching (116, 117). Importantly, the 
quail has reached its reproductive age by approximately 12 weeks. Shortly after hatching, 
affected quails still can return to a standing position after being placed in supine position with 
their wings extended. Six months after hatching their wing extension is impaired due to joint 
contractures. The average life span is reported to be 30 months. Affected animals may have 
a great variation of glycogen storage in their skeletal muscle, like in patients with late onset 
GSDII. 
Mouse models
To have an easy to handle animal model for the infantile form of Pompe’s disease, knockout 
mouse models were made by disrupting the murine acid α-glucosidase gene in embryonic 
stem cells of mouse strain 129 (97, 120, 121). Different targeting vectors were used (Fig.3). 
Neo cassettes were inserted in exon 13 (13neo/13neo) (97) and in exon 6 with fl anking loxP sites 
(6neo/6neo and ∆6/∆6), and  exon 14 was replaced by a neo cassette (∆14neo/∆14neo) (120). 
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Fig. 3. Targeting vectors used for creating mouse modesl for Pompe’s disease.
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The (13neo/13neo) mouse
Disruption of the GAA gene in exon 13 (13neo/13neo) resulted in the absence of acid α-
glucosidase RNA, and the mice were fully defi cient in acid α-glucosidase activity in all 
investigated tissues. Lysosomal glycogen storage was seen as early as eight days after birth 
in skeletal muscle and heart. Accumulation of lysosomal glycogen was also found in Schwann-
cells of the peripheral nervous system, in motor neurons and in the brain, as in the infantile 
form of Pompe’s disease (74, 80). 
The pathological evaluation of this mouse model gave more insight in specifi c clinical features 
of the disease in humans. For example, the extensive glycogen accumulation in smooth 
muscle of the upper digestive tract and masseter muscle could explain the feeding diffi culties 
reported in humans. Pathological changes in the smooth muscle cells of the blood vessels 
could result in weakening of the blood vessel wall and the formation of an aneurysm with risk 
of rupture as reported in the literature about adult Pompe’s disease (85-87, 122). 
However, these (13neo/13neo) mice do not show overt clinical symptoms until adulthood despite 
their total defi ciency of acid α-glucosidase. Although, at 12 weeks of age the knockout mice 
are less active than their wild-type littermates when tested in a running wheel (123). 
However, the difference is not statistically signifi cant due to intra group variation. The mice 
were backcrossed for ten generations into the FVB and C57Bl/6 background in an attempt to 
decrease the variation. It is our impression that the mice with a C57Bl/6 background show 
symptoms earlier than mice with the FVB background, but statistically reliablke information 
is still missing (98).
The (6neo/6neo), (∆6/∆6) and (∆14neo/∆14neo) mice
Disruption of exon 6 (6neo/6neo) was chosen by Raben et al. to create a mouse model of 
infantile Pompe’s disease. But, as it was realised that the phenotype could be ‘embryonic 
lethal’ additional approaches were taken to create a mouse model with milder symptoms. 
Raben et al. predicted that the complete deletion of exon 6 (∆6/∆6) was potentially associated 
with a relatively milder phenotype based on the occurrence of a similar mutation (splicing 
out of exon 6 and inclusion of 7 amino acids) in a patient with juvenile Pompe’s disease, as 
published by Adams et al. (124). Homozygous ∆6/∆6 mice would thus have a better prognosis 
than the 6neo/6neo mice. The two LoxP sites fl anking exon 6 in the targeting construct were 
used to achieve this goal.  Exon 6 was deleted by crossing the 6neo/6neo mice with Cre gene 
expressing transgenic mice of strain FVB. Notably, the 6neo/6neo mouse model was created in 
the C57Bl/6 background so that the ∆6/∆6 KO mice had a mixed background of 129, C57Bl/6 
and FVB.
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The 6neo/6neo and ∆6/∆6 models turned out to be similar with respect to the acid α-glucosidase 
activity in skin, liver, and heart, and the lysosomal glycogen storage in skeletal muscle, 
heart and diaphragm. In an open-fi eld setting, the 6neo/6neo mice were less active than the 
∆6/∆6 mice (36% and 91 %, respectively, compared to heterozygous littermates; ∆6/+ 
mice). The heterozygous 6neo/+ mice were reported to perform at the 50-70 % level of the 
heterozygous ∆6/+ mice(120). Based on the combination of all fi ndings it was concluded that 
the two strategies for knocking out exon 6 had been equally deleterious. The difference in 
performance was ascribed to the different genetic background of the mice.
To further investigate the infl uence of the genetic background on the phenotype of KO mice 
with Pompe’s disease, yet another model was created (121). Exon 14 was replaced by a 
neo cassette (∆14neo/∆14neo). The resulting mice with a 129/C57Bl/6 background were in all 
aspects very similar to the 6neo/6neo mice. Unfortunately the inbred C57Bl/6 were not available 
for testing.
Table 2 summarises the age of onset of clinical symptoms in the various models. Notably, 
there does not seem to be a signifi cant difference in age of onset when comparing the 6neo/
6neo, ∆6/∆6 and ∆14neo/∆14neo mice with the earlier published 13neo/13neo mice. 
Table 2.  Onset of clinical symptoms in three mouse models 
    of Pompe’s disease
Strain Background Males (months) Females (months)
13neo/13neo FVB inbred 7.4 (n = 8) 7.4 (n=8)
6neo/6neo 129xC57Bl/6 8.1 ± 0.3 (n = 19) 7.1 ± 0.3 (n = 29)
∆6/∆6 129xC57Bl/6xFVB 9.8 ± 0.4 (n = 11) 9.0 ± 0.6 (n = 13)
∆14neo/∆14neo 129xC57Bl/6 8.3 ± 0.8 (n = 14) 6.6 ± 0.4 (n = 14)
The relatively slow progression of clinical signs in these four mouse models is not ideal 
for experimental purposes. Therefore, it was attempted to improve the model by crossing 
the 6neo/6neo KO mice with transgenic mice overexpressing either the human GlutI glucose 
transporter or the enzyme glycogen synthase (GS). These transgenic mice have a signifi cantly 
elevated level of cytoplasmic glucose (GlutI) or glycogen (GS) compared to wild type mice 
(125, 126). The knockout mice with either the GS or GlutI transgene have an increased 
lysosomal glycogen storage and develop clinical symptoms at the age of 4-5 months. By 9 
months of age their phenotype is clinically indistinguishable from the knockout mice without 
the Glut I or GS transgene (127). 
Another potential improvement of the KO mouse model of Pompe’s disease was the introduction 
of an α-glucosidase transgene with very low expression, exclusively in the liver (128). The 
purpose of this modifi cation was to prevent an antibody response against recombinant human 
acid α-glucosidase in experiments related to the application of enzyme replacement therapy. 
As anticipated, the response was markedly diminished.
1.6 Therapy for Pompe’s disease
With present day knowledge, the therapeutic options for Pompe’s disease are limited. Bone 
marrow transplantation was attempted but the results of the experiments were disappointing. 
No increase of acid α-glucosidase activity was detected in the muscles of treated patients, and 
the method is no longer applied for the treatment of Pompe’s disease (129, 130). 
There are several reports in which a high protein diet with branched chain amino acids or a 
supplement of L-alanine is advised to help restore the net protein balance and thereby prevent 
muscle breakdown. The studies report improvement of function of respiratory and skeletal 
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muscles in approximately 25% of cases (93, 131-133). Daily exercise may also improve the 
condition of the patient but should not be exhaustive. The variation of disease severity and 
clinical course of patients with Pompe’s disease complicates the evaluation of the effect of any 
form of therapy.
At present ERT is the most promising as the preliminary results of the clinical trials suggest 
that patients with both the early as well as the late onset form of disease can benefi t from this 
type of therapy. The application of gene therapy is still in the pre-clinical phase and dependent 
on the production of safe and effective vectors for gene delivery.
Gene therapy
Amalfi tano et al. and Pauly et al. (134, 135) showed that a single intravenous injection of a 
modifi ed adenoviral vector, expressing human acid α-glucosidase, resulted in effi cient hepatic 
transduction and expression of acid α-glucosidase. High levels of acid α-glucosisdase activity 
were also found in the plasma of the treated animals. The plasma enzyme secreted by the 
hepatocytes can potentially restore the enzyme defi ciency in other tissues via endocytosis. 
Local administration of adenoviral gene constructs by intra-muscular injection in three days 
old mice led to a 50-fold elevation of acid α-glucosidase activity in the muscles at the site of 
injection. Importantly the vector RNA was also detected in the hind limb muscle, the heart 
and the liver for as long as 6 months (136). A similar experiment was performed in acid 
maltase defi cient quails (137) and the results were more or less the same.
Intra-muscular and intra-cardial delivery of acid α-glucosidase gene constructs with a 
recombinant adeno-associated vector resulted in near normal enzyme activities and at least 
a partial restoration of muscle strength in the soleus muscle of KO mice up to 6 months after 
treatment (138). Martin-Touaux et al. performed a similar experiment injecting an acid α-
glucosidase expressing adenoviral vector in the gastrocnemius muscle of KO mouse neonates. 
Strong expression was detected at the site of injection but activity was also found in heart and 
more distant skeletal muscles.
All gene therapy studies use a single injection while expression of the gene is still transient. 
The problem of immune response arising with repeated dosing, especially when using 
adenovirus-derived vectors, has to be overcome. 
Enzyme replacement therapy
The studies towards enzyme replacement therapy in Pompe’s disease were aimed to use the 
mannose 6-phosphate receptor to target the acid α-glucosidase to the muscle and heart (139). 
Once the proof of principle was obtained, efforts were devoted to the large-scale production of 
recombinant human enzyme. The two production systems that were successfully developed 
are described in the following paragraphs. One uses Chinese Hamster Ovary (CHO) cells, the 
other uses transgenic technology to produce recombinant human acid α-glucosidase in the 
milk of mammals (Fig.4).
Fig. 4. α-glucosidase production systems
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Acid α-glucosidase production in CHO cells
Chinese Hamster Ovary cells (CHO) are commonly used for the production of recombinant 
enzymes and are therefore a logical option for the production of human recombinant acid α-
glucosidase. Several gene promoters can be used for this purpose. They are usually linked to 
the cDNA in a suitable vector system. Fuller et al. used the promotor of the human elongation 
factor 1α gene (140). A CMV promoter driven expression vector was used by van Hove et al. 
containing a DHFR gene in tandem with the acid α-glucosidase cDNA (141). This type of vector 
allows for metrotrexate-induced amplifi cation of the construct. Under maximal stimulation 
and optimal circumstances, a production capacity of 91.4 µgr/ml secreted acid α-glucosidase 
over a period of 24 hours was reached in a laboratory setting. The enzyme collected was in 
all aspects very similar to the recombinant human acid α-glucosidase reported by Fuller et 
al. (140). The uptake in fi broblasts was mannose 6-phosphate dependent (141). The enzyme 
was also tested in the quail model for Pompe’s disease. Normal levels of acid α-glucosidase 
activity were reached in the spleen with either a high (14 mg/kg) or a low (4.2 mg/kg) dose 
(142). Martiniuk et al. also reported the production of recombinant human acid α-glucosidase 
in CHO cells but did not harvest the enzyme from the medium but from the cells (143). 
Fibroblasts of patients with Pompe’s disease were corrected by the administration of the 
enzyme to the culture medium. Intra-peritoneal administration of the enzyme preparation 
to KO mice (6neo/6neo) resulted in an increase of acid α-glucosidase activity to heterozygous 
levels in skeletal-muscle, heart, and diaphragm after two intra-peritoneal infusions over 10 
days in a dose of approximately 1 mg/kg. After three infusions improvement of motor activity 
was reported (143).
Production in transgenic animals
Investigations into the large-scale production of acid α-glucosidase in transgenic animals 
started with the expression of cDNA encoded acid α-glucosidase in the milk of transgenic 
mice (144). To regulate expression of the acid α-glucosidase gene constructs, they were 
placed under control of a bovine casein gene promoter. This way a high expression was 
expected in the epithelial cells of the mammary gland. The gene constructs were injected 
into the pronucleus of fertilised oocytes and the embryos were transferred to the uterus of 
foster mothers to further develop into transgenic animals. The transgenic females produce 
acid α-glucosidase in the mammary gland during lactation and the product is secreted in the 
milk from which it can be extracted. The expression was demonstrated to be mammary gland 
specifi c. The mouse milk contained two acid α-glucosidase isoforms of 110 and 76 kD, and the 
therapeutic potential was tested in fi broblasts and KO mice (144, 145). The 110 kD precursor 
was taken up in a mannose 6-phosphate dependent manner and cleared lysosomal glycogen 
from cultured fi broblasts of patients with Pompe’s disease. 
On the way to large scale production and clinical testing, the recombinant human acid α-
glucosidase was produced in the milk of transgenic rabbits using the same bovine αS1 casein 
expression cassette as in the mouse model (146). The procedure was very successful. The 
rabbits produced up to 8-gr recombinant human acid α-glucosidase per litre milk. The 110 
kD product was effective in the long-term treatment of KO mice with Pompe’s disease (13neo/
13neo). The stored glycogen was degraded in a variety of tissues including the target organs 
(heart, skeletal muscle and smooth muscle). But the therapeutic enzyme did not reach the 
brain (146). 
While these pre-clinical studies in the mouse model were ongoing, the Dutch biotechnology 
company Pharming B.V. developed a safe product for clinical testing. After completion of the 
toxicology studies in animals and phase I studies in healthy volunteers, the fi rst clinical trial 
of enzyme replacement therapy for Pompe’s disease started in 1999 in the Sophia Children’s 
hospital.
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1.7 Scope
The studies described in this thesis were aimed to further develop enzyme replacement 
therapy for Pompe’s disease. The potential effi cacy of this therapy had been demonstrated 
in knockout mice but not yet in patients. Four patients with the infantile form of Pompe’s 
disease were included in the fi rst clinical trial that started in 1999. The purpose of this trial 
was to study the long-term safety and effi cacy of repeated intravenous administrations of 
recombinant human acid α-glucosidase from rabbit milk. Survival was chosen as the primary 
clinical end point and several clinical and morphological investigations were done at regular 
intervals to monitor the effect of treatment. Chapter 3 describes the three-year follow up of 
the patients and Chapter 4 presents in more detail the morphological changes that occurred 
in muscle tissue in the fi rst 72 weeks of treatment. 
The mouse model of Pompe’s disease was employed to investigate the cause of hearing loss 
(Chapter 5) that was detected serendipitously when the infants were clinically examined 
before inclusion. Chapter 2 gives a detailed description of the cardiac pathophysiology in 
knock-out mice. These latter investigations were undertaken to develop a non-invasive 
method to follow the effect of therapeutic interventions in mice.
During the clinical studies in humans questions arose about the height of the dose and the 
optimal dosing regimen. These molecular aspects of enzyme replacement therapy were also 
studied in the knockout mouse model and are described in Chapter 6.
The combined studies described in this thesis encourage the further development of enzyme 
replacement therapy for Pompe’s disease and illustrate how the mouse model can be used to 
explore ways to improve the effect of treatment. 
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Summary
Pompe’s disease is an autosomal recessive and often fatal condition, caused by mutations 
in the acid α-glucosidase gene, leading to lysosomal glycogen storage in heart and skeletal 
muscle. We investigated the cardiac phenotype of an acid α-glucosidase knock-out (KO) 
mouse model. Left ventricular weight to body weight ratio were increased 6.3±0.8 mg/g in 7 
KO compared to 3.2±0.2 mg/g in 8 wild-type (WT) mice (P<0.05). Echocardiography under 
ketamine-xylazine anesthesia revealed an increased LV wall thickness (2.17±0.16 mm in 
KO vs 1.18±0.10 mm in WT mice, P<0.05) and a decreased LV lumen diameter (2.50±0.32 
mm in KO vs 3.21±0.14 mm in WT mice, P<0.05), but LV diameter shortening was not 
different between KO and WT mice. LV dP/dtmax was lower in KO than in WT mice under basal 
conditions (2720±580 vs 4440±440 mmHg/s) and during dobutamine infusion (6220±800 
vs 8730±790 mmHg/s, both P<0.05). Similarly, during isofl urane anesthesia LV dP/dtmax 
was lower in KO than in WT mice under basal conditions (5400±670 vs 8250±710 mmHg/s) 
and during norepinephrine infusion (10010±1320 vs 14710±220 mmHg/s, both P<0.05). In 
conclusion, the markedly increased LV weight and wall thickness, the encroachment of the 
LV lumen and LV dysfunction refl ect cardiac abnormalities, although not as overt, of human 
infantile Pompe’s disease and make these mice a suitable model for further investigation of 
pathophysiology and of novel therapies of Pompe’s disease.
Introduction
Pompe’s disease or glycogen storage disease type II (GSD II) is an autosomal recessive 
and often fatal disease caused by mutations in the acid α-glucosidase gene (16). The 
resultant defi ciency of acid α-glucosidase activity prohibits degradation, and causes storage, 
of lysosomal glycogen in predominantly cardiac and skeletal muscle. Early and late onset 
forms of GSD II can be distinguished, which has been attributed to varying degrees of 
residual acid α-glucosidase activity (16,24). The infantile form shows no residual activity and 
patients suffering from this condition present themselves with hypotonia and hypertrophic 
cardiomegaly within a few months after birth. They usually die of cardio-respiratory failure 
before they reach the age of one year (13,24). Milder forms have residual activities up to 
25% of normal values, and are typically characterized by skeletal muscle weakness without 
involvement of the heart. Ultimately, these patients become wheelchair-bound and dependent 
on artifi cial ventilation.
Recently, knock-out (KO) mouse models of GSD II have been developed (5-7, 22). In the 
present study we investigated the cardiac phenotype of our mouse model, in terms of cardiac 
mass, left ventricular (LV) geometry, and LV contractile function and reserve in order to assess 
its usefulness for investigations into the pathophysiology of this disease and assessment of 
novel therapies.
Methods 
All experiments were conducted in accordance with the “Guiding Principles in the Care and 
Use of Laboratory Animals” as approved by the American Physiological Society and with prior 
approval of the Animal Care Committee of the Erasmus University Rotterdam.
Experimental design
In the fi rst part of the study we investigated the LV morphological, geometrical, and contractile 
functional consequences of α-glucosidase defi ciency in ketamine-xylazine anesthetized mice. To 
determine whether the low heart rates (250-300 beats/min) that were produced by ketamine-
xylazine anesthesia infl uenced our results on LV contractile function, we repeated the hemodynamic 
measurements in the second part of the study in isofl urane-anesthetized mice, in which heart rates 
(450-600 beats/min) approximated the values we (450-550 beats/min; unpublished data from our 
laboratory) and others (478±12 beats/min; 21) observe under awake conditions.
Cardiac remodeling and contractile function in KO-mice
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Experimental groups
The acid α-glucosidase defi cient knock-out mice in this study were obtained by targeted 
disruption of the acid α-glucosidase gene in embryonic stem cells as previously described 
(5). For the fi rst part of the study we used seven KO mice of which three had been crossed 
back into FVB background for six generations and four into C57Bl/6 background for three 
generations. Eight wild-type (WT) littermates served as controls. Five of these were FVB and 
three were C57Bl/6. FVB mice were between 10 and 14 months of age and C57Bl/6 mice 
were between 20 and 24 months of age. For the second part of the study we used three KO 
mice, which had been crossed back into C57Bl/6 background for ten generations, while 5 WT 
littermates served as controls. Mice were between 16 and 20 months of age. The night before 
the experiment, mice were starved to deplete cytoplasmic glycogen (5,7).
Experimental protocol
Echocardiography
In the fi rst part of the study, mice were weighed, anesthetized with ketamine (25 mg/kg, 
intraperitoneally) and xylazine (5 mg/kg, intraperitoneally), and hair from the left side of 
the thorax was shaved off. A tracheotomy was performed, a polyethylene tube (inner/outer 
diameter: 0.58/0.80 mm) was inserted and secured with a suture to prevent leakage of air, and 
the mouse was artifi cially ventilated at a rate of 60-70 strokes/min (Harvard rodent ventilator, 
Hilliston, MA). ECG leads were connected, and the mouse was submerged in a water bath of 
37o C, approximately 2 cm below the water surface. Echocardiograms were made with the HP 
sonos 5500 echo device (Hewlett Packard, Andover, MA) using a 12 MHz probe. Images of the 
short axis were obtained in 2D- and M-mode settings, with simultaneous recordings of ECG. 
All measurements were obtained while artifi cial ventilation was temporarily turned off.
Hemodynamic measurements
Following echocardiography mice were removed from the water basin and placed on a heating 
pad. Body temperature was monitored via a rectal thermometer and maintained at 37o C. 
After receiving a second intraperitoneal bolus of anesthetics (25 mg/kg ketamine and 5 mg/
kg xylazine) mice were instrumented for hemodynamic measurements. For this purpose, 
a polyethylene catheter (PE 10) was inserted into the right carotid artery and advanced 
into the aortic arch to measure aortic blood pressure. An identical catheter was introduced 
into the right external jugular vein and advanced into the superior caval vein for infusion of 
dobutamine. After a thoracotomy was performed through the 4th left intercostal space, the 
pericardium was opened and the heart exposed. Subsequently, a 2 French Millar microtipped 
manometer (calibrated prior to each experiment with a mercury manometer) was inserted 
into the left ventricle via the apex to measure left ventricular (LV) pressure and its fi rst 
derivative LV dP/dt (obtained via electronic differentiation).
Following a 15 min stabilization period, baseline recordings were obtained of aortic blood 
pressure, heart rate, LV pressure and LV dP/dt. A continuous intravenous infusion of 
dobutamine (concentration 10 µg/ml) was started at 2 µg/kg/min and the rate of infusion 
was increased at 3 min intervals until LV dP/dtmax did not further increase. At peak responses 
to dobutamine all measurements were repeated.
Hemodynamic measurements under isofl urane anesthesia
In the second part of the study, mice were ventilated with a mixture of O2 and N2O (1/2, 
vol/vol) to which isofl urane (1.5-2.0 vol%) was added. The surgical instrumentation and 
experimental protocol were identical to that in the ketamine-xylazine anesthetized mice of 
part one, but we now used a 1.4 French Millar catheter to measure LV pressure. We observed 
in two pilot experiments in C57Bl/6 WT mice under isofl urane anesthesia, dobutamine 
produced a decrease in blood pressure while it had no effect on heart rate, confi rming 
previous observations by Hoit et al. (17). Therefore, we chose to infuse norepinephrine 
(concentration 20 µg/ml) starting at 2 µg/kg/min iv and doubled the infusion rate every 3 
min until LV dP/dtmax did not increase further.
35
Cardiac remodeling and contractile function in KO-mice
Biochemistry and morphology
At the conclusion of each experiment, the heart was excised and the atria were removed. 
The right and left ventricle were separated, weighed and freeze dried for the determination of 
dry weights and, in the fi rst part of the study, for determination of acid α-glucosidase activity 
and glycogen content. In addition, samples were also obtained from the musculus quadriceps 
femoris and the liver to measure acid α-glucosidase activity and glycogen content. The atria 
and another sample from the musculus quadriceps femoris were fi xed in glutaraldehyde 
(4%), embedded in glycolmethacrylate and histological sections of 4 µm were stained with 
haematoxylin azofl oxin and periodic acid schiff. Tail DNA was extracted to verify the genotype 
by PCR (5).
Atria, muscle and liver samples were homogenized in phosphate buffered saline, using 
an Ultra Turax (TP18-20, 20000 UPM; 170W; see reference 5). Large debris was removed 
after centrifugation at 10,000 g for 15 min. The supernatant was sonicated on ice for two 
times 10 s at an amplitude of 10 µm, and analysed for total protein concentration with the 
Bichionic Acid Protein Assay (Pierce, Rockford, IL) and acid α-glucosidase activity with 4MU 
(4-methylumbelliferyl-α-D-glucopyranoside) as substrate at a pH of 4. The glycogen content 
was measured after dialysis of the sample to remove cytoplasmic glucose, as previously 
described (5,28). 
Data analysis 
Echocardiographic data were collected on an optical disk and stored for off-line analysis. 
Left ventricular (LV) diameters at end-diastole (EDD) and end-systole (ESD) as well as the 
ED and ES thickness of the LV posterior wall were measured from the M-mode images using 
Clemex Vision software package (Clemex Technologies, Quebec, Canada).  Five consecutive 
beats were analyzed in triplicate and averaged. LV absolute shortening (EDD - ESD) and 
fractional shortening ((EDD - ESD)/EDD*100%) were calculated. Hemodynamic data were 
recorded and digitized using an on-line 4-channel data acquisition program (ATCODAS, Dataq 
Instruments, Akron, OH) for post-acquisition off-line analysis with a program written in 
MATLAB (Mathworks, Natick, MA). Fifteen consecutive beats were selected for determination 
of heart rate, LV peak systolic and end-diastolic pressures, diastolic aortic pressure and the 
maximum rate of rise of LV pressure (LV dP/dtmax). In addition, the time constant (τ) of LV 
pressure decay, an index of early LV relaxation, was computed as described earlier (11).
Statistical analysis of anatomical and echocardographic data was performed using unpaired 
t-test or McNemar test as appropriate. Analysis of hemodynamic data was performed using 
two way analysis of variance followed by post-hoc testing with paired and unpaired t-test or 
signed rank test and McNemar test, as appropriate. Statistical signifi cance was accepted when 
P<0.05 (two-tailed).
Results
Biochemistry
The acid α-glucosidase activity in the heart of WT mice that were studied under ketamine-
xylazine anesthesia was 12.6±2.6 nmol 4MU/h per mg protein, but only 1.0±0.1 nmol 4MU/h 
per mg protein in KO mice. Consequently, the glycogen content in the heart was high in KO 
mice (330±30 mg per mg protein in 10-14 months old FVB KO mice, and 3260±980 mg per 
mg protein in 20-24 months old C57Bl/6 KO mice) and very low in WT mice (1.8±0.9 mg per 
mg protein; Fig. 1).
Microscopy. 
Atria and skeletal muscle samples from all KO mice had periodic acid schiff positive arrays of 
glycogen fi lled lysosomes and lace work patterns resulting from lysosomal rupture and loss of 
content, as previously reported (7). Some of the WT mice showed little cytoplasmic glycogen 
content.
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Macroscopy  
The wet weight of the heart (HW) was on average 44% higher in KO compared to WT mice 
(P<0.05), due to increases in both LV weight (LVW, 47%, P<0.05) and RV weight (RVW, 31%, 
P=0.08) (Table 1). Similar increments were observed in the dry weights of the whole heart, 
LV and RV (all P<0.05). Since total body weight (BW) was on average 30% lower in KO than 
in WT mice, it follows that the HW/BW, LVW/BW and RVW/BW were almost doubled in KO 
compared to WT mice. KO mice with the highest glycogen content had the highest LVW/BW 
ratio (Fig. 1).
Table 1.    Anatomic data
Wild-type mice 
(n=8) 
Knock-out mice 
(n=7) 
39 ± 3 29 ± 2* 
Wet weight 151 ± 11 217 ± 27* 
Dry weight 37 ± 3 57 ± 7* 
Wet weight 122 ± 10 179 ± 23* 
Dry weight 30 ± 2 46 ± 6* 
Wet weight 29 ± 2 38 ± 5† 
Dry weight 7.5 ± 0.6 10.7 ± 1.2* 
Wet weight 3.9 ± 0.3 7.6 ± 1.0* 
Dry weight 0.96 ± 0.06 2.00 ± 0.26* 
Wet weight 3.2 ± 0.2 6.3 ± 0.8* 
Dry weight 0.77 ± 0.05 1.63 ± 0.02* 
BW, g 
HW, mg  
LVW, mg  
RVW, mg  
HW/BW, mg/g  
LVW/BW, mg/g  
RVW/BW, mg/g  Wet weight 0.75 ± 0.04 1.32 ± 0.16* 
Dry weight 0.19 ± 0.01 0.38 ± 0.05* 
Values are mean ± S.E.; n = number of observations BW = body weight; HW = heart weight; 
LVW = left ventricular weight; RVW = right ventricular weight. *P<0.05 vs. Wild-type mice; †P = 0.08 vs. 
Wild-type mice
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Fig. 1. Relation between LV glycogen content and LV to body weight ratio (LVW/BW). 
Squares represent 10-14 months old FVB WT mice; diamonds represent 10-14 months old FVB KO mice. Upward triangles 
represent 20-24 months old C57Bl/6 WT mice; downward triangles represent 20-24 months old C57Bl/6 KO mice.
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Echocardiography
The left ventricle of KO mice was characterized by an increased wall thickness (83%, P<0.05), 
and a modest encroachment of the LV lumen, refl ected by an average 22% reduction in 
end-diastolic LV lumenal diameter (P<0.05) (Table 2). There were no signifi cant differences 
between KO and WT mice in absolute (0.74±0.05 vs. 0.99±0.12 mm) or fractional (33±3 
vs. 30±4 %) LV diameter shortening. LV wall thickness showed a good correlation (r2=0.66, 
P<0.01) with the LVW/BW, whereas the LV lumen diameter did not correlate with LVW/BW 
(Fig. 2).
Table 2.    Echocardiographic data
Wild-type mice 
(n=8) 
Knock-out mice 
(n=7) 
LV ThED, mm 
LV ThES, mm 
1.18 ± 0.10 2.17 ± 0.16* 
1.53 ± 0.06 2.39 ± 0.16* 
LV DED, mm 3.21 ± 0.14 2.50 ± 0.32* 
LV DES, mm 2.34 ± 0.22 1.59 ± 0.26* 
Absolute LVD Shortening, mm 0.99 ± 0.12 0.74 ± 0.05 
Fractional LVD Shortening, % 30 ± 4 34 ± 3 
Values are mean±S.E.; n = number of observations LV Th = Left ventricular wall thickness;
LV D = left ventricular lumen diameter; The subscripts ED and ES denote end diastole and end systole, 
respectively. *P<0.05 vs Wild-type mice.
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Fig. 2. Relation between LV wall thickness (left panel) and LV lumen diameter (right panel) and LV to body weight ratio (LVW/
BW). Squares represent 10-14 months old FVB WT mice; diamonds represent 10-14 months old FVB KO mice. Upward triangles represent 
20-24 months old C57Bl/6 WT mice; downward triangles represent 20-24 months old C57Bl/6 KO mice.
Hemodynamics
Baseline 
Under baseline conditions, LV dP/dtmax and diastolic arterial pressure were lower in KO than 
in WT mice. The trends towards a lower heart rate, a lower diastolic arterial pressure and a 
lower LV systolic pressure in KO mice and the trend towards the increase in τ in these mice 
did not reach levels of statistical signifi cance (Table 3).
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Pooling of all individual data points from KO and WT mice revealed an inverse correlation 
between LVW/BW and LV dP/dtmax (r
2=0.76), suggesting that LV contractility becomes 
more impaired with increased LV weight (Fig. 3). However, since there was also an inverse 
correlation between LVW/BW and diastolic arterial pressure (r2=0.74), the lower diastolic 
arterial pressure in KO mice may have contributed to the lower LV dP/dtmax under basal 
conditions. Indeed, diastolic pressure and LV dP/dtmax were correlated (r
2=0.76, P<0.05), 
and stepwise regression analysis revealed that diastolic arterial pressure was an independent 
predictor of LV dP/dtmax (P<0.05). Similarly, there was a positive correlation between LVW/
BW and LV dP/dtmin (r
2=0.85), but also between LVW/BW and LV systolic pressure (r2=0.76). 
The lower LV systolic pressure may have contributed to the lower maximum rate of fall of LV 
pressure, as is suggested by the close correlation between LV systolic pressure and LV dP/
dtmin observed during univariate regression analysis (r
2=0.96, P<0.05). In addition, stepwise 
regression analysis showed LV systolic pressure to be an independent determinant of LV 
dP/dtmin (P<0.05). The time constant τ, which describes the rate of relaxation during early 
diastole, was considerably higher in KO mice with the highest LVW/BW, suggesting impaired 
LV relaxation in these mice (Fig. 3). In contrast, LV end-diastolic pressures were not increased 
in KO compared to WT mice.
Table 3.                  Hemodynamic data during ketamine-xylazine anesthesia
Wild-type mice 
(n=6) 
Knock-out mice 
(n=6) 
HR, beats/min baseline 308 ± 28 234 ± 19 
dobutamine 475 ± 37† 401 ± 25† 
DAP, mmHg baseline 60 ± 3 42 ± 7* 
dobutamine 69 ± 8 50 ± 7 
LVSP, mmHg baseline 83 ± 4 65 ± 8 
dobutamine 117 ± 15† 
LVEDP, mmHg baseline
109 ± 9† 
9 ± 1 6 ± 1* 
dobutamine 9 ± 2 3 ± 2* 
LV dP/dtmax, mmHg/s baseline 4440 ± 440 2720 ± 580* 
dobutamine 8730 ± 790† 6220 ± 800*† 
LV dP/dtmin, mmHg/s baseline -3290 ± 190 -2110 ± 500* 
dobutamine -5960 ± 530† -4730 ± 350† 
 , mτ s baseline 18.6 ± 1.1 71.4 ± 46.2 
dobutamine 13.7 ± 0.5† 13.4 ± 0.6† 
Values are mean±S.E.; n = number of observations. HR = heart rate; DAP = diastolic arterial blood pressure; LVSP = left 
ventricular systolic blood pressure; LVEDP = left ventricular end diastolic blood pressure; LV dP/dt max  = maximum rate of 
rise of left rate of rise of left ventricular pressure; τ = time constant of early diastolic LV pressure decay. *P<0.05 vs Wild-
type mice; †P<0.05 vs baseline;
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Fig. 3. Relation between hemodynamic variables under control conditions (open symbols) and during 
intravenous dobutamine infusion (solid symbols) LV to body weight ratio (LVW/BW), in ketamine-xylazine 
anesthetized mice. Upward triangles represent 20-24 months old C57Bl/6 WT mice; downward triangles represent 20-24 
months old C57Bl/6 KO mice. Squares represent 10-14 months old FVB WT mice; diamonds represent 10-14 months old 
FVB KO mice.
Dobutamine 
Intravenous infusion of dobutamine increased heart rate, diastolic arterial pressure, LV systolic 
pressure, LV dP/dtmax and LV dP/dtmin, and decreased τ, but had no effect on LV end-diastolic 
pressure in both WT and KO mice (Table 3). There were no differences in the responses to 
dobutamine in KO and WT mice. During dobutamine infusion, the inverse correlation between 
LVW/BW and LV dP/dtmax was maintained (r
2=0.62), but the inverse correlation between 
LVW/BW and diastolic arterial pressure was not signifi cant (Fig. 3), indicating that the lower 
LV dP/dtmax during dobutamine was principally the result of a lower global LV contractility. 
During dobutamine infusion, the relation between LVW/BW and LV dP/dtmin was maintained 
but τ was no longer different in KO and WT mice. The doses of dobutamine needed to produce 
maximal increases in LV dP/dtmax in KO and WT mice were 9±2 µg/kg/min and 8±2 µg/kg/
min, respectively.
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Hemodynamics during isofl urane anesthesia
Baseline hemodynamics 
Heart rate and LV dP/dtmax were signifi cantly higher during isofl urane anesthesia (Table 4) than 
during ketamine-xylazine anesthesia (Table 3). Despite these differences in hemodynamics 
produced by the two anesthesia regimen, heart rate (471±28 versus 581±23 beats/min) and 
LV dP/dtmax (5400±670 versus 8250±710 mmHg/s) were again lower in KO than in WT mice 
(both P<0.05), while diastolic arterial blood pressure (64±6 versus 58±5 mmHg) and LV 
systolic pressure (94±10 versus 122±14 mmHg) were not different. In these animals, ratios 
of heart weight, LV weight and RV weight to body weight were respectively 94% (8.00±0.47 
mg/g in KO mice versus 4.12±0.19 mg/g in WT mice), 98% (6.43±0.40 versus 3.25±0.16 
mg/g), and 80% (1.57±0.08 versus 0.87±0.05 mg/g) higher in the C57Bl/6 KO mice at 16-
18 months of age than in WT littermates.
Similar to the study under ketamine-xylazine anesthesia, there were correlations between 
LVW/BW and LV dP/dtmax (r
2=0.79), LVW/BW and LV dP/dtmin (r
2=0.52) and LVW/BW and τ 
(r2=0.52; all P<0.05) in the isofl urane anesthetized mice (Fig. 4). There was also an inverse 
correlation between LVW/BW and heart rate (r2=0.61), suggesting that the lower heart rate 
in KO mice may have contributed to the aforementioned correlations. Univariate regression 
analysis showed a correlation between heart rate and LV dP/dtmax (r
2=0.36, P=0.07) and τ 
(r2=0.47, P<0.05), but not LV dP/dtmin (r
2=0.10), under basal conditions. However, stepwise 
regression analysis showed that heart rate did not add signifi cantly to the prediction of LV 
dP/dtmax (P=0.55), LV dP/dtmin (P=0.48) or τ (P=0.27), in addition to LVW/BW.
Table 4.                          Hemodynamic data during isofl urane anesthesia
Values are mean±S.E.; n = number of observations. HR = heart rate; DAP = diastolic arterial 
blood pressure; LVSP = left ventricular systolic blood pressure; LVEDP = left ventricular end 
diastolic blood pressure; LV dP/dt max  = maximum rate of rise of left ventricular pressure; τ = time constant of early diastolic LV pressure decay. *P<0.05 vs Wild-type mice;
†P<0.05 vs baseline in WT; ‡variable increased or decreased in all three KO mice.
Wild-type mice 
(n=5) 
Knock-out mice 
(n=3) 
HR, beats/min 581 ± 23 471 ± 28* 
557 ± 10† 543 ± 12‡ 
DAP, mmHg 58 ± 5 64 ± 6 
‡92 ± 3  
LVSP, mmHg
96 ± 10†
120 ± 14 94 ± 10 
191 ± 11† 147 ± 26‡
LVEDP, mmHg 10 ± 1 8 ± 1 
10 ± 1 9 ± 1 
LV dP/dtmax, mmHg/s
norepinephrine
baseline
norepinephrine
baseline
norepinephrine
baseline
norepinephrine
baseline
norepinephrine
baseline
norepinephrine
baseline
norepinephrine
baseline
8250 ± 710 5400 ± 670* 
14710 ± 220† 10010±1320*‡ 
LV dP/dtmin, mmHg/s -9260 ± 1270 -4420 ± 860* 
-12200 ± 810† -7630 ± 1120*‡ 
 t, ms 10.5±1.3 16.5±1.6* 
8.4±1.0† 10.3±1.0‡ 
41
Cardiac remodeling and contractile function in KO-mice
Norepinephrine 
Intravenous infusion of norepinephrine increased heart rate, diastolic arterial pressure, LV 
systolic pressure and LV dP/dtmax in both WT and KO mice (Table 4). There were no signifi cant 
differences in the responses to norepinephrine in KO and WT mice, with the exception of heart 
rate which increased only in the KO mice, so that heart rates were no longer different in KO 
and WT mice. During norepinephrine infusion, the inverse correlation between LVW/BW and 
LV dP/dtmax became even more pronounced (r
2=0.62), in the absence of a signifi cant relation 
between LVW/BW and heart rate, diastolic arterial pressure or LV systolic pressure (Fig. 4), 
indicating that the lower LV dP/dtmax during norepinephrine was principally the result of a 
lower global LV contractility. During norepinephrine infusion, the relation between LVW/BW 
and LV dP/dtmin was maintained. Similar to the ketamine-xylazine study, τ was again no longer 
different in KO and WT mice during norepinephrine infusion. The doses of norepinephrine 
needed to produce the maximal responses in LV dP/dtmax in KO and WT mice were 11±3 µg/
kg/min and 11±2 µg/kg/min, respectively.
 
  
 
 
 
 
Fig. 4. Relation between hemodynamic variables under control conditions (open symbols) and during intravenous 
norepinephrine infusion (solid symbols) LV to body weight ratio (LVW/BW) in isofl urane-anesthetized mice. 
Circles represent 16-20 months old C57Bl/6 WT mice; squares represent 16-20 months old C57Bl/6 KO mice.
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Discussion
The major fi ndings of the present study are that (i) mice lacking acid α-glucosidase activity 
show an increase in cardiac mass involving both left and right ventricles, (ii) the increase 
in LV weight is associated with a marked increase in LV wall thickness and encroachment of 
the LV lumen, and (iii) the degree of LV mass increase is inversely correlated with the loss of 
maximal attainable LV global contractility during ß-adrenergic stimulation.
Cardiac mass
Qualitative descriptions of enlarged hearts have been previously reported in naturally 
occurring GSDII in turkey (9), sheep (19), dog (29), and a sub-population of shorthorn 
cattle (18). Heart, LV and RV weights were reported in only one study in two calves, at an 
age of 3-7 months, in which the heart weight to body weight ratio had tripled compared to 
normal, due to more than a doubling of LV weight and a quadrupling of RV weight (25). In 
the present murine study we observed an increase in relative heart weight of up to 160%, 
due to a 166% increase in relative LV weight and a 130% increase in relative RV weight. 
We observed a strong correlation between glycogen storage in the heart and the relative LV 
weight. In approximately 10-14 months old FVB KO mice the average glycogen content was 
around 300 mg per mg protein, while in 20-24 months old C57Bl/6 KO mice glycogen content 
was beween 2200 and 5200 mg per mg protein, resulting in a 40% increase in relative LV 
weight in 10-14 months old FVB and a 166 % increase in 20-24 months old C57Bl/6 KO 
mice. In the three additional 16-18 months old C57Bl/6 KO mice relative LV weight was 98% 
higher than in littermate WT mice. Together, these fi ndings suggest that glycogen continues to 
accumulate in the murine heart up to two years of age. The increase in relative heart weight in 
mice (up to 160% at 24 months + 3 weeks gestation time) approximates that in calves (up to 
200% at 3.7 months + 6 months gestation time), but is signifi cantly less than the increase in 
humans (up to 350% at 3-10 months + 9 months gestation time). Interestingly, the increase 
in relative heart weight in humans appears to level off after approximately 3 months after 
birth, as heart weights are approximately 3 times normal at two weeks of age (n=8) and 4.5 
times normal at 3 months (n=8), but with no signifi cant further increase between 3 and 10 
months (n=40) (1,8,12,20). In contrast, glycogen continues to accumulate in the murine 
heart between 10 months and 24 months of age.
LV wall thickness and lumen diameter
Data on alterations in LV geometry in infants with GSDII have been obtained during autopsy 
and revealed increases in wall thickness of 6-10 mm in the left ventricle (normal range 2-
4 mm) a few weeks after birth, whereas in children who died at approximately two-years 
of age, wall thickness had increased up to a maximum of 25 mm the left ventricle (normal 
range 4-6 mm) (12). More recent echocardiography studies have generally reported severe 
cardiomegaly with extremely thick ventricular walls and relatively normal atria (4). In most 
cases hypertrophy of the LV free wall and septum is more pronounced than in the right 
ventricle (14). Another typical echocardiographic fi nding is the encroachment of the LV lumen 
as was found in two girls of 6-7 months of age (14,23). Encroachment of the lumen may 
become so severe that outfl ow tract obstruction and infl ow impairment develop (12,23,27).
The present study is the fi rst to describe the echocardiographic abnormalities in an animal 
model of GSDII. The main feature of the echocardiographic fi ndings was an increased LV wall 
thickness up to 200% of WT mice together with a modest encroachment of the LV lumen, 
which corresponds well with the echocardiographic fi ndings in infantile GSD II in humans. The 
degree of encroachment was somewhat variable and did not occur in all KO animals (Fig. 1), 
but could refl ect the onset of LV failure with resulting LV dilation.
LV contractile function and reserve
In contrast to the well-described anatomic and echocardiographic abnormalities in patients 
with GSDII, there is surprisingly little information on LV contractile function in GSDII. De 
Dominicis et al (10) reported normal ejection fractions (70% and 68%) measured with 
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echocardiography in two 6 months old patients. Bulkley and Hutchins (4) also reported a 
normal ejection fraction (>70%), measured with LV angiography, in a 5-month-old girl. In 
two other case reports (children up to 9 months of age), invasive assessment of LV function 
using cardiac catherization demonstrated normal LV fi lling pressures (2-3 mmHg), in the 
presence of severe cardiomegaly (12,15). In another case report (4 months of age) normal 
LV hemodynamics and cardiac index were observed, although early diastolic pressure was 
elevated with a restrictive LV fi lling pattern (2). In contrast, markedly elevated LV fi lling 
pressures (up to 20 mmHg) and a depressed cardiac index (2.44 l/min/m2) were found in a 
4-month-old child (26). In all these case studies, children invariably developed progressive 
clinical heart failure and died within 2 months after catherization. Unfortunately, in none of 
these studies LV contractility and LV contractile reserve were determined.
The present murine study also shows a normal fractional LV diameter shortening in KO 
compared to WT mice under basal conditions. However, LV function was not normal as 
we observed decreases in LV dP/dtmax, under basal conditions and, in particular, during ß-
adrenergic stimulation with either dobutamine or norepinephrine infusion. The additional 
experiments with norepinephrine were performed during isofl urane anesthesia to exclude 
that the low heart rates and LV dP/dtmax values observed during ketamine-xylazine anesthesia 
infl uenced the results (21). In addition, we used a 1.4 Fr microtip pressure transducer in 
these experiments to further minimize mechanical perturbation of LV volume and contractile 
performance. The maximal attainable LV dP/dtmax correlated well with the increase in LV weight 
in both series of experiments, thus independent of the anesthesia regimen or size of the LV 
catheter, suggesting that at more severe stages of the disease LV function becomes impaired. 
However, from the present study it also becomes clear that the KO animals are not yet in 
severe cardiac failure. This is suggested by the normal fractional LV diameter shortening, and 
by the comparable doses of both dobutamine and norepinephrine needed to elicit maximal 
responses of LV dP/dtmax in KO compared to WT mice, suggesting normal ß-adrenergic 
receptor sensitivity (3). Moreover, although the less negative LV dP/dtmin and increase in τ in 
KO compared to WT mice indicate a slight impairment of early diastolic function, which is in 
close agreement with human data (2), the normal levels of LV fi lling pressure in KO compared 
to WT mice also suggest the absence of overt heart failure.
Conclusions
The present study demonstrates that the acid α-glucosidase KO mouse model is characterized 
by increased cardiac mass, which is associated with an increased LV free wall thickness 
and with encroachment of the LV lumen, as well as a lower global LV contractility. These 
manifestations of cardiomegaly and left ventricular dysfunction, although not as overt, 
parallel the human conditions of early onset GSD II and make these mice a suitable model for 
further investigation of pathophysiology and novel therapies of infantile Pompe’s disease.
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Abstract
Objective
Recent reports warn that the worldwide cell culture capacity is insuffi cient to fulfi ll the 
increasing demand for human protein drugs. Production in milk of transgenic animals is an 
attractive alternative. We tested the long-term safety and effi cacy of recombinant human 
alpha-glucosidase from rabbit milk for the treatment of the lysosomal storage disorder 
Pompe’s disease. 
Methods: In the beginning of 1999 four critically ill patients with infantile Pompe’s disease 
(2.5-8 months old) were enrolled in a single-center open-label study and treated intravenously 
with recombinant human alpha-glucosidase, 15-40 mg/kg/week. 
Results
Genotypes of patients were consistent with the most severe form of Pompe’s disease. 
Transgenic alpha-glucosidase was tolerated well during more than 3 years of treatment. 
Clinical effects were signifi cant. All patients survived beyond the age of 4 years, whereas 
untreated patients succumb at a median age of 6 to 8 months. Alpha-glucosidase activity 
normalized. Muscle morphology improved markedly in 1 and cardiac hypertrophy in all 
patients. Two infants achieved motor milestones that are unmet in infantile Pompe’s disease, 
but only 1 patient learned to walk. 
Conclusion
Our study shows that a safe and effective medicine can be produced in the milk of mammals 
and encourages further development of enzyme replacement therapy for the several forms 
of Pompe’s disease. Restoration of skeletal muscle function and prevention of pulmonary 
insuffi ciency require dosing in the range of 20-40 mg/kg. The effect depends on residual 
muscle function at the start of treatment. 
Introduction
Production of therapeutic proteins in milk of transgenic animals is a promising new technology 
in light of the rapidly expanding market for protein drugs and the ever-increasing costs 
of healthcare (1). As the transgenic protein concentration in milk is very high, kilogram 
quantities of product per year can be obtained at relatively low costs, even in small animals 
like rabbits (2).
Since the fi rst report in 1988 on alpha-1-antitrypsin production in sheep milk, (3) a variety 
of transgenic proteins has been produced. These range from small unstable peptides (salmon 
calcitonin peptide (4)) to large proteins with complex post-translational modifi cations (factor 
VIII (5, 6) and lactoferrin (7)). However, despite the great promises of this novel production 
platform, there is not yet a single transgenic medicine on the market. Three recombinant 
proteins from milk are being tested in clinical trials: antithrombin III from goats, alpha-1-
antitrypsin from sheep, and alpha-glucosidase from rabbits (8-10).
We have focused on the production of recombinant human acid alpha-glucosidase for the 
treatment of Pompe’s disease, an autosomal recessive muscle disorder. The classic infantile 
form of the disease leads to death at a median age of 6 to 8 months (11) and is diagnosed 
by absence of alpha-glucosidase activity and presence of fully deleterious mutations in the 
alpha-glucosidase gene (12). Cardiac hypertrophy is characteristically present (11). Loss 
of muscle strength prevents infants from achieving developmental milestones like sitting, 
standing, and walking (11-13). Milder forms of the disease caused by less severe mutations 
and partial defi ciency of alpha-glucosidase are also known. Pompe’s disease is a lysosomal 
glycogen storage disorder with an estimated frequency of 1:40,000 births (14, 15) and is 
designated an orphan disease.
We have successfully explored the feasibility of enzyme therapy for Pompe’s disease in 
preclinical studies (16-19). The principle of treatment is based on the capacity of lysosomes 
to engulf exogenous proteins via endocytosis (20). After cloning the human alpha-glucosidase 
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gene, we have focused on production of the enzyme in CHO cells and milk of transgenic 
animals (18, 19, 21-25). The high yield of 2 grams per liter and the short reproduction time 
of rabbits has led to the pharmaceutical production of recombinant human alpha-glucosidase 
(rhAGLU) in milk of transgenic rabbits. The product’s safety and effi cacy were tested in phase 
I and phase II clinical studies (10). Here we report how 4 patients with infantile Pompe’s 
disease responded in a follow-up study to more than 3 years of intravenous treatment. 
Methods
Enzyme purifi cation and characterization
A line of transgenic rabbits producing rhAGLU was obtained (19). Rabbit milk was collected 
and stored at –20 °C until use. An alpha-glucosidase containing whey fraction was prepared 
from skimmed milk by tangential fl ow fi ltration using a Biomax 1000 membrane cassette 
(Millipore, Bedford, MA) and subsequently concentrated by ultrafi ltration using a Biomax 30 
membrane (Millipore, Bedford, MA). Following a virus inactivation step with Tween-80 in 1% 
and tri-n-butylphosphate in 0.3% concentration for 6 hours at 25 °C, the alpha-glucosidase 
was subsequently captured by Q Sepharose Fast Flow chromatography (Amersham Pharmacia 
Biotech, Uppsala, Sweden). After intermediate purifi cation on a Phenyl Sepharose HP column 
(Amersham Pharmacia Biotech, Uppsala, Sweden) alpha-glucosidase was polished by Source 
Phenyl 15 chromatography (Amersham Pharmacia Biotech, Uppsala, Sweden). Following a 
second viral removal step by nanofi ltration, purifi ed alpha-glucosidase was concentrated by 
ultrafi ltration (Biomax 30 membrane; Amersham Pharmacia Biotech, Uppsala, Sweden) and 
sterilized by microfi ltration (0.2 µm dead-end fi lter). The enzyme has a specifi c activity of 
more than 250 µmol/mg/h for 4-methylumbelliferyl-alpha-D-glucopyranoside and is >95% 
pure. Toxicity studies were performed in mice, rats and dogs in doses up to 100 mg/kg. 
A phase I study was successfully completed in humans. All information is contained in the 
Investigator’s Brochures.
Biochemical-genetic studies
Skin fi broblasts and muscle specimens were homogenized in water, and the 2000 x g 
supernatants were used to determine alpha-glucosidase activity, glycogen content and 
protein concentration (19, 26).
Mutation analysis was performed on genomic DNA and cDNA, as described previously (27). 
The functional effects of mutations were studied by assay of alpha-glucosidase synthesis and 
catalytic activity in transiently transfected COS cells (27, 28).
Study design
The study was a single-center, open-label, phase II study approved by the institutional review 
board. Written Informed Consent was obtained from the parents of all patients. The objective 
of the study was to evaluate the safety and effi cacy of rhAGLU.
Inclusion criteria
Patients qualifi ed for inclusion if they had symptoms characteristic of the infantile form of 
Pompe’s disease, including a hypertrophic cardiomyopathy. The upper age limit was 10 
months. Confi rmation of the diagnosis was required by an open biopsy from the quadriceps 
muscle, revealing a virtual absence of alpha-glucosidase activity and the presence of 
lysosomal glycogen storage. 
Clinical studies
RhAGLU was administered intravenously as a 1-2 mg/ml solution in saline with 5% glucose 
and 0.1% human serum albumin, in single starting doses of 20 mg/kg weekly for patients 
under 6.5 kg and 15 mg/kg for patients over 6.5 kg. After 14-23 weeks of treatment, the dose 
was increased to 40 mg/kg weekly for all infants. During infusions, heart rate, temperature, 
transcutaneous oxygen saturation and blood pressure were continuously recorded.  
Before the start of rhAGLU treatment, there was a period of up to 2 weeks in which baseline 
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assessments were performed. Thereafter, patients were assessed at regular intervals. Muscle 
biopsies were taken from the quadriceps muscle via an open muscle biopsy one day after 
rhAGLU infusion. Tissue specimens for measurement of alpha-glucosidase were immediately 
frozen in liquid nitrogen and stored at –80 °C until use. For histology purposes, tissue 
specimens were fi xed in 4% glutaraldehyde and embedded in glycolmethacrylate (GMA). 
Tissue sections (4 µm) were stained with periodic acid-schiff (PAS). Slides prepared at 
different time points were stained in one session.
IgE and IgG antibody titers were detected using a standard ELISA assay in which the plates 
were coated with antigen (1 µg/ml) and the samples were diluted 5 fold for IgE and 100 fold 
for IgG. Samples from healthy volunteers served as negative controls.
Left ventricular dimensions were determined by M-mode echocardiography, in compliance 
with the guidelines of the American Society of Echocardiography, using a Hewlett Packard 
Sonos 5500 (29). The LVPWd and the calculated LVMI were used as measures of hypertrophic 
cardiomyopathy (30). Psychomotor development was assessed using the Alberta Infant 
Motor Scale (AIMS) (31), the Bayley Scales of Infant Development (BSIDII) (32) and regular 
standardized neurological examinations.
Results
RhAGLU from rabbit milk
To achieve high level expression of rhAGLU in the mammary gland, we placed the entire 
alpha-glucosidase gene under control of the bovine alphaS1-casein gene promoter. The gene 
construct was injected into fertilized rabbit oocytes and these were implanted in foster 
mothers. Thus, we obtained a line of transgenic rabbits with high level expression of rhAGLU 
during lactation (18). The production line yields on average 2 g of crude rhAGLU per liter of 
milk during the fi rst 3 weeks of lactation. The molecular mass of alpha-glucosidase from milk 
is 110 kDa (Fig. 1A), similar to the mass of the acid alpha-glucosidase precursor produced 
in genetically engineered CHO cells and both enzyme species contain uncleaved N- and C-
terminal pro-peptides (18, 24, 33).
P
A.
110-
76-
70-
M P3 PF
110-
95-
76-
pre post
B.  
Fig. 1. Characterization of rhAGLU from rabbit milk. A. SDS-PAGE (8%) analysis under reducing conditions. The gel was 
loaded with 50 µg of protein per lane and stained with Coomassie brilliant blue. The 110 kDa precursor from rabbit milk (M) 
is compared with the 76 and 70 kDa mature forms of acid alpha-glucosidase from human placenta. B. Western blot analysis 
of alpha-glucosidase derived from muscle of patient 3 (P3) pre- (t=0) and post (t=3) treatment. Alpha-glucosidase from 
fi broblasts of a healthy individual is used to mark and identify the various molecular forms. 
Clinical condition and molecular delineation of patients
RhAGLU from rabbit milk was tested for its safety and therapeutic effi cacy in an open-label 
study in four patients with the most severe infantile form of Pompe’s disease fulfi lling the 
inclusion criteria as described in the methods. The clinical status of the 4 patients at baseline 
is summarized in Table 1. To sustain the diagnosis of classic infantile Pompe’s disease the 
patients were characterized with regard to the degree of acid alpha-glucosidase defi ciency, the 
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pattern of alpha-glucosidase synthesis, and the type of alpha-glucosidase gene mutations.
The alpha-glucosidase activity in skeletal muscle and fi broblasts of all four patients was below 
the lower limit of detection (<2% of normal) (Table 2). The 95, 76, and 70 kDa biosynthetic 
forms of alpha-glucosidase were missing in three of the four patients, when investigated by 
Western blot analysis (Fig. 2A). A trace amount of the naturally occurring 95 kDa biosynthetic 
intermediate was seen in cultured fi broblasts from the fourth patient (patient 1).
Table 1.  Clinical Characteristics of Patients at Baseline
Patient No. Sex/Age at Start   
of Treatment 
Clinical Appearance 
1 M/3 months Cardiac hypertrophy, head-lag, slipping 
through, axial hypotonia 
2 moF/7 nths Cardiac hypertrophy, heart failure, hypercapnia, 
oxygen need, head-lag, slipping through, axial 
hypotonia, poor head balance, paresis arms, 
paralysis legs, nasogastric tube feeding 
3 F/2.5 months Cardiac hypertrophy, heart failure, tachypnoea, 
borderline oxygen saturations, extreme 
perspiration, head-lag, slipping through, axial 
hypotonia, poor head balance, nasogastric tube 
feeding 
4 F/8 months Cardiac hypertrophy, heart failure, oxygen 
need, atelectasis left lung, head-lag, slipping 
through, axial hypotonia, poor head balance, 
paresis arms, paralysis legs, nasogastric tube 
feeding, growth retardation, intractable fever 
Table 2.  Biochemical-Genetic Delineation of Patients
Patient α-glucosidase a activity Genotype Amino acid
Substitution
1 0.6 G1799A/del exon 18 R600H/del55AA 
2 0.5 A1115T/delT525 H372L/ - b
3 0.1 delT525/delT525 - / - b  
4 0.7 G1913T/silent  G638V/ - c 
Control 40-160  
a. The activities are expressed as nmol 4-Methylumbelliferon (MU) formed per hour per mg
 cellular protein.
b. The delT525 is not expressed at the protein level.
c. The G1913T mutation was heterozygous in genomic DNA and homozygous in cDNA obtained
 by RT-PCR, indicating that only the G1913T allele is expressed.
When we used a more sensitive detection method, 35S methionine incorporation, we could 
detect low-level synthesis of alpha-glucosidase in three of the four patients (patient 1, 2, and 
4) and some post-translation modifi cation from 110 kDa to 95 kDa in one of them (patient 1) 
(Fig. 2B). Patient 3 remained totally defi cient with both detection methods (negative for cross 
reactive immunologic material: CRIM negative). As third mode of molecular delineation we 
analyzed the genotype of the patients (Table 2). The CRIM-negative patient (patient 3) turned 
out to be homozygous for deltaT525; a mutation known to lead to unstable mRNA, frame 
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shift and absence of cross reactive immunologic material (34). Both her parents are carriers 
of this mutation. Each of the other three patients has at least one alpha-glucosidase allele 
with a mutation permitting low level synthesis of the 110 kDa precursor when overexpressed 
in COS-cells (Fig. 2C). In two cases (patient 2 and 4) the precursor is degraded, but in one 
(patient 1) the Arg600His substitution is compatible with the formation of some 95 kDa 
intermediate. Importantly, none of the mutant alleles generates catalytically active alpha-
glucosidase, despite over-expression. Thus, the genotype of all patients enrolled in the study 
is consistent with the classic infantile phenotype of Pompe’s disease.
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Fig. 2. Molecular forms of alpha-glucosidase.
A, Western blot analysis. Alpha-glucosidase was immunoprecipitated from fi broblast lysates with rabbit anti-human-alpha-
glucosidase antibodies and subjected to SDS-PAGE. Alpha-glucosidase on the Western blots was visualized with mouse 
anti-human-alpha-glucosidase antibodies and chemoluminescence. The numbers above the lanes correspond to the patient 
number. N are cells from a healthy individual. Each lane shows the relative amount and molecular mass of the alpha-
glucosidase species present in an aliquot of lysate containing 1mg of total cellular protein. 
B, Synthesis and post-translational modifi cation of alpha-glucosidase. Fibroblasts were incubated for 8 hours in medium 
containing 35S methionine and then harvested. Alpha-glucosidase was immunoprecipitated from cell lysates with rabbit anti-
human alpha-glucosidase antibodies and subjected to SDS-PAGE. The autoradiogram shows the processing forms of alpha-
glucosidase. The numbers above the lanes correspond to the patient number. N are cells from a healthy individual. Equal 
numbers of cells were labelled per lane. 
C, Functional effects of novel mutations. Mutations were introduced in wild type cDNA by site-directed mutagenesis and 
transiently expressed in COS cells. Alpha-glucosidase was immunoprecipitated from cells and media at 72 hours after 
transfection and analysed by Western blotting, as described above. The numbers above the lanes correspond to the patient 
number. N is the wild type construct. Equal numbers of cells and equal volumes of media were used per lane.
RhAGLU tolerability
RhAGLU was administered intravenously, in an initial dose of 15 to 20 mg/kg per week. The 
dose was later increased to 40 mg/kg per week. The duration of the infusions ranged from 
4 to 6 hours. Infusion associated reactions were observed in the initial phase of treatment 
(starting at week 5-7) as reported previously. They comprised fever, malaise, erythematous 
rash, sweating, hypoxia, fl using and tachycardia (10). Corticosteroids and antihistamines 
were given in this period, but did not have a signifi cant effect and were discontinued. The 
reactions disappeared and did not occur when low infusion rates were applied (2 to 10 ml/h) 
for the fi rst 2 hours. They did not reoccur when the dose was doubled. In the later phase of 
treatment infusion reactions only occurred sporadically in the form of low-grade fever and 
rash. They were transient and mild. None of the patients receives at present antihistamines 
or corticosteroids. The infusions are easily manageable on an outpatient basis. One patient 
receives the infusions at home.  
The IgE titer did not rise above background levels during the study. Anti-rhAGLU IgG titers 
increased to levels between 5 and 13 times baseline values during the fi rst 20 to 48 weeks 
and declined to 1 and 8 times baseline values during the following infusions. IgG titers against 
rabbit whey also increased (4-12 times baseline values) during the fi rst 24 weeks and then 
stabilized between 3 and 9 times baseline values. There was no consistent difference in 
antibody formation comparing the CRIM-negative with the CRIM-positive patients. Notably, 
we measured the highest IgG titer in a 34-year-old patient with 10-20 % of normal CRIM who 
received the same enzyme preparation. 
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Alpha-glucosidase activity in tissues
During the fi rst 12 weeks of treatment, muscle alpha-glucosidase activity increased from 
<2% to 10-20% of normal in all patients (Table 3A). In order to optimize the therapeutic 
effect, we increased the rhAGLU dose in all infants to 40 mg/kg and this resulted, 12 weeks 
later, in normal alpha-glucosidase activity levels. These were maintained until the last 
measurement in week 72. Importantly, all four patients, including the patient without any 
endogenous alpha-glucosidase (CRIM-negative), revealed mature 76 and 70 kDa forms of 
alpha-glucosidase on Western blot after treatment with the 110 kDa (precursor) rhAGLU 
(Fig.1A and B). As the fi nal steps of enzyme maturation occur in lysosomes, this observation 
provides evidence that rhAGLU reaches its target.
Table 3.  Uptake of Alpha-Glucosidase in Muscle and Correction 
    of Glycogen Storage
A.
Patient Alpha-Glucosidase Activity*
 t=0 t=1 t=2 t=3  
1 0.2/0.4 4.9/3.7 27.4/29.3 27.1/25.8 
2 0.3/0.3 2.7/3.1 8.0/9.5 28.9/12.1 
3 0.2/0.7 2.1/3.8 13.0/7.4 8.2/8.9 
4 0.4/0.2 2.7/1.8 16.2/11.3 5.8/4.4 
Control 8-40 
B.
Patient Glycogen Concentration*
 t=0 t=1 t=2 t=3  
1 747/1022 755/1351 892/1440 86/503 
2 2810/2543 3270/3199 2450/3190 2460/3020
3 1650/1397 2330/1847 2020/2440 2300/2550
4 3690/2720 4630/3700 3060/2720 2130/2310
Control 30-180  
*Multiple measurements of alpha-glucosidase activity (nmol/mg/h) (A) and glycogen concentration (microgram/mg) (B) in 
muscle at baseline (t=0) and after 12 weeks of treatment  with 15 to 20 mg/kg (t=1), 12 more weeks of treatment with 40 
mg/kg (t=2) and 72 more weeks of treatment (t=3). Values at each time point were obtained from two different pieces of
muscle.
Muscle morphology
At baseline, all patients had severe glycogen storage in the quadriceps muscle as revealed 
by strong PAS-positive staining and lacework patterns in HE-stained tissue sections. The 
two older patients had more severely affected muscle at inclusion than the two younger 
ones. The muscle pathology correlated at each time point with the severity of signs. After 12 
weeks of treatment with 15 or 20 mg/kg rhAGLU, the PAS intensity had diminished, while 
the number of vacuoles had increased. Twelve weeks after dose elevation we observed signs 
of muscle regeneration in three of the four patients. An obvious improvement of muscular 
architecture was only seen in the patient who learned to walk (Fig. 3A). A detailed account 
of the morphological changes in muscle is given in reference 37. The glycogen concentration 
in muscle stabilized in patients 2, 3 and 4, and decreased in patient 1 during the course of 
treatment (Table 3B).
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Fig. 3. Correction of muscle pathology and improvement of cardiac and skeletal muscle function. 
A. Longitudinal sections of a muscle biopsy from patient 1 at baseline (left) and 72 weeks of treatment (right). Sections are 
stained with PAS to visualize lysosomal glycogen.
B. Changes in LVPWd during treatment for patients 1-4. Piece-wise linear regression (“broken-stick” method) is used to 
illustrate the statistically signifi cant change in slope after start of treatment.
Cardiac morphology and function
All four patients had the characteristic cardiac hypertrophy at start of treatment, with a 
left ventricular mass index (LVMI) exceeding 170 g/m2 (normal value P97.5 86,6 g/m
2 for 
infants from 0-1 years old (35)). During 84 weeks of treatment, the LVMI decreased from 
171, 203, 308 and 599 g/m2 at baseline to 70, 160, 104 and 115 g/m2 for patients 1, 2, 3, 
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and 4, respectively. The decrease of the LVMI along time appeared linear (r = -0.86, -0.91, 
-0.89 and -0.80 for the four respective patients; all P <0.01). The diastolic thickness of the 
left ventricular posterior wall (LVPWd) was increased before start of rhAGLU treatment. We 
found a signifi cant change of slope for LVPWd against time at t=0 for each separate patient 
(P <0.01) (Fig. 3B). The decrease in LVPWd after the start of treatment leveled out in two 
patients (patients 3 and 4) when the P95 of normal was approached, as evidenced by a second 
signifi cant change of slope using the “broken stick” method (P <0.05). The systolic function 
normalized and the diastolic function improved in all patients. 
Respiratory condition
During the fi rst 2 years of life, the two younger patients (patients 1 and 3) remarkably showed 
no signifi cant respiratory problems. Patient 3 recovered from a life-threatening bronchiolitis at 
the age of 1 year without sequelae, despite borderline oxygen saturation at inclusion. At the 
age of two she became ventilator-dependent after surgical removal of an infected Port-A-Cath. 
The respiratory course of patient 1, now 4 years old, remained uneventful. Patients 2 and 4, 
who were older and more severely affected at inclusion, had a marginal respiratory condition 
from the start of treatment, and both required oxygen. Patient 2 (pCO2 10.6 kPa equivalent 
to 80 mm Hg at start; normal range 4.5-6.8 kPa) became ventilator-dependent before the 
fi rst rhAGLU infusion and remained fully ventilated. Patient 4  (pCO2 9.8 kPa equivalent to 75 
mm Hg at start) became ventilator-dependent during a bout of pneumonia after 10 weeks of 
low-dose treatment. She could gradually be weaned from the ventilator after one year of high 
dose treatment and was eventually completely ventilator free for 5 days, but this situation 
could not be maintained. At the age of 4 her ventilator needs are 22-23 hours per day. 
Motor development
The most remarkable progress in motor development was seen in the younger patients 
(patients 1 and 3, Fig. 4). Patient 1 learned to crawl (12 months), walk (16 months), squat (18 
months) and climb stairs (22 months). Patient 3 learned to sit unsupported (Fig 4), and her 
condition further improved until the age of 2, when she became ventilator dependent. At the 
age of 4 years and 3 months she died quite suddenly after a short period of intractable fever of 
more than 42 0C, unstable blood pressure and coma. At baseline, the older patients (patients 
2 and 4) could hardly lift their arms while in a supine position, and their legs lay immobile on 
the surface. During treatment, the muscle function of the arms improved signifi cantly. Patient 
2, however, lost her regained muscle strength after a series of airway infections. In her case, 
restoration of function appears to be a diffi cult process. Patient 4 maintained the strength 
in her arms. When she was 24 months old, she could roll over onto her side and play for 
longer periods while seated in a wheel chair. Her condition has not improved since then. The 
AIMS score for patients 2, 3 and 4 remained far below the p5. Patient 1 followed the p5 of 
normal (Fig 5). For patient 1 the psychomotor development on the BSID II, based on raw 
score equivalents, progressed from 2 to 37 months developmental ages at chronological ages 
of 3 to 37 months. The psychomotor developmental index (PDI) progressed from 79 to 97. 
In patients 2, 3 and 4 the PDI was below 50, and a motor developmental age could not be 
calculated.  
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Fig. 4. Motor development.
A. Patient 1 stands on one leg at 4.5 years of age.
B. Patient 3 sits without support at the age of 19 months.
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Fig. 5. The AIMS scores of the patients during enzyme replacement therapy.
The upper age limit of the test is 18 months.
Mental development
As rhAGLU is unlikely to pass the blood-brain barrier, we had concerns about long-term mental 
development and neurologic performance. Neurologic examinations performed from the start 
of treatment at preset time points showed no signs of CNS involvement so far. As unexpected 
fi nding we measured an elevated response threshold of brainstem auditory evoked potentials 
(BAEP) in all patients at inclusion. This did not change during treatment. 
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For patient 1 the mental development on the BSID II, based on raw score equivalents, 
progressed from 3 to 31 months developmental ages at chronological ages of 3 to 37 
months. The mental developmental index (MDI) was 101 and 79 at 3 months and 37 months, 
respectively. The BSID II was inadequate to test the mental development of patient 2 because 
of her severe hypotonia. For patient 3 the mental development progressed from 2 to 18 
months at chronological ages of 3 to 22 months. The MDI was 81 and 72, respectively. 
The mental development of patient 4 progressed from 5 to 27 months at chronological ages 
of  8 to 37 months. The MDI of patient 4 was 76 and 67, respectively. 
In practice, the BSID II scores are not a true refl ection of mental development. Items were 
missed through motor handicaps and hearing problems rather than through mental delay. All 
patients were interested in their environment, interacted with their parents and were able to 
attend school.
Survival
Three of the 4 patients are alive. All 4 patients reached the age of 4 years, whereas the life 
expectancy of untreated patients with the classic infantile form of Pompe’s disease is typically 
less than 1 year (10-13).
Discussion
Our study demonstrates that a safe and effective medicine for IV treatment of human disease 
can be produced in the milk of transgenic animals, in this case rhAGLU from rabbit milk for 
patients with Pompe’s disease. The safety of the product is proven by the fact that more 
than 700 infusions were well tolerated by critically ill patients. The effi cacy of the therapy 
is evident from several observations. First, all 4 patients have reached the age of 4 years, 
whereas babies with classic infantile Pompe’s disease typically succumb before they are one 
year old (10-13). Second, the cardiac hypertrophy diminished and cardiac function improved, 
whereas cardiac failure is a major cause of death in infantile Pompe’s disease. Third, patients 
gained muscle strength, whereas there normally is a progressive loss of muscle function. Two 
patients achieved developmental milestones that are unmet by untreated patients. Notably, 
the motor score on the Bayley Scale of Infant Development of one patient normalized at the 
age of two years. 
The effi cacy of treatment is further supported by biochemical fi ndings. Correction of alpha-
glucosidase defi ciency occurred in skeletal muscle of all four patients. After three months of 
single weekly doses of 15 to 20 mg/kg the correction was partial. A 100% correction was 
achieved after three additional months on a weekly dose of 40 mg/kg. Conversion of the 110 
kDa precursor from milk to mature 76/70 kDa alpha-glucosidase provides evidence that the 
enzyme is targeted to lysosomes, where this proteolytic processing occurs (36). Moreover, 
we observed a decrease of the PAS-staining intensity and the appearance of empty vacuoles 
in the quadriceps muscle of all patients, suggestive for an effect on the lysosomal glycogen 
pool. In the best performing patient this resulted in greatly improved muscle morphology and 
glycogen content (37).
It is evident that the 4 patients respond differently to the treatment, and we have tried to 
fi nd an explanation. All patients appeared to have molecular-genetic defects and clinical 
characteristics consistent with classic infantile Pompe’s disease (11-13). Notably, the best 
performing patient had the most severe hearing defi cit (50-80dB). This makes it very unlikely 
that the difference in response is explained by inclusion of patients with milder non-classic 
infantile phenotypes. 
We fi nd it equally unlikely that an inhibitory immune response, as described in a study 
by Amalfi tano et al. (38) with alpha-glucosidase from CHO-cells, explains the difference in 
effi cacy. The latter study claims, that neutralizing antibodies caused the loss of treatment 
benefi t at the age of 8 months in two CRIM-negative patients. This counter-effect did not 
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occur in our study. On the contrary, our truly CRIM–negative patient was the second best 
responder. Enzyme therapy studies for Gaucher’s disease, Fabry’s disease and MPS I do not 
indicate either that a CRIM-negative status per se or antibody formation interferes with the 
effi cacy of enzyme replacement therapy (39-43). 
In our view, the degree of impairment of skeletal muscle function and the age of the patient 
at start of treatment play the decisive roles in outcome. The two patients, included at 2.5 and 
3 months of age, had milder symptoms at inclusion and responded clearly better than the 7 
and 8 months old patients who were in an end stage of the disease at the time of inclusion. 
The patient who had the best muscle function at start of treatment learned to walk. This may 
indicate that active muscle movement is required to correct the lysosomal glycogen storage 
and restore the muscle morphology (37). 
Despite the signifi cant effects of our therapy, we warn that patients with infantile Pompe’s 
disease are at risk of developing residual disease with contractures, scoliosis, or respiratory 
insuffi ciency if treatment is started too late or with a too low a dose. The therapeutic window 
is small. We may have lost precious time by treating the patients for 3 to 6 months with a 
sub optimal dose. 
The results of our study are encouraging for the further exploration of enzyme replacement 
therapy. This is true for infants but even more so for patients with milder forms of Pompe’s 
disease. The therapeutic window is larger as we experienced in our pilot study with 3 patients 
aged 12 to 33 years. One of them, who was wheelchair-bound for 4 years, started to walk 
again after 2 years of treatment with rhAGLU, 20 mg/kg/week (44).
 
The effective dose of rhAGLU is high compared with the 1 mg/kg dose of glucocerebrosidase 
used for the treatment of type 1 Gaucher’s disease and the 0.2-1 mg/kg dose of alpha-
galactosidase used for treatment of Fabry’s disease (39-41, 43, 45). These differences are 
explainable by the different target tissues. In Pompe’s disease, the target tissue (skeletal 
muscle) is shielded from the enzyme by the capillary endothelium and the interstitial tissue. 
In contrast, the targets in Gaucher’s disease (liver and spleen macrophages) and Fabry’s 
disease (endothelial cells) are directly exposed to circulating enzyme. Notably, in Fabry’s 
disease 3 mg/kg alpha-galactosidase is suffi cient to reach the endocardium but insuffi cient 
to reach the cardiomyocytes (40). The higher dose required to correct enzyme activity in 
skeletal muscle is supported by studies in animal models and was demonstrated for various 
enzyme species among which recombinant human alpha-glucosidase from both transgenic 
mammals as well as genetically engineered CHO cells (19, 33, 46, 47).
Conclusion
The results of our study demonstrate both the safety and effi cacy of enzyme replacement 
therapy in Pompe’s disease as well as the feasibility of producing medicines in the milk 
of transgenic animals. This novel production platform can potentially reduce the costs of 
therapeutics, but scale-up persists as major challenge in the rhAGLU production process. The 
currently used transgenic rabbit production line supplies approximately 10 g of rhAGLU per 
animal per year. At a dose of 10-40 mg/kg per patient per week, the production of rhAGLU in 
rabbit milk is feasible in the initial phase of product development, but falls short of supplying 
patients with Pompe’s disease world-wide. The more conventional production system in 
genetically modifi ed CHO cells can be used as alternative, but also has a capacity limitation 
(1). Thus, timely investments need to be made in the development of alternative production 
platforms. Our studies show that production in milk of sheep, goat, or cow is the option of 
choice. 
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Abstract
Pompe’s disease (glycogen storage disease type II; GSDII) is an autosomal recessive 
myopathy caused by lysosomal α-glucosidase defi ciency. Enzyme replacement therapy (ERT) 
is currently under development for this disease. We evaluated the morphological changes 
in muscle tissue of four children with infantile Pompe’s disease who received recombinant 
human α-glucosidase (rhAGLU) from rabbit milk for 72 weeks. The patients were aged 2.5 
– 8 months at entry. Prior to treatment, all patients showed lysosomal glycogen storage in 
skeletal and smooth muscle cells, vascular endothelium, Schwann cells, and perineurium. 
The fi rst response to treatment was noticed in vascular endothelium and in peripheral nerves 
after 12 weeks of treatment at an enzyme dose of 15-20 mg/kg. Increasing the dose to 40 
mg/kg led, after 72 weeks of treatment, to a reduction of glycogen storage and substantial 
improvement of muscle architecture in the least affected patient. Not all patients responded 
equally well, possibly due to differences in degree of glycogen storage and concomitant 
muscle pathology at the start of treatment. We conclude that intravenous administration of 
rhAGLU from rabbit milk can improve muscle morphology in classic infantile Pompe’s disease 
when treatment is started before irreversible damage has occurred.
Introduction 
Pompe’s disease (glycogen storage disease type II) is an autosomal recessive lysosomal 
storage disorder, caused by acid α-glucosidase defi ciency 13.
Classic infantile Pompe’s disease presents in the fi rst months of life. Affected infants have 
respiratory and feeding diffi culties, severe hypotonia, and a hypertrophic cardiomyopathy. 
Other frequent symptoms are macroglossia and hepatomegaly. Major milestones are typically 
not achieved, and most infants die within their fi rst year of life (median survival, 6-8 months) 
13, 23.
Enzyme replacement therapy (ERT) is presently under development and appears to be a 
realistic option for treatment of Pompe’s disease 13, 24. The method was fi rst investigated in 
vitro and later in animal models before it was tested in patients 2, 10, 14, 26-28. Seven patients (4 
infants, 2 teenagers and 1 adult) started experimental treatment with recombinant human 
α-glucosidase from rabbit milk in our hospital in 1999. Based on the preliminary fi ndings in 
the infantile group we concluded that ERT with recombinant human α-glucosidase is safe and 
effective 24. 
During the clinical trial of ERT multiple muscle biopsies were performed at different intervals 
after the treatment was started. The purpose of this paper is to describe the fi ndings in these 
biopsies, particularly with regard to how ERT may modify the storage of glycogen in skeletal 
muscle, intramuscular nerves, and blood vessels.
Methods 
Patients
Four patients with classic infantile Pompe’s disease were included in our open-label study 
to assess the safety and effi cacy of ERT with recombinant human α-glucosidase from rabbit 
milk 24, 25. The diagnosis was based on clinical symptoms and defi ciency of acid α-glucosidase 
activity, and confi rmed by mutation analysis. The study was approved by the medical ethics 
committee of our hospital. At the time of entry to the study, the patients were 2.5 to 8 months 
old and all four had complete α-glucosidase defi ciency 24, 25. The least affected patient (patient 
1) then was a 3-month-old boy in relatively good condition. The other three patients were 
girls. Patient 3 (2.5 months old) was more affected than patient 1, but less than patients 2 
and 4 who were then 7 and 8 months old, respectively, and in an end stage of their disease 24, 
25.  Clinically, patient 1 responded well to treatment. At the time of each consecutive biopsy, 
he was able to move his legs against gravity and showed close to normal motor development. 
Patient 3 showed delayed motor development; she could move her legs, but not against 
gravity. Patients 2 and 4 were unable to move their legs.
Morphologigal changes in muscle tissue during ERT
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Therapeutic regimen
Pharming/Genzyme LLC supplied recombinant human α-glucosidase from rabbit milk 4, 5. The 
patients received this drug intravenously on a weekly basis. Figure 1 shows the dose regimen 
per patient.
Fig.1.                               Dose and weeks of treatment at time of biopsy
Patient 1
Patient 2
Patient 3
Patient 4
Dose 20 mg/kg15 mg/kg 40 mg/kg
12 21 33 726828260
Biopsy no 1         2           3          4             5
Weeks of treatment
  
Processing of biopsies
Muscle biopsies were taken from the quadriceps muscle at preset time points, using a standard 
open surgical procedure (Fig.1). The surgeons were asked to avoid the sites of previous 
biopsies. Samples were split for light (LM) and electron microscopy (EM) and fi xed overnight 
in 0.1M cacodylate buffered glutaraldehyde (4%) pH 7.3. After dehydration in a graded series 
of acetone, LM sections were embedded in glycolmetacrylate (GMA) and stained with periodic 
acid Schiff reagent (PAS) 1. Diastase digestion was performed to positively identify glycogen 
as opposed to acid mucin. EM sections were postfi xed with OsO4 and embedded in Eppon 7. 
Ultrathin sections (EM) were contrasted with uranyl acetate and lead citrate and examined 
with a Philips Morgagni Electron Microscope 286D (Philips, Eindhoven, The Netherlands).
Timing of biopsies
For all patients, the fi rst biopsy (Fig.1) was taken before start of treatment and the second 
biopsy was after 12 weeks of treatment with 15-20 mg/kg. The third biopsy was only 
performed for patient 1 and 2 after an additional 9 weeks with the same dose. Another biopsy 
was obtained from all patients after 12 weeks of treatment with 40 mg/kg. The last biopsy 
was for patient 4 after 68 weeks and for patients 1-3 after 72 weeks of treatment with 40 
mg/kg.
Semiquantitative rating
To minimize artifi cial differences in staining intensity, all tissue sections from the same 
patient but from different time-points were collected on the same glass slide and stained 
simultaneously. The sections were then assessed in a blinded fashion by 6-8 observers. 
A qualitative rating system was designed to codify the glycogen storage in and its effects on 
the various tissues in the biopsy and to allow possible differences in extent of glycogen storage 
between skeletal muscle cells, blood vessels, and intramuscular nerves to be tabulated. The 
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system is intended to allow comparison in sequential biopsies from the same patient and not 
between patients, because of interpatient variation (Table 1). 
The PAS-staining intensity of muscle was rated from 0 (no staining) to 3 (very strong), the 
cross-striation from 0 (normal) to 3 (absent), and the number of vacuoles from 0 (none) 
to 3 (many). These three ratings together form the “muscle score”. We similarly rated the 
PAS-staining intensity of endothelial and smooth muscle cells in the wall of blood vessels, 
(arteries and veins) and the staining intensity of the Schwann cells and the perineurium of 
peripheral nerves. The “total score” is the sum of all ratings. A high total score refl ects severe 
pathology (maximum = 27) and a low score signifi es good morphology (best score = 0 = 
near normal). 
Table 1.    Rating system for pathological changes
PAS intensity Score Striation Score Vacuoles score
No staining 0 None at all 3 None at all 0 
Little in some 0 Significant in most 2 Little in some 0 
Little in most 1 Significant in all 1 Little in all 1 
Little in all 1 Normal 0 Significant in some 1 
Significant in most 2 Significant in all 2 
Strong in most 2 Many in some 2 
Very strong in most 3 Many in all 3 
Very strong in all 3 
Some/all/most refers to fi bers when skeletal muscle is involved, to vessels when blood vessels are involved and to peripheral 
nerves when these are involved.
Results
Pathology before treatment 
Before the start of treatment, there was a marked accumulation of glycogen in skeletal 
muscle, smooth muscle of arteries and veins, vascular endothelium, Schwann cells, and 
the perineurium of peripheral nerves of all patients. In each case the global structure of the 
tissues was preserved, and irreversible damage in the form of fi brosis was not observed (Fig. 
2). The best performing patient (patient 1) showed the overall best muscle architecture at 
the time of inclusion. The cross-striation was relatively well preserved, although most fi bers 
were substantially affected and had (lysosomal) glycogen deposits varying in number and 
size (Fig. 2A). In contrast, the most affected patient (patient 2) had severe muscle damage 
with virtually complete loss of cross-striation and a sizeable number of relatively large empty 
spaces (vacuoles). Only an estimated 5% of muscle fi bers was relatively unaffected (Fig. 
2B). Patients 3 and 4 had an intermediate level of pathology (Fig. 2C and D, respectively) 
compared to the least and most affected patients.
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Fig. 2. Pre treatment variation of pathology in muscle sections.
Longitudinal sections of the quadriceps femoris of patients 1-4 (A-D) were stained with periodic acid-Schiff (PAS) to 
demonstrate glycogen storage. Glycogen storage is seen in cross-striated muscle, in smooth muscle, in vascular endothelium, 
and in Schwann cells and perineurium of peripheral nerves. Magnifi cation: A, 250x; B-D, 400 x
EM images taken before the start of treatment provided more detailed information about the 
severity of the glycogen accumulation. The muscle architecture of patient 1 was only mildly 
disturbed (Fig. 3A). The contractile fi laments were still intact, while there were lysosomal and 
extra-lysosomal glycogen deposits. The most affected patient (patient 2) had muscle fi bers 
with far more and larger lysosomes and cytoplasmic fi elds of glycogen causing fi bril splitting 
(Fig. 3B). Lysosomal glycogen storage was also seen in vascular endothelial cells, which are 
recognizable by their pinocytotic vesicles (Fig. 3C). The pinocytotic function of these cells is 
apparently not disturbed.
Fig. 3. Electron microscopy of muscle sections at baseline. 
Lysosomal (L) and cytoplasmic (V) inclusions in skeletal muscle of patient 1.
The arrows point to the lysosomal membrane (A); Fibrils are split by glycogen deposits in muscle of patient 2 (B); Lysosomal 
glycogen storage (L) in endothelial cells of patient 3. The arrows point to pinocytotic vesicles(C) Magnifi cation: A, 4400x; 
B, 5600x; C, 22000x
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Glycogen degradation and morphological changes during treatment
The muscle pathology of patient 1 diminished after the start of treatment, mainly during 
weeks 33 to 72. In contrast, the morphological changes in the biopsies of patients 2, 3 and 4 
were much more subtle. In these latter three cases, a clear loss of glycogen occurred from the 
intramuscular nerves and blood vessels and less so from the skeletal muscle, but this effect 
was accompanied by increased loss of muscle architecture.
Figure 4 depicts the changes observed in patient 1. Figure 4A was taken prior to treatment 
and shows PAS-staining in a peripheral nerve, artery, and skeletal muscle fi bers. After 12 
weeks of treatment at a dose of 15 mg/kg, the fi rst therapeutic effects were observed (Fig. 
4C). The overall PAS-staining intensity was still high, but glycogen had disappeared from 
the peripheral nerves (Schwann cells and perineurium) and from the vascular endothelium. 
The PAS-staining intensity of the smooth muscle cells of the vascular walls was diminished 
but some glycogen storage was still present. The least effect was noticed in skeletal muscle. 
The fi bers appeared as affected as before treatment, and the number of vacuoles (empty 
spaces) seemed slightly increased (Fig. 4A, C). These fi ndings were confi rmed by electron 
microscopy (Fig. 4B, D). Treatment for an additional 9 weeks, with the same dose, did not 
lead to further morphological improvement (not shown). We then increased the dose to 40 
mg/kg for a subsequent 12 weeks period. After this period we observed reduction of PAS-
staining intensity and improvement of muscle morphology in patient 1 (Fig. 4E). The vascular 
smooth muscle cells still contained some glycogen deposits, but these were mostly restricted 
to the outer layer of the blood vessel wall. The EM pictures showed some vacuoles and fi elds 
of glycogen disturbing the normal muscle architecture (Fig. 4F). After 72 weeks of treatment 
(21 weeks with 15 mg/kg plus 51 weeks with 40 mg/kg), there were large areas with virtually 
normal muscle morphology (Fig. 4G). All fi bers were cross-striated (Figs. 4G and 4H) and the 
sarcomers were nicely aligned (Fig. 4H), although some fi bers still contained small vacuoles. 
Cytoplasmic and lysosomal glycogen had disappeared, also from the walls of arteries and 
veins.
The different response to treatment of patient 1 compared to 2 is illustrated in Figure 5. At 
the start of treatment, patient 2 had a high proportion of affected fi bers, more vacuolization 
and larger fi elds of cytoplasmic glycogen than patient 1 (Fig. 5C, A). Cross-striated muscle 
fi bers were hardly seen in the biopsy of patient 2. After 72 weeks of treatment the PAS-
staining intensity was diminished in the biopsies of both patients. By then, however, the 
muscle morphology of patient 1 had substantially improved (Fig. 5B), whereas the muscle 
morphology of patient 2 was still poor due to an increase of the number of vacuoles (Fig. 5D). 
Comparison at the EM level confi rmed these fi ndings. Sections of patients 3 and 4 showed a 
muscle architecture comparable to that of patient 2 (not shown).
In one of the EM sections obtained after 72 weeks of treatment, we observed lysosomal 
glycogen deposits in a satellite cell, demonstrating that the storage process continued despite 
ERT (not shown).
 
70
Chapter 4
Fig. 4. Effect of ERT on muscle morphology. 
All images are derived from patient 1. The left panel is 
stained with PAS, the right panel are electron micrographs. 
A and B: skeletal muscle pathology at baseline; C and D: 
the changes after 12 weeks of treatment with 15 mg/kg 
weekly. Note the clearance of glycogen in peripheral nerves 
and vascular endothelium; Muscle morphology has not 
changed; E and F: the changes after 12 additional weeks 
of treatment with 40 mg/kg: Note the overall reduction of 
PAS staining intensity. Muscle morphology has improved; 
there are still fi elds of cytoplasmic glycogen and some 
vacuoles; G and H: after 72 weeks of treatment: hardly 
any glycogen is left in skeletal muscle and blood vessels. 
Magnifi cation: A, C, E and G: 400x; B&H: 7100x; D: 
5600x; F: 2800x
Fig.5. Differences in therapeutic 
response between patients 1 and 2.  
The left panel represents the situation 
at baseline, the right panel after 72 
weeks of treatment. All sections are 
stained with PAS. A and B are from 
patient 1, and C and D are from 
patient 2. Reduction of PAS staining 
intensity is seen in both patients, with 
concomitant improvement of muscle 
morphology in patient 1, whereas 
muscle morphology in patient 2 shows 
little improvement. Magnifi cation: 
A-D, 400x
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Clinical response to treatment
After 72 weeks of treatment, all patients had normal muscle α-glucosidase activity. The 
glycogen concentration in the muscle of patients 2, 3 and 4 had not changed signifi cantly, but 
was decreased to normal in patient 1 (unpublished results). Patient 1 also showed signifi cant 
clinical improvement. He achieved normal major milestones of motor development (rolling, 
sitting, standing and walking) as established by AIMS scores. Patient 2 initially showed some 
improvement of skeletal muscle function. She learned to move her arms and had improved 
head balance, but lost these abilities again after a series of pulmonary infections. Patient 4 
learned to sit with support, but did not reach the milestones of standing and walking. Her 
arm function improved signifi cantly. Patient 3 learned to sit without support, could move her 
legs, but could not stand. All four patients were in a better clinical condition after 72 weeks of 
treatment than they were at entry into the trial 24, 25. 
Semiquantitative rating of muscle pathology
PAS-stained muscle tissue sections were microscopically inspected and ratings were given 
for PAS-staining intensity, number and size of vacuoles and cross-striation as outlined in the 
Methods section (Table 1). 
The muscle score at inclusion was 8 for the most affected patient (patient 2) and 7 for the 
others (Table 2). The total score was 23 for patient 2 and 25 for the other three patients. 
After 12 weeks of treatment none of the patients had an improved muscle score, but the total 
score had fallen to 13-14. This was mainly due to a lower rating of the PAS-staining intensity 
of the endothelium, peripheral nerves, and smooth muscle cells of the blood vessels. After the 
following 12 weeks of treatment with 40 mg/kg, the total score was further diminished by a 
lower rating of the PAS-staining intensity of the muscle. After 72 weeks of treatment, patient 
1 had a near-normal total score. Treatment of the other three patients led to a lowering of 
the total score but their muscle score stayed the same because the diminished PAS-staining 
intensity was counterbalanced by an increase of vacuolization. 
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Table 2.     Patients scores
Patient no
Biopsy number
Item 1 2 3 4 5
PAS 1 3 3 3 2 0
2 3 3 2 1 2
3 3 3 - 2 1
4 3 3 - 3 2
Cross-striation 1 2 2 2 2 0
2 3 3 2 2 3
3 2 2 - 3 3
4 2 3 - 3 2
Vacuoles 1 2 2 3 2 1
2 2 2 3 3 3
3 2 3 - 2 3
4 2 3 - 3 3
Muscle scorea 1 7 7 8 6 1
2 8 8 7 6 8
3 7 8 - 7 7
4 7 9 - 9 7
Vessel score 1 12 5 5 4 0
2 10 5 3 0 1
3 12 4 - 0 0
4 12 5 - 3 0
Nerve score 1 6 2 0 - 0
2 5 - 0 0 0
3 6 2 - 2 0
4 6 - - 6 0
Total scoreb 1 25 14 13 10 1
2 23 13 11 6 9
3 25 14 - 8 7
4 25 14 - 18 7
a The muscle score is the sum of PAS intensity, cross striation, and vacuoles
b The total sore is the sum of  the nerve , vessel, and muscle scores
Discussion 
While treating patients with infantile Pompe’s disease with recombinant human α-glucosidase 
from rabbit milk, we had the opportunity to study the muscle pathology at various stages of 
the disease. At the start of treatment, the four patients were affected to a different degree as 
judged by clinical and histopathological fi ndings. In all cases, the glycogen storage was not 
limited to striated muscle, but was also present in peripheral nerves and blood vessel walls. 
The patient with the best baseline condition responded most favorably to the treatment in 
terms of clearance of lysosomal glycogen, improvement of tissue morphology, and overall 
physical performance. Therapeutic effects were fi rst observed in the blood vessels and the 
peripheral nerves, and only later in the skeletal muscle. The response was dose related and 
clearly depended on the stage of the disease before treatment.  
Pathology and Pathogenesis
The muscle biopsies taken at the start of treatment confi rmed the generalized nature of 
infantile Pompe’s disease. Muscle biopsy specimens fi xed and stained with routine procedures 
typically show fi bers with vacuoles of different size and shape, what is referred to as 
lace-work pattern 9, 13, 16-18. In our procedure, glycogen is preserved with a strong fi xative 
(glutaraldehyde), after which the sections are embedded in glycolmetacrylate so that the 
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extent of glycogen storage is dramatically exhibited. Before treatment, all four patients had 
severely affected skeletal muscle fi bers. However, not all muscle fi bers in the same section of 
the same patient were equally affected, and there was interpatient variation. Moreover, we 
noticed that structural damage can vary substantially along the fi ber length, as if the storage 
process spreads from discrete foci.
The biopsies taken prior to and during treatment are informative about the possible course of 
the pathogenic process, which starts in lysosomes. As the lysosomal compartment expands, it 
can be envisioned that the contractile machinery of the muscle is hampered by fi bril splitting 
resulting in diminished vectorial strength 12. Reduced lysosomal function and rupture of the 
lysosomal membrane by contractile forces will lead to an increase of the cytoplasmic glycogen 
concentration. Increased autophagy results in even more lysosomal storage and dysfunction. 
Release of lysosomal enzymes into the cytoplasm contributes to the cascade of damage.
The glycogen storage in smooth muscle cells of the arteries and veins is quite dramatic. It 
is conceivable that the integrity of the blood vessel wall is lost as the disease progresses. 
This may explain the occurrence of aneurysms in the basal arteries of patients with Pompe’s 
disease as described in some case reports 6, 15, 19. We have also seen vascular pathology in the 
knockout mouse model of Pompe’s disease 3, and storage of glycogen in smooth muscle along 
the digestive tract and in other organs with a smooth muscle component. Storage in Schwann 
cells and epineurium of peripheral nerves also was noted earlier, but is not known to have 
functional consequences 17, 18.
Therapeutic response and dosing
The vascular endothelium and the peripheral nerves are the fi rst sites where a response to 
treatment is noted. After 12 weeks of low-dose treatment (15 or 20 mg/kg), the glycogen 
had disappeared from the endothelial and Schwann cells, but it was still present in skeletal 
muscle fi bers and vascular smooth muscle cells. This is not unexpected as the endothelial cells 
are directly exposed to the circulating enzyme, whereas Schwann cells and perineurium are 
optimally supplied by the anastomosing vascular system that feeds the nerve bundles. 
We consider it likely that cell- and tissue-specifi c differences in accessibility explain in part 
the much lower dose of α-galactosidase needed for the treatment of Fabry’s disease (0.2-1 
mg/kg) 8, 20 compared to the dose needed to correct the muscle pathology in Pompe’s disease. 
In Pompe’s disease the administered α-glucosidase must pass the endothelial barrier and the 
endomysium before it reaches the muscle fi bers.
Judging from the changes in muscle morphology over time, we believe that the dose of 15-20 
mg/kg of α-glucosidase, during the fi rst 21 weeks of treatment, was insuffi cient to achieve 
correction of smooth and skeletal muscle. The higher dose of 40 mg/kg seems necessary 
because the PAS-staining intensity became less, and the vascular smooth muscle started to be 
cleared after 12 weeks of additional treatment at this dose. The skeletal muscle morphology 
of the least affected patient (patient 1) had clearly improved after 72 weeks of treatment.
The rating system that we used to evaluate the morphological changes during the course of 
treatment proved to be helpful in obtaining objective measures. The total scores and muscle 
scores correlated well with the clinical observations. 
Therapeutic mechanism and differential response
Even at the high dose of 40 mg/kg per week, not all patients responded suffi ciently well. This 
may relate to the different glycogen load and the associated muscle immobility of the patients 
prior to and during treatment. From both aspects, patient 1 had the best starting point with 
the least glycogen accumulation and the best muscle function.
The various muscle sections revealed that fi bers with solely lysosomal glycogen storage 
maintained a relatively normal sarcomeric organization and were cross-striated. It is to be 
expected that normal function is regained after clearance of lysosomal glycogen by ERT. 
Likewise, it is conceivable that massive accumulation of cytoplasmic glycogen complicates 
the repair process. An immobile volume of cytoplasmic glycogen mechanically blocks the 
intracellular/vesicular transport pathways required for lysosomal targeting of the therapeutic 
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enzyme. Moreover, when the lysosomal compartment is emptied, autophagic activity is needed 
to clear the cytoplasmic glycogen. This process requires a proper intracellular organization, 
which is completely lost at a severe stage of the disease.
Muscle movement is required for activation, proliferation, and fusion of myogenic satellite 
cells with existing muscle fi bers 11, 21, 22, 29. Patient 1 had substantial muscle strength in his legs 
at the start of treatment and he currently walks, whereas patients 2 and 4 could not move 
their legs, and their muscle function is still extremely compromised. Patient 3 could move her 
legs, but could not stand. 
Conclusion
We have shown that intravenous administration of recombinant human α-glucosidase from 
rabbit milk can improve muscle morphology in classic infantile Pompe’s disease. Preservation 
of muscle architecture and residual muscle function at start of treatment seems a prerequisite 
for the successful outcome of treatment. A high dose of enzyme is required to obtain an effect 
on skeletal muscle. 
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Abstract
Hearing defi cit occurs in several lysosomal storage disorders but has so far not been recognized 
as a symptom of Pompe’s disease (glycogen storage disease type II). We discovered quite 
unexpectedly 30-90 dB hearing loss in four infants with Pompe’s disease, who participated in 
a study on the safety and effi cacy of enzyme replacement therapy. Three other patients with 
juvenile Pompe’s disease did not have this symptom. The ABR (auditory brainstem response) 
thresholds but not the inter peak latency times were increased. This pointed to middle or 
inner ear pathology rather than to involvement of the central auditory nervous system. The 
possible occurrence of cochlear pathology was supported by the absence of oto-acoustic 
emissions. We investigated this hypothesis in a knock-out mouse model of Pompe’s disease 
and found glycogen storage in the inner and outer hair cells of the cochlea, the supporting 
cells, the stria vascularis, and the spiral ganglion cells. 
We conclude that cochlear pathology is the most likely cause of hearing loss in infantile 
Pompe’s disease and possibly a characteristic feature of this clinical subtype.
Introduction
Lysosomal storage diseases typically show a variety of histopathological features with 
associated loss of tissue specifi c functions. As lysosomal storage disorders are genetically 
determined the consequences of a lysosomal enzyme defi ciency are not confi ned to a certain 
cell type but generalized. Nevertheless each lysosomal disorder has its prominent tissue 
involvement which is in part determined by the biological compounds that are recycled in 
a particular cell type, and in part by the level at which the missing enzyme is normally 
expressed in that cell type.
Pompe’s disease (OMIM:232300) is one of the more than 40 lysosomal storage disorders 
and is characterized by lysosomal glycogen storage due to acid α-glucosidase defi ciency 
(OMIM:GAA;3.2.1.20) (Hirschhorn and Reuser, 2001). Skeletal muscle weakness is the 
most conspicuous feature and seen in all clinical subtypes independent of the degree of α-
glucosidase defi ciency (Reuser et al.,1995). Cardiac hypertrophy becomes manifest as second 
major feature only when acid α-glucosidase is totally defi cient as in the classic infantile form 
of Pompe’s disease. The original report by J.C. Pompe and the many descriptions that followed 
emphasize the generalized nature of this disease (Pompe, 1932). Involvement of muscle and 
heart is a dogma but smooth muscle, liver, spleen, endothelium, lungs, nerves, brain, and 
other tissues are affected as well (Martin et al., 1973).
Knock-out mice with Pompe’s disease demonstrate a similar broad distribution of tissue 
pathology (Bijvoet et al., 1998; Raben et al., 1998). Among the affected tissues are striated 
and smooth muscle, heart, liver, spleen, lungs, and peripheral nerves and brain. There is also 
storage in kidneys, salivary glands, cartilage and adipose tissue (Bijvoet et al., 1998; Bijvoet 
et al., 1999;). None of the case reports mentions involvement of the auditory system nor 
does any case report describe hearing loss in Pompe’s disease (Van den Hout, et al., 2003). 
Four years ago we started a study on the safety and effi cacy of enzyme replacement therapy 
in Pompe’s disease with recombinant human α-glucosidase from rabbit milk. We realized that 
progressive brain damage could occur during treatment, as the therapeutic enzyme cannot 
pass the blood brain barrier. Therefore we decided to monitor the auditory brainstem response 
(ABR) as a measure of neuronal function. 
When we investigated the four infants who were selected for our study we noticed to our 
surprise that they all had a hearing loss. The present study suggests that the hearing 
loss relates to cochlear dysfunction. Insight in the pathogenic process was obtained by 
investigating the cochlear pathology in knock-out mice with this disease. The purpose 
of our communication is to raise general awareness that hearing loss can be part of the 
symptomatology of infantile Pompe’s disease.
Hearing loss in infantile Pompe’s Disease
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Methods
Patients
Seven patients with Pompe’s disease were included in a clinical study to asses the safety and 
effi cacy of recombinant human acid α-glucosidase (rhAGLU) produced in the milk of transgenic 
rabbits (Bijvoet et al., 1999). Relevant information about these patients and their condition is 
summarized in Table 1. Four of them were affected with classic infantile Pompe’s disease (Van 
den Hout et al., 2000) and three had a milder juvenile form. The study protocol was approved 
by the institutional review board and the drug was supplied by Pharming/Genzyme LLC.
Table 1.   Hearing loss in Pompe’s disease
Patient Clinical  
subtype
Age* 
(months) 
Hearing loss (dB)
Left  Right
Type 
1 Infantile  3 50-60 ? cochlear
2 Infantile  7 60 60 cochlear
3 Infantile  2.5 60-70 40 cochlear
4 Infantile  8 30-40 30-40 cochlear
5 Juvenile 16 (years) ND ND
6 Juvenile 32 (years) ND ND
7 Juvenile 11 (years) ND ND
* age at inclusion; ND, hearing loss was not detected
Brainstem Electric Response Audiometry
Auditory brainstem responses (ABR) were measured according to conventional methods. 
Silver-silver-chloride cup electrodes were attached at the vertex, at both mastoids and at the 
forehead. Inter-electrode impedances were kept below 3 kOhm. The stimulus used was a 0.1 
ms click with alternating polarity presented by a TDH49 headphone. The threshold stimulation 
level was determined from the response pattern acquired with stimulation levels at 100 
dBnHL, lowered stepwise in 10 dB steps. The response patterns were judged and scored by 
an experienced audiologist.
Click-Evoked Oto Acoustic Emissions, cEOAE
Oto acoustic emissions are vibrations at frequencies in the acoustic spectrum. They are 
presumably generated by the outer hair cells in the cochlea. These cells contain contractile 
elements and bare some similarities to muscle cells. The cEOAE was measured with standard 
clinical equipment (ILO DPT96, Oto Dynamics, UK) according to the standard protocol. A 
repetition rate of 40 stimuli/sec and a post stimulus recording time of 20 ms were used.
Impedance Audiometry
The tympanogram was made according to standard operating procedures and shows the 
compliance of the middle ear to sound transferred to the cochlea, under variation of the 
air pressure in the outer ear canal. The tympanogram is abnormal in case of middle ear 
dysfunction. The different shapes of the abnormal tympanogram are indicative for different 
middle ear pathologies. The tympanogram was recorded with a standard clinical impedance 
meter (GSI 33, GRASON STADLER, US).
81
Hearing loss in infantile Pompe’s Disease
Pure tone Audiogram
The pure tone audiogram was made with standard equipment (OB822, Madsen, Denmark). 
Pure tone threshold levels indicate the ear’s sensitivity to sound of frequencies between 0.25 
and 8 kHz. The hearing loss is expressed in dB. The normal range is -10 to +10 dB. 
Mice
The mice used in this study are completely defi cient in acid α-glucosidase and were obtained 
by targeted disruption of exon 13 of the GAA gene. The line was crossed back for over 10 
generations in the FVB background (Bijvoet et al., 1998). The mouse model mimics the 
infantile form of Pompe’s disease both biochemically and pathologically and has generalized 
glycogen storage. Mice in different age groups were selected for ABR measurement and 
investigation of inner ear pathology. All experiments were conducted in accordance with the 
“Guiding Principles in the care and use of Laboratory animals” as approved by the animal care 
committee of the Erasmus MC Rotterdam, the Netherlands
Brainstem Electric Response Audiometry in Mice
To enable ABR measurements in alert mice, platinum electrodes were mounted in an acrylic 
pedestal and fi xed to the skull. To do so the mice were anaesthetized with a mixture of O2, 
N2O and 2% halothane. The two recording electrodes were placed in previously localized spots 
in the left and right occipital bone (Crus 2 level of the Cerebellum). The ground electrode was 
located in the frontal bone plate. The central reference electrode was fi xed between the two 
parietal bones as close to the sagital suture as possible. Both recording electrodes and the 
reference electrode were wired to a three-poled connector and fi xed to the skull by use of 
dental cement. At the time of measurement, the mice were placed in a fi xed position inside an 
insulated chamber so that sound stimuli could be presented from a constant distance (40 mm 
from the external auditory canals). Thresholds were obtained in alert mice at frequencies of 
4, 8, 16 and 32 kHz (duration 1 ms and tone pip repetition rate of 80/s) and clicks (repetition 
rate: 23 and 80/s). Responses were averaged to 500 pips of alternating polarity. Several age 
groups of mice (Table 2) were included to study the progress of hearing loss.
Histology
Mice were anaesthetized with ketamine and xylazine (25 and 5 mg/kg, respectively), and 
the systemic circulation was perfused with a physiological salt solution (saline) to expel the 
circulating blood. The brain was taken out with forceps, the temporal bones were removed 
from the skull and the bony labyrinth was separated from the middle ear along a suture line 
(Bohne and Harding, 1997). Specimens were fi xed in glutaraldehyde and paraformaldehyde 
in a concentration of 1% and 4%, respectively, dehydrated in a graded series of alcohol and 
embedded in Durcupan (Fluka) or paraffi n. The unstained total cochlea’s were contrasted 
with OsO4 before dehydration and embedding in Durcupan, or decalcifi ed using EDTA before 
dehydration and embedding in paraffi n. Periodic acid Schiff (PAS) staining was used to 
visualize lysosomal glycogen storage in light microscopy. For electron microscopy (EM), the 
ultrathin sections were contrasted with uranylacetate and lead citrate (De Bruijn and Den 
Beejen, 1975)
Results
Patients at baseline and during treatment
Seven patients with Pompe’s disease were enrolled in a study on the safety and effi cacy of 
Enzyme Replacement Therapy (ERT) with recombinant human acid α-glucosidase from rabbit 
milk. Four of these patients had the classic infantile form of Pompe’s disease and three the 
late onset juvenile form (Table 1). All seven patients received weekly enzyme infusions and 
underwent diagnostic tests before and during treatment.
Brainstem audiometry (ABR) was included in the clinical protocol as one of the tools to monitor 
Central Nervous System (CNS) involvement in the infants with classic Pompe’s disease. The 
fi rst ABR measurement was performed in the week before the fi rst enzyme infusion and 
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revealed a hearing loss of 50-60 dB for patient 1. Patients 2, 3 and 4, who entered the study 
later, also had a severe hearing loss (in the range of 30-60 dB) before they were treated and 
this remained so during the course of treatment (Fig. 1).
FIG. 1.   ABR response thresholds during treatment
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Figure 1 shows the ABR’s of patient 4 at decreasing stimulation level (vertically ordered) and 
the calculated latency times compared to normal subjects. For both ears, peaks I, III and V 
were recordable above 50 dB but not below. Other than the raise in response threshold, the 
four infants had close to normal nerve conduction patterns. For patient 1, the interval between 
peaks I and V was initially somewhat longer than normal (0.1-0.2 msec) but became normal 
for age during follow up. In all four cases we concluded that the brainstem and auditory nerve 
were not affected, but that the problem was located in the cochlea or middle ear.
 
After the start of therapy additional investigations were undertaken to trace the cause of 
hearing loss. Informative oto-acoustic emission recordings were obtained for two of the four 
patients and showed dysfunction of the cochlea. Alarmed by the unexpected hearing loss of 
the infants we also subjected three juvenile patients to pure tone audiometric tests within six 
months after they entered the study. Although they were in different stages of the disease, 
none of them had complaints of hearing loss, and normal threshold levels were found. 
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Fig. 2. ABR recordings in infants with Pompe’s disease.
The upper panels show the ABR recordings of the right and left ear with peaks I-V at different dB levels. The latency times 
of the peaks I, III and V are plotted in the lower two panels. The dark curves, with 95% confi dence intervals in gray, present 
the normal latency times at different sound levels. 
ABR in mice
We hoped to fi nd further clues as to the cause of hearing loss in infantile Pompe’s disease by 
studying the auditory function and the cochlear morphology in the knock-out mouse model of 
Pompe’s disease. The mice were also subjected to ABR measurements (Table 2). In contrast 
to what we observed in the infants, the hearing function of the knock-out compared to the 
wild type mice was not signifi cantly different. This accounted for all tested frequencies and 
for mice in different age groups. Some hearing loss was seen with increasing age but was not 
disease related (Fig. 3).
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                   Table 2.
Age 
(months) 
Wild-type  
(number) 
Knock-out
(number) 
10 4
12 4
14 0
16 2
18
4
3
2
2
2 2
Cochlear pathology in KO mice
We dissected the cochlea from the mastoid bone for histological examination. The unstained 
cochlear transversal section in Fig. 4A was derived from a wild-type mouse and shows the 
ordered arrangement of cochlear structures. The asterix marks the tunnel of Corti with the 
outer hair cell region above and the inner hair cell region with irradiating sensory nerves 
below. The knock out mice (Fig. 4C) showed granular deposits (arrow heads) in the outer hair 
cell region that were not seen in wild-type mice (Fig. 4B).
The stained microscopical sections (Fig. 5 A - D) showed PAS positive inclusions in not only 
the inner and outer haircells (IHC’s - OHC’s) but also in the support cells, as there are Deiter 
and Pillar cells. The architecture of the organ of Corti was impaired in some cases. The cubic 
epithelial cells of the stria vascularis and the endothelial cells of the numerous capillaries also 
showed marked accumulation of glycogen in knock-out mice.   
A third prominent site of glycogen storage was the spiral ganglion (Fig. 6). The majority of 
neurons had numerous PAS positive inclusions of various sizes (Fig. 6B) which occupied a 
substantial part of the perikaryon (Fig. 6D).
Fig. 3. Threshold levels in ABR 
recordings of wild type and 
knockout mice in two different 
age groups. Panels A and C are 
recordings of wildtype mice at the 
age of 10 (A) and 18 (C) months. 
Panels B and D are the recordings 
of knock-out mice of the same age 
(panel B, 10 months old and panel 
D, 18 months old).
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Fig. 4. Unstained sections of the cochlea 
of the wild-type (A and B) and knock-
out mice (C).
The arrow heads mark the location of the 
granular deposits in the knock-out mice. 
The asterix marks the location of the 
tunnel of Corti.
A
B
C
Fig. 5.  Sections of the inner ear showing the cochlea 
(A) and magnifi cations of the organ of Corti (B, C, D). 
All sections are stained with PAS. Sections A, B and C are 
embedded in paraffi n, and D in Durcupan. Sections A and B 
are from wild type mice, sections C and D are from knockout 
mice. The position of the outer hair cells (OHC), the inner hair 
cells (IHC), and the tectorial membrane (TM) are indicated.
Fig. 6. Sections of the Spiral ganglion of wild-type (A 
and C) and knock-out ( B and D) mice.
A and B are Durcupan embedded and PAS stained sections. 
Panels C and D are electron micrographs.
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Discussion
Hearing loss in Pompe’s Disease
Hearing-loss occurs in several lysosomal storage disorders (Hayes et al., 1980; Brown et al., 
1981; Lacey and Terplan, 1984; Peck, 1984; Morgan et al., 1990; d’Azzo et al., 2001; Thomas, 
2001) and has different causes. The conductive hearing loss in the Mucopolysaccharide 
storage diseases results from ossicles articular alterations and occurs in this group of diseases 
together with sensorineural hearing loss (Peck, 1984;  Hayes et al., 1980). The sensorineural 
hearing loss in α-mannosidosis (Thomas, 2001), metachromatic leucodystrophy (Brown et 
al., 1981), Fabry’s disease (Morgan et al., 1990), Galactosialidosis (d’Azzo et al., 2001), and 
Gauchers disease type 2 (Lacey and Terplan, 1984) relates to a combination of cochlear and 
central nervous system dysfunction. 
The hearing defi cit that we serendipitously discovered in four infants with classic infantile 
Pompe’s disease is of cochlear nature as demonstrated by the normal nerve conduction 
patterns and normal inter-peak latency times combined with the disappearance of peak I in 
the lower dB levels of stimulation. It is surprising that this symptom was not reported earlier. 
It may have been missed because the medical attention is drawn to the cardio-pulmonary 
complications that lead to death in the fi rst year of life, before adequate speech develops. 
Hearing defi cits seem not to be present in patients with the milder forms of Pompe’s disease 
who survive longer. The three patients with juvenile Pompe’s disease that took part in our 
study had an uneventful history of speech and language development which is incompatible 
with an existing hearing defi cit. Moreover, their hearing ability was found normal, and a recent 
survey among 54 patients with late-onset Pompe’s disease showed that the frequency of 
hearing defi cit in this group of patients was the same as in the general population.
Sensorineural hearing loss in infantile Pompe’s disease could have been anticipated 
considering the well documented glycogen storage in brain and other parts of the central 
nervous system (Martin et al., 1973). For instance, nuclei of the brain-stem, as well as the 
neurones of the spinal ganglia and the anterior horn contain lysosomal glycogen deposits. 
Balloon shaped neurones were also seen in the thalamic nuclei. The cortical neurones showed 
minimal glycogen storage and normal myelination (Martin et al., 1973). 
Based on the normal nerve conduction patterns combined with the normal development of 
the cognitive functions of the infants in our study we conclude that the CNS storage does not 
aggravate to a level that it interferes with function. Our best performing patient on enzyme 
therapy is at present 4 years old and has reached normal developmental milestones. The 
other patients did not show any signs of central nervous system involvement either. It is 
important to continue monitoring the CNS function of patients receiving life prolonging 
enzyme replacement therapy, because the therapeutic enzyme does not pass the blood 
brain barrier. As the hearing loss of the patients did not improve during treatment we have 
prescribed hearing devices as supportive communication tool.
The cause of hearing loss
The cause of hearing loss in infants with Pompe’s disease remains uncertain by lack of means 
to investigate the inner ear pathology. In other lysosomal storage disorders, such as MPS VII, 
knock-out mice were shown to have the same type of inner ear pathology as patients. If such 
similarity holds for Pompe’s disease there is a strong suggestion from the mouse model that 
the cochlear dysfunction is related to storage of glycogen in the cells forming the organ of 
Corti. Both the inner and outer hair cells as well as the supporting cells were clearly affected. 
Not only did they have PAS positive inclusions but they had also lost their ordered array. A 
similar but more severe pathology in humans can explain the loss of oto-acoustic emissions. 
Glycogen storage in the spiral ganglia may add to the increased response threshold in the 
ABR measurements. Considering the pathologic changes in the cochlea of knock-out mice it 
is surprising that the mice did not have a recordable hearing defi cit. It is known however that 
knock-out mice develop symptoms at a later age than infants with Pompe’s disease, and that 
hearing defi cit in mice can be masked by the age related hearing loss.
When comparing our observations in mice and infants it is evident that inner ear pathology 
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can lead to hearing loss in the classic infantile form of Pompe’ s disease and may even be a 
typical feature. We therefore recommend regular evaluation of the auditory function and early 
implementation of hearing support and speech or sign-language lessons for infants receiving 
enzyme replacement therapy.
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Summary 
The introduction of enzyme replacement therapy for the treatment of lysosomal storage 
diseases is vividly pursued. Utilization of the mannose receptor for enzyme targeting was the 
key to the fi rst successful application of this therapy in Gaucher’s disease type I. The mannose 
6-phosphate receptor is seen as suitable tool for enzyme targeting in several other lysosomal 
storage disorders, as it is exposed on the surface of many cell types. We investigated the role 
of mannose 6-phosphate receptor mediated endocytosis in enzyme replacement therapy for 
Pompe’s disease. The uptake of phosphorylated, non-phosphorylated and de-phosphorylated 
forms of acid α-glucosidase was studied in vitro and in vivo using a knock-out mouse model 
of Pompe’s disease.
Our data demonstrate that the mannose 6-phosphate recognition marker has a great impact 
on the uptake of acid α-glucosidase by cultured fi broblasts but less so on the uptake by heart 
and skeletal muscle, the target organs in Pompe’s disease. The half-life of acid α-glucosidase 
in liver, heart and skeletal muscle was, 9, 4.7, and 3.3 days, respectively. Our fi ndings are 
discussed in relation to the ongoing studies of safety and effi cacy of enzyme replacement 
therapy for Pompe’s disease and indicate what the optimal dosing regimen could be for 
infantile, juvenile and adult patients.
Introduction
The mannose 6-phosphate (M6P) receptor was discovered through its role in the binding 
and internalization of lysosomal enzymes by cultured fi broblasts. Low and high uptake forms 
of these enzymes had been identifi ed and shown to have a different number of exposed 
M6P groups (free-M6P) (1-5). Later, the M6P receptor was recognized for its function in the 
intracellular targeting of lysosomal proteins (6-8). At that time, enzyme replacement therapy 
(ERT) for the treatment of lysosomal storage disorders had already been investigated for 
more than 10 years without decisive success (9) and the focus was shifted towards bone 
marrow transplantation as therapeutic approach (10). The clinical application of receptor 
mediated enzyme replacement therapy awaited the development of procedures for large-
scale production of native and recombinant human lysosomal enzymes. The fi rst success 
was obtained with glucocerebrosidase for the treatment of Gaucher’s disease type I (11). 
The enzyme was initially obtained from human placental tissue, and is presently produced 
in genetically engineered chinese hamster ovary cells (CHO). In both cases it is modifi ed to 
expose mannose residues in order to bind to the mannose receptors of the glycolipid-storing 
macrophages. At present enzyme replacement therapy is approved for two lysosomal storage 
disorders, and clinical studies in four others are in progress (12-17).
We investigated the benefi t of M6P receptor mediated endocytosis for enzyme replacement 
therapy in Pompe’s disease, one of the more than 40 lysosomal storage disorders. A defi ciency 
of acid α-glucosidase in this condition results in lysosomal accumulation of glycogen, affecting 
primarily the skeletal muscle function (18,19). Cultured fi broblasts and muscle cells from 
patients were corrected with M6P containing acid α-glucosidases from bovine testis and 
human urine, and with recombinant human isoforms from genetically engineered mammalian 
cells and mouse milk (20-26). In vivo studies were performed as well and showed that the 
uptake of phosphorylated bovine testis acid α-glucosidase in muscle and heart of normal 
mice was twice as effi cient as the uptake of non-phosphorylated human placental acid α-
glucosidase (27). The acid α-glucosidase from mouse milk manifested, both in vitro and in 
vivo, the same uptake characteristics as the phosphorylated acid α-glucosidases from bovine 
testis and human urine, and the recombinant acid α-glucosidases from genetically engineered 
CHO and BHK cells. Alternative studies were performed in quail with Pompe’s disease whereby 
recombinant human acid α-glucosidase from CHO cells was used (28).
A second-generation recombinant product, meant to be used for enzyme replacement 
therapy in humans, was successfully produced in transgenic rabbits. Repeated doses of this 
product led to correction of the lysosomal glycogen storage in almost all tissues of KO mice 
(29), although in vitro experiments indicated that the free-M6P content of this rabbit milk 
product was low (A.J.J.R. unpublished data). After completion of a phase 1 safety study in 
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healthy volunteers, we started phase 2 studies with recombinant human acid α-glucosidase 
from rabbit milk in infants and adults with Pompe’s disease. The clinical responses were very 
promising (12,30). 
In another study, at Duke University NC, three infants received recombinant human acid α-
glucosidase from genetically engineered CHO cells, and speculative conclusions were drawn 
on the effi cacy of the one product compared with the other (31). As we found it diffi cult to 
compare the results of both clinical studies, we decided to investigate the role of the M6P 
receptor system for the targeting of acid α-glucosidase to heart and skeletal muscle in greater 
depth. The present study compares the molecular characteristics and the uptake properties 
of phosphorylated, non-phosphorylated and de-phosphorylated forms of acid α-glucosidase 
in vitro and in vivo.
Experimental procedures
Enzymes
Native forms of acid α-glucosidase were purifi ed from bovine testis and human placenta 
according to previously described procedures (32). The enzyme from bovine testis (bAGLU, 
70 kD) contains free-M6P residues and is taken up by human fi broblasts and muscle cells in 
a M6P receptor-dependent manner (high uptake) (21). The human homologue purifi ed from 
placenta (pAGLU) is a mixture of 70 and 76 kD isoforms, contains high mannose carbohydrate 
side chains but lacks the M6P recognition marker (low uptake) (21,33). Recombinant human 
acid α-glucosidases were produced in genetically engineered CHO cells (cAGLU) and in the 
milk of transgenic mice (mAGLU) and rabbits (rhAGLU) (23,25). The fi nal products were 
concentrated and dialyzed by centrifugation (Amicon, Centricon YM-3, Milipore USA) against 
phosphate buffered saline (PBS) (GIBCO™ Invitrogen corp. UK) and sterilized by passage 
through a 0.2 µm syringe fi lter. Recombinant human forms of acid α-glucosidase are currently 
produced in CHO cells and transgenic rabbits by Genzyme/Pharming LLC and tested for their 
safety and effi cacy in ERT for Pompe’s disease (12,31)(table 1).
Table 1   Properties of acid α-glucosidases
Source Symbol Mol. Mass (kD) Specifi c activity
(nmol/mg/hr)
*M6P receptor
dependent uptake 
Human placenta pAGLU 76-70 280 -       (a)
Bovine testis bAGLU 70 230 +++  (a) 
CHO cells cAGLU 110 297 +++  (a) 
Rabbit milk rhAGLU 110 233 +      (a) 
Mouse milk mAGLU 110 269 +++  (b) 
* degree of phosphorylation is a relative measure based on the data in Fig.1 (a) and ref. 25 (b)
De-phosphorylation
De-phosphorylation of acid α-glucosidase was performed with acid phosphatase from sweet 
potato (Sigma, St Louis MO USA) in a dialysis tubing for 16 hours at 37oC, and pH 5.2 (0.2 
M sodium acetate). Samples without acid phosphatase were incubated in parallel. Uptake of 
phosphorylated acid α-glucosidase species by cultured fi broblasts was inhibited with 5 mM 
M6P  (Sigma, St Louis MO, USA).
Biochemistry
Liver, heart, and quadriceps muscle were homogenized in PBS in a concentration of 100 
mg wet weight per ml by using an ultra turax (Pro 200, Pro Scientifi c inc. Monroe CT USA). 
Homogenates were subsequently sonicated and debris was removed by centrifugation at 
10,000 g for 15 min. Lysates were stored at -80oC until use. The acid α-glucosidase activity 
was measured with 4-methylumbelliferyl-α-D-glucopyranoside at pH 4.0, and the protein 
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concentration of the samples with the BCA protein assay (Pierce, Rockford, USA).
SDS-PAGE and Western Blotting
Rabbit anti human acid α-glucosidase antibodies coupled to protein A sepharose beads were 
used to immunoprecipitate acid α-glucosidase from the tissue lysates. The immune-complexes 
were applied to 10% SDS-PAGE (34). The proteins were blotted on to nitrocellulose fi lters, 
and acid α-glucosidase was visualized with mouse anti human acid α-glucosidase antibodies 
using the ECL detection kit (Amersham Pharmacia Biotech, Benelux).
Immunocytochemistry
Acid α-glucosidase was localized in paraffi n embedded sections of liver, heart, and quadriceps 
muscle. All sections (5 µm) were deparafi nised in xyleen and a graded series of alcohol, and 
heated in a microwave for 13 minutes (750W). The endogenous peroxidase activity was 
blocked with 2 ml 2% H2O2 and 1 ml azide dissolved in 100 ml PBS, and the sections were 
washed consecutively in PBS (2 min) and PBS with Protifar (5 mg/L) plus glycine (1.5 mg/L). 
Rabbit anti acid α-glucosidase IgG antibodies were used as primary antibody in a dilution of 
1:120 and 1:40. A conjugate of swine anti rabbit antibodies and peroxidase was used for 
detection. Slides were stained with DAB-substrate (DAKO, Danmark) washed in water and 
counterstained with Meyers haematoxylin solution for 5 min. The staining procedure was 
completed by rinsing with tap water and dehydration in alcohol (90% and 100%) followed by 
xyleen.
Cell culture
Acid α-glucosidase defi cient fi broblasts were cultured in Dulbecco’s modifi ed Eagle medium 
supplemented with 10% fetal calf serum and antibiotics, in an atmosphere of 10% CO2 
and 90% air. Uptake studies were performed in 24 well tissue culture plates with confl uent 
cells. 3 mM PIPES was added to the medium to lower the pH to 6.8 and stabilize acid α-
glucosidase. The enzyme was added to the medium in a concentration equivalent to 1 µmole 
4-methylumbelliferone formed per hr using 4-methylumbelliferyl-α-D-glucopyranoside in 0.2 
mM sodium acetate pH 4.0 as artifi cial substrate. The cells were harvested after 24 hrs. 
Mice
The acid α-glucosidase defi cient knockout mice (KO) used in this study were obtained by 
targeted disruption of the acid α-glucosidase gene in embryonic stem cells as previously 
described (35). Mice were crossed back for 10 generations to the FVB background. All 
animals in one experiment were of the same gender. Mice received a single dose of enzyme 
via the tail vein. Injection volumes were between 100 and 200 µl, with acid α-glucosidase 
concentrations varying from 1-10 mg/ml. At pre-set time points, the mice were anaesthetized 
with Ketamine/Xylazine in standard dose (Dopharma, Raamsdonksveer the Netherlands/Ceva 
Sante Animale B.V., Maasluis the Netherlands), the circulation was fl ushed with PBS and the 
organs were isolated. Aliquots of tissue were snap frozen in liquid nitrogen for biochemical 
analysis and small pieces were fi xed in paraformaldehyde (4%) for immunocytochemistry. In 
comparative dose fi nding studies, the mice were sacrifi ced either 24 or 48 hrs after enzyme 
administration. In the studies on the half-lives of ingested enzyme, groups of mice were 
sacrifi ced on day 1-9 post treatment. 
Results
Molecular characteristics of the acid α-glucosidases
Four forms of acid α-glucosidase with different molecular properties were compared for 
uptake by cultured fi broblasts and tissues of acid α-glucosidase defi cient knock-out mice. 
The molecular characteristics of these forms are summarized in Table 1. Three of the four 
human acid α-glucosidases were produced with recombinant DNA technology in CHO cells 
(cAGLU) and in milk of transgenic rabbits (rhAGLU) and mice (mAGLU). These are acid α-
glucosidase precursors with a molecular mass of 110kD. The fourth human acid α-glucosidase 
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was extracted from human placenta (pAGLU) and constitutes a mixture of 76 kD and 70 kD 
mature enzyme species. The fi fth form of acid α-glucosidase was extracted from bovine testis 
(bAGLU), known as a source of M6P rich lysosomal enzymes, and has a molecular mass of 70 
kD. The molecular properties of mAGLU were published previously (25). 
In vitro uptake of acid α-glucosidases
Fig. 1 illustrates that cAGLU and bAGLU were taken up by acid α-glucosidase defi cient 
fi broblasts in a M6P receptor-dependent manner. The uptake of rhAGLU from rabbit milk was 
less effi cient, but similarly mediated by the M6P receptor. Uptake of the non-phosphorylated 
human placental acid α-glucosidase was barely detectable. These results confi rmed our 
previous conclusions about the free-M6P content of bAGLU, cAGLU and pAGLU, but were 
unexpected for rhAGLU from rabbit milk, as acid α-glucosidase from transgenic mouse milk 
was taken up in a M6P receptor-dependent manner by fi broblasts, equally effi cient as bAGLU 
and cAGLU (25).
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Fig. 1. Uptake of acid α-glucosidases by human fi broblasts. Acid α-glucosidases were added to cultures of acid α-
glucosidase defi cient fi broblasts in a dose equivalent to 1 µmol 4MU/hr/ml in the absence (solid symbols) or presence (open 
symbols) of 5 mM M6P. The intracellular activity was measured in duplicate 24 hrs later and is expressed in nmol MU/mg/hr. 
The acid α-glucosidase activity of normal fi broblasts ranges from 40 -160 nmol MU/mg/hr.
In vivo uptake of acid α-glucosidases
We subsequently investigated the role of the M6P recognition signal for targeting of acid α-
glucosidases to tissues of enzyme defi cient knock-out mice. In each series of experiments, 
the mice were sacrifi ced 24 hours after a single intravenous injection via the tail vein. Fig. 
2 (series A) shows the dose dependent uptake of rhAGLU in liver, heart, and muscle. The 
comparison of rhAGLU, bAGLU, and pAGLU in Fig. 2 (series B) shows for each enzyme the 
same dose dependent uptake, without obvious saturation in the range from 10 to 80 mg/kg. 
The dose of 10-20 mg/kg was already suffi cient to obtain normal activity levels in the liver 
with enzyme from all sources, but 20-40 mg/kg was required to fully correct the defi ciency in 
heart, and 40 mg/kg for correction of skeletal muscle. Notably, the uptake of M6P containing 
bAGLU was not better than the uptake of rhAGLU having a substantially lower free-M6P 
content.
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Fig. 2. Dose dependent uptake of acid α-glucosidases in vivo. 
Mice received a single dose of acid α-glucosidase from different sources. The mice were sacrifi ced 24 hrs later, and the acid 
α-glucosidase activity was measured in liver, heart, and skeletal muscle. Series A shows the dose dependent uptake of 
rhAGLU and series B compares the uptake of rhAGLU (black), bAGLU (hatched) and cAGLU (grey).
To further investigate the role of the M6P receptor for in vivo enzyme targeting we 
compared high and low uptake forms of the same acid α-glucosidase species by removing 
the phosphate groups from bAGLU with acid phosphatase. The phosphatase treatment 
of bAGLU reduced its uptake by fi broblasts to the level of rhAGLU (Table 2). The residual 
uptake was inhibited by M6P (5mM) to the same extent as the uptake of rhAGLU, indicating 
that some of the M6P groups were resistant to the acid phosphatase treatment. 
Table 2.  Effect of de-phosphorylation on uptake in vitro
Enzyme Treatment* intra cellular activity (nmol MU/mg/hr)
- M6P + M6P
bAGLU - 112.41 1.55
bAGLU + 12.76 1.16
rhAGLU - 13.63 1.15
 
 * (+) is treated with acid phosphatase
When this de-phosphorylated bAGLU was administered to knock-out mice, in a dose of 40 
mg/kg, the acid α-glucosidases activity in the liver increased from 0.02 to 2.4 times the wild 
type activity (Fig. 3). Similar levels were reached with the phosphorylated acid α-glucosidases 
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from bovine testes (bAGLU) and CHO cells (cAGLU), and the rhAGLU from transgenic rabbit 
milk despite its substantially lower content of free-M6P. For uptake in heart and muscle, 
the importance of the M6P recognition marker was not evident either. Approximately three 
times the normal activity level was reached in heart and 1.5 to 2 times the normal activity in 
muscle for the different enzymes that were used (Fig. 3). The de-phosphorylation procedure 
was repeated with an injection dose of 10 mg/kg and gave very similar results. We obtained 
correction of enzyme defi ciency in liver, heart and skeletal muscle independent of the enzyme 
source or phosphorylation status (results not shown).
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Fig. 3. Uptake of phosphorylated and dephosphoryated acid α-glucosidases in vivo.
Knock-out mice received a single dose (40 mg/kg) of acid α-glucosidase from different sources and different degrees of 
phosphorylation (bAGLU- stands for acid phosphatase treated bAGLU). The α-glucosidase activity was measured 24 hrs later 
in liver, heart, and skeletal muscle. Each mouse is plotted individually.
In a following series of experiments we studied the intracellular localization of rhAGLU and 
cAGLU in liver and heart, and the localization of phosphorylated versus de-phosphorylated 
versions of these isozymes in the muscle with immunocytochemical methods. Like in previous 
experiments, the acid phosphatase treatment abolished the uptake of both enzymes by acid 
α-glucosidases defi cient fi broblasts, but had no differential effect on the uptake in vivo. 
At the cellular level we observed that the phosphorylated cAGLU targeted to both Kupffer cells 
and hepatocytes whereas rhAGLU localized mainly to Kupffer cells and less so to hepatocytes 
(Fig. 4, upper panels). By contrast, cAGLU and rhAGLU had a very similar distribution in 
the heart (Fig. 4, lower panels) despite their different free-M6P content. The membrane 
boundaries of vacuoles inside the cardiomyocytes were stained as sign of lysosomal targeting. 
However, the most outspoken labelling was found in the interstitium closely associated with 
the cardiomyocytes, and in the endothelial cells lining the blood vessels.
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Fig. 4. Immunocytochemical localisation of acid α-glucosidase in liver and heart.
The upper four panels show the DAB stained liver sections of KO mice injected with 40 mg/kg rhAGLU (A) and cAGLU (C). 
Panels B and D show untreated sections of knock-out and wild type animals. The lower four panels show sections of the 
heart in the same order.
The localization in muscle was diffi cult to interpret (Fig. 5). Strong labeling was seen at 
the periphery of the muscle fi bers independent of the enzyme source. We were unable to 
localize the endogenous acid α-glucosidase of wild type mice possibly due to the low acid 
α-glucosidase content of the muscle and the poor specifi city of the antibodies for the mouse 
isozyme. Further, we noticed very strong labeling of foci with infl ammatory cells (not shown), 
which will contribute to the increase of activity in muscle.
The immuno-blot in Fig. 6 illustrates that only processed forms of rhAGLU and cAGLU were 
present in the tissues (approximately 76 kD), whereas these enzymes were administered as 
110 kD precursors. The 70 kD bAGLU, either phosphorylated or dephosphorylated, remained 
unchanged after uptake in the tissues.
Liver
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Fig. 5. Immunocytochemical localisation of phosphorylated and de-phosphorylated forms of acid α-glucosidase 
in skeletal muscle. 
The upper four panels show the DAB stained skeletal muscle sections of knock-out mice injected with 100 mg/kg rhAGLU 
(A, phosphorylated and B, de-phosphorylated), and cAGLU (C, phosphorylated and D, de-phosphorylated). The bottom two 
panels show sections of knock-out (E) and wild type animals (F).
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Fig. 6. Western blot analysis of α-glucosidase species in tissues of knock-out mice after enzyme administration.
The blots were stained with anti α-glucosidase antibodies as described in the materials and method section. Panel A shows 
the molecular mass of bAGLU (70 kD), rhAGLU and cAGLU (both 110 kD). Panels B and C demonstrate the uptake of these 
enzymes by heart, liver and skeletal muscle. bAGLU, rhAGLU and cAGLU were found in all three organs. rhAGLU and cAGLU 
were converted to 76 kD mature enzymes. The phosphorylated and de-phosphorylated (bAGLU--) forms of bAGLU were 
present in equal amounts.
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The tissue half-lives of acid α-glucosidases
rhAGLU and cAGLU are currently used in clinical studies on the safety and effi cacy of enzyme 
replacement therapy in Pompe’s disease. To optimize the dosing regimen, we determined 
the in vivo half-lives of these two forms of acid α-glucosidase in liver, heart, and skeletal 
muscle. The mice received a single dose of 100 mg/kg and were sacrifi ced group wise over 
a period of 9 days to measure the acid α-glucosidase activity in the target organs. The half-
lives, calculated on the basis of a non-compartment model, were very similar for both forms 
of recombinant human acid α-glucosidase (9, 4.7, and 3.3 days for, liver, heart, and skeletal 
muscle, respectively). 
Discussion
The fi rst successful trial of enzyme replacement therapy was based on the perception that 
the mannose receptor could be used for delivery of glucocerebrosidase to the Gaucher 
cells (36,37). The large volume of enzyme needed for therapeutic application in Gauchers 
disease type I was initially extracted from human placentas and later produced in genetically 
engineered CHO cells (16,38,39). The glucocerebrosidase from both sources is subjected 
to treatment with exo-glycosidases to expose mannose residues that function as targeting 
signal. 
When we started to develop ERT for Pompe’s disease we focused our efforts on the M6P 
receptor to facilitate uptake of acid α-glucosidase by muscle and heart (27,40). The potential 
of this approach was demonstrated in vitro by the clearance of lysosomal glycogen from 
cultured fi broblasts and muscle cells (21,41,42). In vivo experiments also pointed to the 
importance of the M6P recognition signal for enzyme targeting (27). As the M6P receptor is 
constitutively expressed on the surface of many cell types it is believed to be a suitable target 
for enzyme replacement therapy in lysosomal storage diseases (43,44). Production wise, it 
is convenient that most lysosomal enzymes produced in mammalian cell lines are at least to 
some degree equipped with phosphorylated mannose residues. There are to our knowledge 
no specifi c measures being taken to enrich the M6P content of the lysosomal enzymes that 
are currently used for enzyme replacement therapies (12-17).
Clinical trials were started with enzymes from different sources while little or no information 
was published on the precise carbohydrate structures of the therapeutic enzymes. Clinical 
responses were reported in all instances, in the case of Pompe’s disease with recombinant 
human acid α-glucosidases from both rabbit milk and CHO cells (12,30,31). We have observed 
improvement of cardiac parameters, skeletal muscle morphology and skeletal muscle function 
in a phase II study on the safety and effi cacy of recombinant human α-glucosidase from rabbit 
milk, as predicted by the outcome of pre-clinical studies in mice (29). 
Our experiments show an unexpected difference in M6P receptor dependent in vitro uptake 
of rhAGLU (from rabbit milk) and mAGLU (from mouse milk). Apparently, the enzyme from 
mouse milk has more free-M6P. It is known that two enzymes, GlcNAc-phosphotransferase 
and phosphodiesterase, are involved in the phosphorylation process of lysosomal enzymes. 
It could either be that the activity of the GlcNAc-phosphotransferase is higher in mice than in 
rabbits or alternatively that the activity of phosphodiesterase is lower in rabbits than in mice. 
In the later case the M6P groups of rhAGLU can be blocked by terminal N-acetyl-glucosamine. 
Surprisingly, the same levels of corrective activity were reached in liver, heart and skeletal 
muscle, with phosphorylated, dephosphorylated and non-phosphorylated forms of acid α-
glucosidase, as if the free-M6P content does not play a major role in the uptake of the enzyme 
in vivo. If the M6P groups are blocked by N-acetyl-glucosamine they are possibly exposed by 
the action of phosphodiesterase known to cycle between the trans Golgi network (TGN) and 
the plasma membrane (45).
An effect of phosphorylation was seen in liver where the phosphorylated forms of acid α-
glucosidase were distributed over hepatocytes, Kupffer cells and endothelial cells, whereas 
rhAGLU localized almost exclusively to the Kupffer and endothelial cells. A similar differential 
distribution was reported for phosphorylated versus non-phosphorylated forms of β-
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glucuronidase, and is obviously related to the presence of M6P receptors and the absence of 
mannose receptors on the hepatocytes (46).
In heart and skeletal muscle most of the administered acid α-glucosidase was localized at the 
cellular periphery, irrespective of the degree of phosphorylation and direct proof of lysosomal 
localization was not obtained. On the other hand, the presence of mature forms of acid α-
glucosidase in the tissues indicates that the enzyme resides probably intra-lysosomal (47,48). 
The best proof of internalization of rhAGLU by the lysosomal system of skeletal muscle fi bers 
is the disappearance of lysosomal glycogen storage in knockout mice and in patients with 
Pompe’s disease receiving ERT (12,29).
In contrast to what we observed for acid α-glucosidase, the M6P content of β-glucuronidase is 
important for uptake by muscle and heart (46). However, the experimental setting was slightly 
different. In our experiments we isolated the tissues 24 hours after enzyme administration, 
whereas the uptake of β-glucuronidase was measured 5 hrs after the infusion. When the 
phosphorylated and non-phosphorylated isozymes have different pharmacokinetic profi les, 
the time of sampling may make the difference. The age of the mice may also play a role as 
the number of M6P receptors declines from the early embryonic stage till adulthood. 
Based on our present results, it cannot be decided which form of acid α-glucosidase is the 
most desirable for the treatment of Pompe’s disease. In practice, clinical responses have 
been reported with enzymes from rabbit milk as well as CHO cells (12,30,31). The clinical 
studies continue and time will tell which dose of each enzyme is needed to obtain the best 
clinical response. Our dose fi nding studies reveal the very simple rule of higher uptake at 
higher dose. The correlation between dose and increase of acid α-glucosidase activity is close 
to linear for liver, heart and skeletal muscle. All acid α-glucosidases gave the same dose-
response curve despite their different degrees of phosphorylation and maturation. It seems 
that the preference for uptake of enzyme by liver, heart, and skeletal muscle -in decreasing 
order- is only in part determined by the cell types and the cell surface receptors. We think 
that differences in the micro-vascularization and the permeability of the endothelial barrier 
play an equally important role in enzyme distribution. The blood brain barrier is a well-known 
problem for the correction of lysosomal pathology in the central nervous system. By contrast, 
the endothelial lining of the blood sinusoids in the liver is fenestrated and fully permeable 
even to protein-lipid complexes as large as 150 nm. As a consequence, the hepatocytes are 
in direct contact with the therapeutic enzyme. The Kupffer cells reside in the sinusoidal spaces 
and are directly immersed in the bloodstream. The heart is extremely well perfused by the 
coronary system. The physiologic network of cardiomyocytes is embedded in the immediately 
surrounding connective tissue harboring the multitude of capillaries that continuously supply 
oxygen and nutrients to the heart. By contrast, skeletal muscle tissue consists of fi bers that 
have arisen by myoblast fusion and occupy a relatively large space in comparison to the 
connective tissue in which they are embedded. The micro-vascularisation is less extensive 
than in heart. Thus, from a histological perspective it is quite understandable that much 
higher dosing is required for correction of the muscle pathology in Pompe’s disease than for 
solving the reticulo-endothelial and endothelial cell related problems in Gaucher’s and Fabry’s 
disease, or the hepatic storage of mucopolysaccharides in Hurler-Scheie syndrome (49). The 
histologic differences between the target tissues in the various lysosomal storage diseases 
cannot be overcome solely by sophisticated design of the carbohydrate composition of the 
therapeutic enzymes.  
As the height of the dose is important to obtain uptake of acid α-glucosidase in muscle and 
to elicit a clinical response so is the dosing regimen. Patients with the adult form of Pompe’s 
disease have up to 25 % residual activity. This implies that an activity of more than 25 % 
must be reached to prevent or reverse glycogen storage. This reasoning appears to hold also 
for mice (50). The critical level of 25 % of normal activity in muscle is surpassed by a factor of 
4 when a single dose of 40 mg/kg is given but the activity decays with an estimated half-life of 
3.3 days. Fig. 7 shows two hypothetical dosing regimens that are based on these fi gures. The 
fi rst one employs a dose of 40 mg/kg every week (approximately 2 times t ½) and the second 
40 mg/kg every second week (approximately 4 times t ½). In the weekly dosing regimen the 
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activity in muscle is increased with maximally 133 % and minimally 33 % of normal. When 
patients are treated every second week the increase is maximally 107 % and minimally 7 % 
of normal. Infantile patients without any residual activity need a weekly dosing regimen to 
remain above the critical threshold of 25 %. Patients with late-onset Pompe’s disease have 
10-20 % residual activity and may benefi t already at a dose of 40 mg/kg every second week. 
The 40 mg/kg every second week is preferred over a dosing regimen of 20 mg/kg weekly 
because higher peek values are reached. Moreover the high dose regimen poses a lower 
burden on the patient.
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Fig. 7. Hypothetical model showing the increment of acid α-glucosidase activity in skeletal muscle using two 
different dosing regimens.
The upper panel shows the increment of acid α-glucosidase activity with a weekly dose of 40 mg/kg, and the lower panel 
with a dosing regimen of 40 mg/kg every second week. The model is based on a half life of 3.5 days for the enzyme in 
skeletal muscle.
In summary, we have shown that the increase of acid α-glucosidase activity in heart and 
skeletal muscle of mice, after a single dose, is largely independent of the enzyme’s free-
M6P content. The dose required to correct the enzyme defi ciency in muscle is high. This is 
to our opinion in part related to the micro-vascular architecture of the muscle. Our fi ndings 
support the notion that similar therapeutic effects can be obtained with recombinant human 
α-glucosidases from CHO cells and milk of transgenic animals. 
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7 Discussion
Animal models can be very helpful for understanding the pathophysiology of human diseases. 
They may shed light on clinical features that were so far not assigned to the disease. 
Further they may be instrumental for the design of therapeutic strategies like bone marrow 
transplantation (Haematopoietic Cell Transplantation), enzyme replacement therapy and 
gene therapy. For Pompe’s disease animal models also have proven their value. Dogs with 
Pompe’s disease (1) were originally diagnosed because they could not retain their food. A 
dilation of the oesophagus was noted upon X-ray examination and the discovery underscored 
the generalised nature of the muscle weakness in Pompe’s disease. When specifi cally asked 
for, patients with Pompe’s disease also have chewing and swallowing diffi culties. This bares 
the risk of a low calorie intake leading to a catabolic state of the patient, increased protein 
turnover, and further decline of muscle structure and function. The smooth muscle cell 
pathology was very striking in the genetically modifi ed mouse model of Pompe’s disease. This 
fi nding shed new light on the causative relation between smooth muscle cell pathology and 
the occurrence of aneurysms in Pompe’s disease (2, 3). Chapter 5 of this thesis demonstrates 
the usefulness of the mouse model to investigate the cause of the newly discovered hearing 
defi cit in infantile Pompe’ s disease. In other collaborative studies the emphasis was laid on 
understanding the pathogenesis of muscle dysfunction in humans and mice with Pompe’s 
disease (4). Affected mice and quail have been particularly useful for demonstrating the 
feasibility of enzyme replacement therapy for this otherwise incurable disease (5).
This thesis covers the period that the mouse model was established but not yet fully 
characterised with respect to its clinical, cardiac, and skeletal muscle dysfunction. At the same 
time the fi rst clinical trial of enzyme replacement therapy started at the Erasmus MC-Sophia 
and the lessons learned from the mouse model were applied in clinical practice. The mouse 
model was used to approach questions that came up during the clinical study. 
This discussion focuses on the value of the mouse model for investigating in particular the 
pathophysiology of the heart, skeletal muscle, and the hearing organ, and for answering 
questions related to dosing and mechanisms of enzyme replacement therapy.
7.1 The heart in Pompe’s disease
Cardiac dimensions
The echocardiography study in the knockout (KO) mouse with Pompe’s disease (Chapter 2) 
shows that KO mice have a similar progressive cardiomyopathy leading to cardiac hypertrophy 
as patients with infantile Pompe’s disease. The heart weight of the KO mice (FVB background) 
is 160% of normal at the age of 25 months due to hypertrophy of both the left and right 
ventricle (6). The heart weight of C57Bl/6 KO mice, in the same age group as the FVB KO 
mice, increases to approximately 200% (both FVB and C57Bl/6 mice were back-crossed for 6 
generations. Studies in humans show an increase of the left ventricular (LV) mass from close 
to 1.5 times normal at birth to 5 times normal at the end stage of disease. The encroachment 
of the LV lumen can ultimately lead to outfl ow tract obstruction (7, 8). Hyperthrophic 
cardiomyopathy has also been described in a sub-population of Shorthorn cattle (200% at 
the age of 6.7 months), Turkey (round heart disease), sheep, and dog, but is not a feature 
in Japanese quail (9-15). In general, the cardiac hypertrophy in the known animal models is 
less than in humans.
The abnormal LV geometry in the KO mouse parallels the human situation. The increase of 
LV wall thickness is most prominent, and the encroachment of the lumen is variable. The 
progressive hyperthrophic cardiomyopathy in Pompe’s disease is very much the same as 
seen in Anderson Fabry’s disease (16, 17). In both these diseases the lysosomal storage 
leads to a disruption of the cardiac muscle architecture and triggers the heart’s compensatory 
mechanisms, which may lead to proliferation of contractile proteins and cellular hypertrophy 
(18-20). The cardiomyopathy in infantile Pompe’s disease is more conspicuous than in Fabry’s 
disease. 
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Cardiac function
The mouse model allows to study the cardiac pathophysiology in more detail than in humans 
(Chapter 2). Monitoring of the intra-cardiac blood pressure in the left ventricle and aorta 
during infusion of a β-adrenergic stimulant showed that the LV contractility reduces when 
the disease progresses. Nevertheless even one-year-old mice do not suffer from overt 
heart failure as patients with infantile Pompe’s disease. At that age, the KO mice still have 
a normal fractional shortening of the LV diameter, and the dose of a β-adrenergic stimulant 
needed to elicit maximal response in LV contractility is the same as in normal mice. There is 
little information available in the literature about the cardio-dynamics of Pompe’s disease in 
humans. Ejection fractions of approximately 70% were reported for humans, and normal LV 
fi lling pressures were found using cardiac catheterisation in patients from 6-9 months of age 
(7, 21). 
Response to therapy
When infants with Pompe’s disease were treated with weekly infusions of recombinant human 
acid α-glucosidase from rabbit milk, the cardiac dimensions decreased signifi cantly. The 
left ventricular mass index decreased up to 16% of pre-treatment value after 9 months of 
treatment (unpublished data). Similar results were obtained in patients with Fabry’s disease 
who received enzyme replacement therapy (16, 17).
The cardiac hypertrophy is believed to arise from the interference of the glycogen fi lled 
lysosomes with the normal muscle architecture leading to a diminished force transmission. 
Cellular stress induced by the lysosomal deposits may also play a role in the increase in 
cardiac muscle cell volume. 
The three year follow-up study of the safety and effi cacy of ERT in four patients with infantile 
Pompe’s disease (Chapter 3) shows that the cardiac response to lysosomal glycogen storage 
is largely a reversible process (22). The heart remodels to approximately normal dimensions 
and the systolic function improves signifi cantly whereas cardiorespiratory failure is the major 
cause of death of untreated patients (23). When treated in time patients with classic infantile 
Pompe’s disease are no longer at risk to succumb from cardiac failure. The therapeutic effect 
must be brought about by the uptake of the rabbit milk acid α-glucosidase by the cardio-
myocytes as fi rst demonstrated in the Langendorf perfusion system and later in knock-out 
mice with Pompe’s disease (24, 25). 
7.2 The muscle in Pompe’s disease 
Pathology
The KO mouse model parallels the human infantile form of Pompe’s disease by its complete 
defi ciency of acid α-glucosidase (26). However, the rate of glycogen storage and the ensuing 
pathological effects seem to progress slower in mice than in humans. The mice reveal only 
limited glycogen storage in muscle and other tissues at the time they are born. They show 
absolutely no clinical signs, whereas almost all infants with classic infantile Pompe’s disease 
present as fl oppy baby’s with cardiomegaly and massive lysosomal glycogen storage in many 
cell types and tissues (27, 28).
When the mice are eight months old they have developed substantial muscle pathology 
and start to exhibit weakness of the hind limbs. The average life span of affected animals 
is only slightly shortened whereas affected infants succumb in their fi rst year of life (29). 
Otherwise, the disease develops similar in both species in that the glycogen storage is 
progressive. Besides the heart and skeletal muscle, smooth muscle is typically involved. 
The glycogen deposits in the wall of blood vessels of mice and humans is very striking. One 
can envisage that the integrity of the tissue structure is lost when the disease progresses. 
This may ultimately lead to formation of an aneurysm. The occurrence of aneurysms in the 
basal arteries of patients with Pompe’s disease are mentioned in some case reports (30). 
A minor intriguing difference between the pathology in mice and humans is the storage in 
endothelial cells. It was not observed in mice but is obvious in patients. Notably clearance of 
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glycogen from the endothelial cells was one of the fi rst signs of therapeutic effect of enzyme 
replacement therapy (Chapter 4) (3).  
Muscle function
Progressive skeletal muscle weakness is one of the most prominent features in infantile and 
late onset Pompe’s disease. The skeletal muscle function is assessed by performance tests. 
In infants, physical capabilities are assessed with validated tests like the AIMS and BSIDII. In 
infantile Pompe patient’s milestones of normal development are not reached. Symptoms of 
muscle weakness start shortly after birth (median age 1.6 months), hospitalisation follows at 
an age of approximately 3-4 months (28). Most patients die younger than 1 year old (median 
age 7.7 and 6.0 months for the Dutch and world-wide population, respectively) (28).
The muscle function of mice with Pompe’s disease was analysed using the ∆6/∆6  
And the 13neo/13neo strain (31, 32). At fi rst in was suggested that the ∆6/∆6 mice had an 
earlier onset of disease than the13neo/13neo mice. But, more recent publications revealed 
the same disease progression in both mouse models (33). As a matter of fact it was very 
diffi cult to judge and compare the phenotypes of the different mouse models because of the 
different methodologies that were used to measure muscle function. The ∆6/∆6 mice were 
tested in open-fi eld studies and had lower scores than their healthy littermates (8-11 months 
of age). This test was not available for the 13neo/13neo mice. Their performance was tested 
in running wheels and signifi cant differences were not noted before 8 months of age. Other 
tests that were implemented later such as a hanging wire and vertical pole also revealed the 
start of clinical symptoms around eight months of age an age of 30 weeks (data not shown). 
The variable test results obtained with the ∆6/∆6 mice are in part explained by differences 
in genetic constitution. The 13neo/13neo mice are back-crossed to the FVB and C57Bl/6 
background for ten generations whereas the ∆6/∆6 model has mixed 129, C57Bl/6, and FVB 
background. 
The most sophisticated assessment of muscle performance in the C57Bl/6 13neo/13neo mice 
(4, 34) shows that the absolute maximum torque of the muscles of 18-month old mice is 
two fold reduced compared to wild-type littermates. These 18-month old mice were severely 
affected and showed a splayed limb posture, a waddling gait, and they suffered from thoracic 
kyphosis. The reduction in muscle strength was associated with a 1.3 fold decrease in muscle 
mass. When tested in a fatigue contraction protocol, the muscles of both the KO mice and 
their control littermates responded in a similar fashion indicating that the mechanisms 
involved in muscle fatigue are not affected in mice with Pompe’s disease. It is speculated that 
the lysosomal glycogen storage leads to interruption of the myofi brils whereby longitudinal 
force transmission is hampered, leading to muscle weakness (35). Apparently the muscle 
impairment is not due to metabolic disturbances but mainly due to a decrease of muscle mass 
and interference of glycogen fi lled vacuoles with the contractile structures. This hypothesis is 
not yet confi rmed in patients with Pompe’s disease.
Response to therapy
By lack of reliable methods for clinical assessment, the effect of enzyme replacement therapy 
in mice was evaluated by measuring the increase of acid α-glucosidase activity in the tissues 
and the reduction of tissue pathology. Correction of enzyme defi ciency and improvement of 
tissue morphology was demonstrated after a six-month treatment period. The patients in 
the clinical study were evaluated for muscle function using the AIMS test and the BSIDII. 
One patient had normal scores at the age of two. This best responding patient is at present 
5 years old, ventilator free and fully mobile without support. Two patients of the same age 
are ventilator dependent and wheelchair bound. They initially gained muscle strength in the 
upper extremities, but further improvement halted. The fourth patient who participated in the 
study manifested steady progress in the fi rst two years that she was treated. She could use 
her arms and sit upright unsupported. In the third year of the study she became ventilator 
dependent during a portacath infection and her muscular condition gradually decelined. She 
died quite suddenly at the age of 4 years and 3 months after a period of intractable fever.
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After the fi rst three months of treatment with a dose of 15-20 mg/kg the acid α-glucosidase 
defi ciency in muscle was partly corrected (36). An increase of the dose to 40 mg/kg resulted in 
correction of the activity to a normal level (Chapter 3) (3). Several muscle biopsies were taken 
during the course of treatment to monitor the therapeutic effect. The fi ndings are described 
in Chapter 4, and are informative for understanding the process of muscle wasting and for 
estimating the chance of successful treatment. Three of the four patients included in the study 
had advanced muscle pathology at the start of treatment. Glycogen loaded lysosomes were 
seen over the entire length of virtually all muscle fi bres. The fourth patient was also clearly 
affected but the pattern of muscle damage was less severe. All fi bres showed lysosomal 
glycogen storage but not always over the entire length of the fi bre. The glycogen load per 
fi bre also varied. After the start of treatment the glycogen load of the muscle decreased 
in all patients when judged by the diminished PAS staining intensity although this was not 
confi rmed by the quantitative measurement of the glycogen content of the whole muscle 
biopsy. The disappearance of glycogen in the muscles of the three most affected patients 
resulted in a lace work pattern of empty spaces that were previously occupied by glycogen, 
but there was little left of the muscular architecture. Clearance of glycogen from the muscle of 
the least affected patient also resulted in empty spaces but these were interspersed between 
the still ordered arrays of contractile elements. As we observed, the muscle morphology of 
this patient slowly improved during the 72 weeks of continuous treatment, using the still 
intact muscle structure as a matrix. The residual contractile function of the muscle may have 
helped to feed and oxygenate the muscle during the treatment and deliver acid α-glucosidase 
to the muscle. The myogenic satellite cells may have assisted in the repair of the muscle 
damage. When muscle fi bres have lost all architecture and function, as in the biopsied muscle 
of the three severely affected infants in our study, they are probably beyond repair. It is 
therefore that the muscle morphology and the residual function can be used as an indicator 
for the outcome of enzyme replacement therapy. In the line of this reasoning it is important 
to keep the muscles in optimal condition before and during enzyme replacement therapy by 
a proper diet and moderate exercise. But surprisingly little has been done to investigate the 
role of diet and exercise in the treatment of Pompe’s disease (37, 38). 
For muscle as for heart, the KO mouse is a suitable model to study pathogenesis, function and 
response to therapy. The impact of diet and exercise on the therapy has to be investigated in 
the patient population because of differences in metabolism and feeding behaviour between 
mice and humans.
7.3 Hearing loss in Pompe’s disease
Before the start of enzyme replacement therapy, hearing loss was not known as a feature 
of classic infantile Pompe’s disease. It had not been reported either in any of the animal 
models. The discovery was serendipitous, as we had included the measurement of brainstem 
auditory evoked potentials in the study protocol as a tool to monitor brain function. The latter 
was important because the blood brain barrier prevents the therapeutic enzyme to enter the 
brain. The four infants in our study all had severe hearing loss. When we communicated this 
fi nding to colleagues, they specifi cally tested their patients and confi rmed our fi ndings. So 
far we have not discovered any hearing loss in our patients with late onset Pompe’s disease. 
Further investigation into the basis of hearing loss was limited to non-invasive tests like BERA, 
OAE and tympanogram, and this pointed to cochlear dysfunction rather than central nervous 
system involvement (Chapter 5).
The mouse model was again used as a reference. The mice manifested cochlear pathology 
as suspected from the investigations in humans, but did not have hearing loss. The latter is 
explainable by the slower course of the disease in mice compared to humans. The cochlear 
pathology consisted of lysosomal glycogen storage in the inner- and outer hair cells, the 
support cells of the cochlea and the neurons of the spiral ganglion. Hearing loss has been 
observed in various other lysosomal storage disorders but the direct causes differ (39-45).
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Response to therapy
Despite the improvement of the cardiac and muscular parameters in the infantile patients 
participating in our clinical trial, there was no effect on the hearing loss, although threshold 
values did not increase either during therapy. The lack of response may be inherent to the 
cochlear structure wherein the hair cells and support cells are not positioned directly adjacent 
to the blood supply.
7.4 Concluding remarks about the mouse model of
Pompe’s disease
The mouse model of Pompe’s disease has proven its value both for understanding the 
pathology of the disease as well as for the development of therapy. The parallel between 
mice and humans is close but species-specifi c differences do exist and fi ndings need to be 
interpreted with caution. The most striking difference between the KO mice and patients with 
classic infantile Pompe’s disease is the slower disease progression and the longer survival of 
mice compared to humans. It was reasoned previously that lysosomal glycogen storage starts 
in the single cell embryonic state and that the total length of the pathogenic process counts 
more than the relative age. 
The following paragraphs specifi cally discuss the value of the mouse model for studying the 
safety and effi cacy of enzyme replacement therapy with a focus on enzyme targeting and 
dosing.
7.5 Development of enzyme replacement therapy 
Gene therapy and enzyme replacement therapy have in common that the basic principles of 
these approaches are easy to conceive, but the problems associated with clinical application 
are far greater than originally anticipated. Taken the state of present day technology and the 
actual therapeutic achievements, the fi rst clinical trial of enzyme replacement therapy, 40 
years ago, was futile and far from realistic (46). In retrospect, the development of enzyme 
replacement therapy for Pompe’s disease has also been a painstakingly slow process. One 
to two decades of unsuccessful studies in humans were followed by a series of in vitro 
experiments to re-explore the feasibility of enzyme replacement therapy, using the then 
newly acquired knowledge on the role of the mannose 6-phosphate (M6P) receptor for 
lysosomal targeting of exogenous ligands (24, 25, 47-53). The basic criteria were met in that 
the lysosomal glycogen storage in cultured fi broblasts and muscle cells of Pompe patients 
was corrected by enzyme supplementation. Subsequent studies indicated that the principles 
of in vitro correction also applied in the experimental set-up of the ex vivo rat heart perfusion 
and the in vivo administration of enzyme via the tail vain of mice (24, 52). The dose used 
in the latter experiment was used as a guide for the design of all following studies on the 
feasibility of enzyme replacement therapy in patients with Pompe’s disease. In a study with 
affected Japanese quail 4.2 to 14 mg/kg of recombinant human α-glucosidase manufactured 
in genetically modifi ed CHO cells was administered. KO mice were treated with weekly doses 
of 17 mg/kg recombinant human α-glucosidase from rabbit milk (25, 53). Under these 
conditions the α-glucosidase activity of the mice was corrected to normal levels in all tissues 
except the brain, and the glycogen was cleared from the target tissues. 
When protocols were designed for a clinical trial with recombinant human acid 
α-glucosidase from rabbit milk, the starting dose for adult patients was set at 10 mg/kg per 
week and for infants at 15-20 mg/kg based on their higher metabolic (Chapter 3).
The fi rst patient was enrolled in our study in January 1999. Since then several other studies 
with CHO enzyme were started, some have already ended, and yet others are planned for 
testing the safety and effi cacy of enzyme replacement therapy in infantile and late onset 
Pompe’s disease.
Genzyme Corp., from Boston, USA is engaged in the commercial development of enzyme 
replacement therapy for Pompe’s disease and intends to fi le for approval of the therapy 
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in 2004. This is 40 years after the fi rst historical study of enzyme replacement therapy in 
Pompe’s disease was published.
Upcoming questions about the optimal dose, dosing regimen, and the mechanism of enzyme 
targeting marked the most recent investigations into the feasibility of ERT for Pompe’s 
disease. The following paragraphs are devoted specifi cally to these two issues.
The mechanism of enzyme replacement therapy
The choice of the mannose 6-phosphate (M6P) receptor as target for enzyme therapy in 
Pompe’s disease was born out of the fi nding that this receptor was involved in the exchange 
of enzymes between cultured fi broblasts. The 300 KD M6P receptor appeared to be exposed 
on the surface of many cell types including cultured myoblasts derived from a muscle biopsy 
and differentiating in vitro into myotubes. A fi rst indication for the in vivo importance of the 
M6P receptor for enzyme targeting was obtained in a rat heart perfusion system and in normal 
mice. A higher uptake was obtained with phosphorylated compared to non-phosphorylated 
acid α-glucosidase, in several organs of normal mice (24, 52). When larger supplies of 
recombinant human acid α-glucosidase became gradually available from production in 
transgenic mouse milk, rabbit milk, and genetically engineered CHO cells, these experiments 
were repeated and extended in KO mice (Chapter 6).
As demonstrated in this thesis the M6P content of acid α-glucosidase appeared less crucial 
than anticipated, and the dose more critical. The impact of the precise carbohydrate structure 
varies by the cell type and the localisation of the cell type within the tissue. As discussed in 
Chapter 4, the correction of the reticulo-endothelial cells in Gaucher’s disease by Cerezyme 
approaches the in vitro experimental situation. Glycoproteins containing carbohydrate 
side chains with exposed mannose residues bind to cells with mannose receptors and are 
internalised. Free access of enzyme to the target cells is guaranteed in vivo because the 
glycolipid-storing macrophages (such as the Kupffer cells in the liver) reside in the blood 
sinusoids. A similar comparison between the in vivo and in vitro situation exists in Fabry’s 
disease, presently treated with Replagal (TKT) and Fabrazyme (Genzyme) (54, 55). The 
endothelial cells have free access to the therapeutic enzyme, and highly effi cient binding of 
ligands via the M6P receptor leads to the described effect seen in these cells. 
The hepatocytes also respond as expected. These cells have virtually free access to 
administered enzymes, so that the ligand-receptor functions are directly operative. The more 
effi cient uptake of phosphorylated versus non-phosphorylated α-glucosidase measured in 
vitro (in fi broblasts) is similarly seen in vivo (in hepatocytes) (Chapter 6). The recombinant 
α-glucosidase from rabbit milk with a lower number of freely exposed M6P residues will be 
less effective in clearing glycogen from the lysosomes of hepatocytes than the α-glucosidase 
from CHO cells with a higher free M6P content. But, liver is not a target organ in Pompe’s 
disease. 
There is no question that the intravenously administered acid α-glucosidase reaches many 
different cell types in the body including the cardiomyocytes and the skeletal muscle cells that 
are shielded off from the bloodstream by the endothelium of the capillary wall. The evidence is 
provided by the clearance of glycogen from the tissues of KO mice and children with Pompe’s 
disease after 72 weeks of treatment (22, 25) (Chapters 3 and 4). The clinical improvement of 
the patients in our study is the best evidence that the target cells are reached (56). But, after 
the many years of advocating the importance of M6P receptor mediated endocytosis in the 
therapeutic process we are left with questions about the underlying mechanisms. Certainly, 
one of the most intriguing questions is how acid α-glucosidase passes the endothelial 
barrier. 
Ceredase and Cerezyme using the mannose receptor for entry into cells are localised in both 
Kupffer and endothelial cells of the liver after intravenous administration. Fabrazyme and 
Replagal, thought to utilize the M6P receptor for cell entry, are also routed to the lysosomal 
system of the endothelial cells where they degrade the stored globotriosylceramide (54, 55). 
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Notably, α-glucosidase follows the same route because the removal of lysosomal glycogen 
from the vascular endothelium is one of the fi rst events after start of ERT. To cross the 
endothelial barrier a substantial proportion of enzyme has to escape the lysosomal route of 
no return and alternatively enter the pathway of transcytosis.
Studies on the molecular and cellular aspects of transcytosis indicate that the plasmalemmal 
vesicle transport system is a quite import mode to transport molecules across endothelial 
cells. Two fundamentally distinct mechanisms have been identifi ed. Receptor mediated 
and non-receptor (or fl uid phase) mediated transcytosis. Receptor mediated transcytosis is 
believed to be mediated by clathrin coated vesicles or caveolae. It is thought to occur for 
plasma molecules like insulin, transferrin, ceruloplasmin, and albumin. Co-localisation of acid 
α-glucosidase with albumin suggests a similar pathway for the transcytosis of this lysosomal 
enzyme (57). Further studies are obviously needed to resolve the pending questions about 
the nature of trans-endothelial transport of recombinant human acid α-glucosidase.
Dosing
As mentioned in the previous paragraph about enzyme targeting, the initial weekly dose used 
in the clinical study was set at 15-20 mg/kg for the four infants and at 10 mg/kg for the three 
older patients. This dosing was based on pre-clinical studies in mice and quail (25, 53). The 
study protocol did not foresee in dose fi nding but allowed for dose adaptation when indicated 
by study results. It was realized beforehand that the evaluation of dose related clinical effects 
would be diffi cult in the short time span that patients with classic infantile Pompe’s disease 
live. As it happened, the condition of one of the patients became extremely critical after 12 
weeks of treatment and it was decided, after long debate, to double the dose to 40 mg/kg/
week. All patients remained on this dose for more than 3 years. There was no reason to lower 
the dose for safety reasons, and the response to treatment was still not optimal for all infants. 
Moreover, there were no reference studies indicating what the optimal dose for the treatment 
of classic infantile Pompe’s disease should be. There was just one other study that could serve 
as a guide (58). Three patients received recombinant human acid α-glucosidase from CHO 
cells in a reported dose of 2 times 5 mg/kg/week. The fi rst results were publicly available in 
April 2001. All three patients had an improved muscle function after the fi rst fi ve weeks of 
treatment but two of the patients deteriorated in the period thereafter. Both these patients 
became ventilator dependent at the age of age of 8 months (5 months of treatment), and the 
dose of one patient was raised to 5 times 10 mg/kg/week (59). This higher dosing regimen 
did not improve the clinical condition of the patient and resulted in nephrotic syndrome, as 
also occurred in the pioneering study of Hug et al. using acid α-glucosidase from Aspergillus 
niger (60). The third patient responded very well to the low dose treatment of 2 times 5 mg/
kg/wk.  Recently, it was communicated that this patient did not have the classic-infantile form 
of Pompe’s disease, which makes it diffi cult to estimate the effect of treatment (dr P. Kishnani, 
personal comunication).
A new study with α-glucosidase from CHO cells has started. Eight patients with infantile 
Pompe’s disease received weekly doses of 10 mg/kg. The preliminary results indicate that this 
dose was suffi cient for 4 of the 8 patients (61). 
The patients receiving acid α glucosidase from rabbit milk were kept on a weekly dose of 40 
mg/kg. Meanwhile we tried to get more insight in the optimal dose and dosing regimen using 
the mouse model (Chapter 6).
The results obtained in the mouse model cannot be directly translated to the human situation, 
as the mode of enzyme administration is quite different. The mice received a bolus injection 
whereas the patients received the enzyme over a period of several hours. The mouse model 
shows that uptake of acid α-glucosidase by liver, heart, and skeletal muscle is dose dependent 
and linear up to 80 mg/kg. Further, it is evident that muscle and heart (to a lesser extent) are 
diffi cult to correct compared to liver. The minimal dose to obtain normal enzyme activities in 
skeletal muscle is 40 mg/kg but lower doses starting from 10 mg/kg are suffi cient to reach 
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the skeletal muscle. The important question is how much activity is needed to correct the 
lysosomal glycogen storage. Mother Nature provides the best answer. Patients with late onset 
Pompe’s disease have rarely more than 25% of normal activity (23). Higher activity levels do 
apparently not lead to lysosomal glycogen storage. Based on this fi gure and the estimated 
half-life of recombinant human acid α-glucosidase from rabbit milk in the skeletal muscle of 
the knockout mice, a tentative dosing scheme was proposed in Chapter 6 as a guideline for 
future studies on enzyme replacement therapy in Pompe’s disease. Only after completion of 
the clinical studies in patients, the optimal dose and the limits of the possibilities to change 
the natural course of Pompe’s disease into the better will be known.
7.6 Future prospects
Several hurdles on the road to enzyme replacement therapy for Pompe’s disease have been 
taken successfully. The safety of the procedure has been proven and the benefi cial effects 
cannot be ignored, but pivotal clinical studies are still needed for ultimate proof of effi cacy 
and drug approval. The innovative process of producing therapeutic enzymes in the milk of 
transgenic animals has demonstrated its clinical safety and potential. The more conventional 
production system using genetically engineered CHO cells is currently under development.
The challenge of the future is to solve the problems related to the high dose of enzyme that 
is required to obtain clinical effects. Problems related to production capacity and high costs 
may be solved by further development of the transgenic production platform. Molecular 
modifi cations of acid α-glucosidase may result in an enzyme species with improved uptake 
by the target organs. 
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Summary
Pompe’s disease or glycogen storage disease type II is a lysosomal storage disorder with an 
autosomal recessive mode of inheritance. The lysosomal glycogen storage is caused by the 
defi ciency of acid α-glucosidase. This lysosomal enzyme normally degrades glycogen into 
glucose. The glycogen storage is most prominent in skeletal muscle and leads to muscle 
weakness and wasting. The disease occurs in different degrees of severity largely determined 
by the precise nature of the mutations in the acid a-glucosidase gene (GAA), but is modulated 
by as yet unknown genetic and environmental factors. Patients with two fully deleterious 
mutations are usually diagnosed within their fi rst three months of life. They present as fl oppy 
babies with a typical cardiac hypertrophy. Their life expectancy is less than one year. Milder 
mutations whereby some residual acid a-glucosidase function is preserved are typically 
associated with later onset forms of Pompe’s disease. The fi rst complains are diffi culties 
with climbing stairs or rising from a chair. When the disease progres  ses patients become 
wheelchair bound and dependent on artifi cial ventilation.
Mouse models for Pompe’s disease were developed. They mimic the classic infantile form of 
Pompe’s disease in that the animals have no residual acid a-glucosidase activity and rapidly 
progressive lysosomal glycogen storage. However, these mice do not show overt clinical 
symptoms till the age of 8-9 months. 
The studies described in this thesis relate to the development of enzyme replacement therapy 
for Pompe’s disease. The mouse model was used to investigate specifi c aspects of the disease 
such as cardiac remodeling and hearing loss. Further, it was used to study dosing and other 
molecular aspects of enzyme replacement therapy.
Chapter one provides a brief introduction into the fi eld of lysosomal storage disorders. It 
reviews the current knowledge about the function of the lysosomal system, the biosynthesis 
of lysosomal proteins, and the mannose 6-phosphate mediated routing to the lysosomal 
compartment. Receptor mediated endocytosis is discussed in the context of enzyme 
replacement therapy. Several paragraphs are devoted to Pompe’s disease. They summarise 
the under lying genetic defect, the clinical aspects, and heterogeneity of the disease. Several 
mouse models are presented as one of these models (13neo/13neo) was used in the studies 
described in the chapters 2, 4, 5 and 6 of this thesis.
Three paragraphs refer to the historic development of enzyme replacement therapy for 
Pompe’s disease and other lysosomal storage disorders and focus on to the production of 
recombinant human acid a-glucosidase in CHO cells and in the milk of transgenic animals.
As described in the introduction (Chapter 1) cardiac hypertrophy is a characteristic feature 
in classic infantile Pompe’s disease. Chapter 2 reports the results of a study on the cardiac 
remodeling and contractile function in the 13neo/13neo mouse model of Pompe’s disease. The 
increase in cardiac mass is associated with an increase in left ventricular (LV) wall thickness 
and an encroachment of the LV lumen. This results in a lower global contractility of the heart. 
These manifestations parallel the human condition of early onset Pompe’s disease, but are 
less overt.
A switch is then made from the mouse model to the clinical study on safety and effi cacy of 
enzyme replacement therapy in patients with infantile Pompe’s disease. (Chapter 3). Four 
critically ill patients were treated intravenously with recombinant human acid a-glucosidase 
from rabbit milk in a dose of 15-40 mg/kg weekly over a period of 3.5 years. The treatment 
with this novel medicine was tolerated remarkably well and benefi cial effects were obtained. 
Improvement of the cardiac dimensions was a relatively early response that lasted during the 
course of treatment. The best responding patient is at present 5 years old and able to walk, 
whereas the natural life expectancy is less than a year. Two other patients of about the same 
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age are ventilator dependent and wheelchair bound. The fourth patient manifested steady 
progress in the fi rst two years of the study but became ventilator dependent after a bout of 
pneumonia and died quite suddenly after a short period of high fever.
Muscle biopsies were taken at preset time points during the study to evaluate morphological 
changes (Chapter 4). The fi rst response was noted in the vascular endothelial cells and the 
peripheral neurones, after 12 weeks of treatment with a dose of 15-20 mg/kg. Increasing 
the dose to 40 mg/kg led, after 72 weeks of treatment, to a reduction of glycogen storage 
and improvement of muscle architecture in the least affected patient. This is in accordance 
with the improved clinical performance. The glycogen content of the muscle of the other 
three patients stabilized did not result in a substantial improvement of the skeletal muscle 
architecture. The different response of the four patients can be ascribed to the clinical and 
pathological variation at baseline. We learned that treatment needs to be started before 
serious damage has occurred to the muscle tissue.
Chapter 5 describes the unexpected fi nding of hearing loss in Pompe’s disease. The discovery 
was serendipitously made as the measurement of the auditory brainstem response was used 
to monitor central nervous system function. As it turned out, the nerve conduction times 
were found to be within normal limits, but there was a severe hearing loss possibly due to 
cochlear dysfunction. The later hypothesis was investigated in the knockout mouse model of 
Pompe’s disease and glycogen storage was found in the inner and outer hair-cells, the support 
cells, the stria vascularis, and the spiral ganglion cells of the cochlea (Chapter 5). If these 
fi ndings would be representative for the human situation they could explain the hearing loss 
of the patients. The problem of hearing loss seems to be restricted to classic infantile Pompe’s 
disease, as far as we can tell from the limited investigations that we did in patients with late 
onset Pompe’s disease.
Chapter 6 addresses the issue of enzyme targeting and dosing in relation to enzyme 
replacement therapy. As the mannose 6-phosphate (M6P) receptor is exposed on the surface 
of many cell types it is considered a suitable tool for enzyme targeting in lysosomal storage 
disorders. The importance of M6P receptor mediated endocytosis for the treatment of Pompe’s 
disease seemed well established based on several pre-clinical studies. But the issue gained 
new interest when we discovered that recombinant human acid α-glucosidases from different 
sources had different specifi cations with respect to the M6P content.
As described in Chapter 6, the acid α-glucosidases, produced in CHO cells and mouse milk are 
taken up more effi cient by fi broblasts than the same enzyme from rabbit milk when tested in 
vitro. However, the difference was not measurable when comparing the uptake by liver, heart, 
and, skeletal muscle, the target organs in Pompe’s disease.
These results urge to further investigations regarding the role of carbohydrate structures for 
targeting acid α-glucosidase to muscle with the fi nal aim to optimize enzyme replacement 
therapy for Pompe’s disease.
The later is of critical importance taken the high dose of enzyme needed to obtain a clinical 
effect. The studies described in Chapter 6 indicate that not only the height of the dose is 
important but also the dosing regimen.
The results of the experimental work described in Chapters 2-6 are discussed in Chapter 7.
The mouse model of Pompe’s disease has in several ways proven its value for understanding 
the pathophysiology of Pompe’s disease and for development of enzyme replacement therapy. 
It is a suitable model to help answering future questions related to the application of enzyme 
replacement therapy and other therapies for Pompe’s disease.
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Samenvatting
De ziekte van Pompe, ook wel glycogeen stapelingsziekte type II genoemd, is een metabole 
ziekte die autosomaal reccesief overerft. De aandoening wordt veroorzaakt door een 
defi ciëntie van het enzym “zure alfa-glucosidase”. Dit enzym breekt normaliter glycogeen af 
tot glucose in een specifi ek compartiment van de cel, het lysosoom.
De ziekte van Pompe manifesteert zich door spierzwakte. Het klinisch beeld is variabel. De 
“infantiele” vorm van de ziekte leidt al kort na de geboorte tot ernstige en progressieve 
spierzwakte. De wand van de hartspier is verdikt wat ten koste gaat van de hartfunctie. De 
meeste patiëntjes overlijden voor het eerste levensjaar aan hart- en ademhalingsproblemen. 
Presenteert de ziekte zich op de kinder- of volwassen leeftijd dan is er wel progressieve 
spierzwakte maar geen betrokkenheid van het hart. De ziekte begint vaak met problemen bij 
het traplopen of opstaan uit een stoel. Op latere leeftijd worden deze patiënten afhankelijk 
van een rolstoel en hebben soms ademhalingsondersteuning nodig.
In 1998 werd een muis model voor de ziekte van Pompe ontwikkeld. De muizen hebben net 
als de “infantiele” patiëntjes een totale defi ciëntie van het enzym zure α-glucosidase en ook 
zij lijden aan lysosomale glycogeen stapeling. Zij hebben een progressieve spierzwakte en 
een vergroting van het hart. Desondanks vertonen deze muizen pas klinische symptomen op 
de leeftijd van 8 maanden.
In dit proefschrift zijn een aantal studies opgenomen die betrekking hebben op de ontwikkeling 
van enzym vervangingstherapie voor de ziekte van Pompe. 
Het eerste hoofdstuk dient als algemene inleiding in het veld van de lysosomale 
stapelingsziekten. Het behandelt in het kort de functie van de lysosomen, de productie en 
het transport van lysosomale eiwitten en het proces van receptor gemedieerde opname van 
macro-moleculen in het lysosoom. Het hoofdstuk gaat verder in op de ziekte van Pompe, met 
een speciale aandacht voor de klinische heterogeniteit, de onderliggende genetische defecten 
en de eigenschappen van de diverse muis modellen die er voor deze ziekte zijn ontwikkeld. 
Tot slot worden in dit hoofdstuk de mogelijkheden voor therapie besproken met nadruk op de 
ontwikkeling van enzym vervangingstherapie en de productie van recombinant humaan zure 
α-glucosidase in de melk van zoogdieren en CHO cellen (Chinese Hamster Ovary).
Verdikking van de hartspier is een van de karakteristieke gebeurtenissen bij de “infantiele” 
vorm van de ziekte van Pompe. Hoofdstuk twee beschrijft dit fenomeen in het muismodel 
van de ziekte van Pompe. De massa van het hart neemt toe en het volume van de kamers 
neemt af. Dit resulteert in een globale afname van de hartspierfunctie, hoewel de muizen, in 
tegenstelling tot de patiënten, geen uitdrukkelijke hartfunctiestoornis hebben.
In hoofdstuk drie worden de resultaten beschreven van enzym vervangingstherapy.
Vier patiëntjes met de infantiele vorm van de ziekte van Pompe kregen eens per week 
recombinant humaan α-glucosidase intraveneus toegediend gedurende een periode van 3,5 
jaar. Het enzym werd gewonnen uit de melk van transgene konijnen en toegediend in een 
dosis van 15-40 mg/kg. De behandeling werd goed verdragen en herstel van de hartspier 
was een van de eerste klinische effecten die bij alle patiënten werd gezien. De patiënt die 
het beste reageerde is nu 5 jaar oud en kan lopen terwijl de levensverwachting zonder 
behandeling niet langer dan een jaar is. Twee andere patiënten van ongeveer dezelfde leeftijd 
zijn afhankelijk van een rolstoel en kunstmatige beademing. De vierde patiënt maakte in 
de eerste twee jaren een periode van klinische verbetering door maar werd afhankelijk van 
kunstmatige beademing na een long ontsteking. De patiënt overleed na een korte periode van 
onbegrepen hoge koorts.
Tijdens de behandeling van de patiënten werden op geregelde tijden spier biopten genomen 
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om de morfologie van de spieren te bestuderen (Hoofdstuk 4). Na 12 weken werd een afname 
van de glycogeenstapeling in de perifere zenuwen en in de endotheel cellen van de bloedvaten 
gezien bij een dosis van 15-20 mg/kg. Na verhoging van de dosis tot 40 mg/kg werd ook 
een vermindering van de glycogeenstapeling en een verbetering van de spierarchitectuur 
van de best reagerende patiënt gezien. Bij de andere patiënten werd wel een vermindering 
van het glycogeengehalte waargenomen maar bleef een substantiële verbetering van de 
spiermorfologie uit. Het is dan ook sterk aan te bevelen om zo vroeg mogelijk met de 
behandeling te beginnen.
Bij het includeren van de patiënten, voor aanvang van de behandeling, werd onverwacht bij 
alle patiënten een ernstig gehoorsverlies vastgesteld (Hoofdstuk 5). Aanvullend onderzoek 
wees uit dat de gehoorszenuw en de hersenstam normaal functioneerden. Een verminderde 
functie van de cochlea werd gezien als meest voor hand liggende verklaring voor het 
gehoorsverlies. Omdat pathologisch onderzoek bij de mens niet mogelijk was werd voor 
verder onderzoek naar de oorzaak van het gehoorsverlies gebruik gemaakt van het muis 
model. De studies laten zien dat er glycogeen stapeling optreedt in zowel de binnenste- als 
de buitenste haarcellen en de steun cellen van de cochlea. Deze bevindingen ondersteunen de 
resultaten van het klinisch onderzoek. Het gehoorsverlies komt alleen voor bij patiënten met 
de infantiele vorm van de ziekte van Pompe.
Hoofdstuk 6 beschrijft experimenten die betrekking hebben op de mannose 6-fosfaat receptor 
gemedieerde opname van recombinant humaan zure α-glucosidase in die organen die voor de 
behandeling van de ziekte van Pompe van belang zijn. Er wordt een vergelijk gemaakt tussen 
de opname van verschillende vormen van recombinant humaan zure α-glucosidase in vitro 
(fi broblasten ) en in vivo (muis model). Het recombinant humaan α-glucosidase geproduceerd 
in CHO cellen en in de melk van transgene muizen wordt effi ciënter opgenomen door 
fi broblasten dan het zure α-glucosidase geproduceerd in de melk van transgene konijnen. 
Maar bij toediening van de verschillende enzymen aan muizen met de ziekte van Pompe is dit 
verschil niet meetbaar. 
Op grond van deze resultaten blijven er vragen over de rol van de mannose 6-fosfaat receptor 
bij enzym vervangingstherapie voor de ziekte van Pompe. De effi cientie van enzym therapie 
kan mogelijk verhoogd worden door de rol van de suiker ketens bij de opname van zure 
α-glucosidase verder te bestuderen; dit in relatie tot de hoge dosis die nodig is voor het 
bereiken van klinische effect. 
Het muis model voor de ziekte van Pompe heeft een waardevolle bijdrage geleverd aan het 
begrip van het ziektebeeld en is uitermate geschikt voor de verdere ontwikkeling van enzym 
vervangingstherapie en onderzoek naar andere therapeutische mogelijkheden.
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Curriculum vitae 
(Door R. Kamphoven)
Joep Kamphoven kwam, overigens zonder dat zelf te weten, al vroeg in aanraking met de 
medische stand. Hij werd in 1970 in deze wereld opgevangen in de handen van gynaecoloog 
Joep Vos in het oude Carolusziekenhuis in ‘s-Hertogenbosch. Dat feit, plus de geboortedatum 
19 maart, feest van St.-Jozef, bepaalde zijn naam. In zijn kleuterjaren had hij een 
‘abonnement’ bij de KNO-specialist dr. Verhaegh. Dat beviel hem kennelijk zo goed dat hij 
toen zelfs ‘assistent van de dokter’ wilde worden. Verder groeide hij voorspoedig op, praatte 
al vroeg als Brugman en had behoudens de normale kinderziekten, nergens meer last van. 
Behalve dan die ene keer, op oudejaarsavond, dat zijn blinde darm eruit moest. Hij was toen 
17. Altijd iets bijzonders dus.
Als heel klein jongetje stond Joep op en ging naar bed met een pet of hoedje op z’n bol. Hier 
werd een trend in gang gezet: nu hoort een pet bij standaarduitrusting van jongeren. Bij Joep 
groeide deze tic uit tot een verzameling van zeker honderd hoeden en petten.
De basisschool in Boxtel was een Jenaplan-school. Dit onderwijs probeert kinderen al zo 
vroeg mogelijk heel zelfstandig, sociaal en creatief te maken. Niets is gek, alles moet kunnen, 
meende zijn moeder. Zelfs het dragen van een knickerbocker. Dat leverde hem een enorme 
frustratie op die nog lang heeft doorgewerkt. Want toen al was een knickerbocker helemaal 
fout.
Joep werd een jongen dus die ‘altijd iets bijzonders’ had. Bij het afzwemmen voor het diploma 
B bij voorbeeld was er één jongetje dat iets toch niet goed had gedaan. Joepje dus. Die moest 
voor een volle zwemzaal opnieuw een aantal meters onder water zwemmen… en hij redde 
het. Met gemak. Applaus dus. Joep ging ook op muziekles, en koos natuurlijk een bijzonder 
instrument: de accordeon… Dat instrument ruilde hij overigens na zijn afstuderen in voor een 
elektrische basgitaar. Verder ging hij met zijn zus Aukje in zijn havo-tijd op naailes, want hij 
wilde per se zijn eigen rits in zijn eigen broek kunnen zetten. Als enige jongen kwam hij op 
de dansschool terecht bij het tapdansen. Dat ging prima. Zo goed dat hij bij het lezen van 
een oproep in de krant voor audities bij het Scapino-ballet, dacht: ‘dat kan ik ook’. Hij schreef 
erop, en kreeg een uitnodiging die hij op het laatste moment toch maar afzegde. 
De studie havo ging goed, in ieder geval zo goed dat hij daarna het atheneum kon halen. 
Maar eerst probeerde hij op de opleiding tot piloot te komen bij de Rijksluchtvaartdienst. 
Daar kon men brildragers minder goed gebruiken, en bovendien: qua postuur was hij aan 
de kleine kant. Na het atheneum ging de militaire dienst aan hem voorbij: na een paar keer 
uitstel hoefde het niet meer van hare majesteit. Als cadeautje voor het behalen van zijn 
atheneumdiploma kreeg hij een ‘enkele reis’ met een vliegtuigje aangeboden: eenmaal boven 
moest hij gewoon ‘uitstappen’. Het werd met de instructeur een duo-parachutesprong om 
nooit te vergeten. 
Op het atheneum had hij al het idee verder te studeren. Geneeskunde leek hem wel wat. 
Bezig zijn met mensen. Niet zo gek, want Joep had zich tot een echt sociaal mens ontwikkeld. 
Hij koos de Universiteit van Maastricht, vooral om het onderwijssysteem. En hij werd meteen 
de eerste keer nog ingeloot ook, de bofkont. Het was een goede keuze, zo bleek. Hij haalde in 
het eerste jaar zijn propedeuse, en heeft daarna zijn studiejaren wel volledig opgesoupeerd. 
Natuurlijk werd Joep onmiddellijk betrokken bij het befaamde dispuut Ormètikos, waar hij 
later de feuten sokken liet breien, en een uniforme bloes liet naaien voor de inauguratie. Er 
werd zelfs een keer een tuinbroek voorgeschreven… Over een knickerbocker werd later een 
veto uitgesproken: iemand vond dat zijn kuiten niet goed uitkwamen. Joep ritselde verder 
bij de Maastrichtse brandweer een aantal afgeschreven brandweerjassen, en zo was het 
Ormètikos-uniform compleet. 
Aanvankelijk was het zijn bedoeling kinderarts te worden. Tijdens zijn co-schappen kwam 
hij met diverse specialisaties in aanraking maar kindergeneeskunde bleef bovenaan staan; 
zijn laatste stage was een wetenschapsstage bij kinderoncologie in Rotterdam waar hij met 
onderzoek geconfronteerd werd. Een boeiende kant van het vak, vond hij. Joep kwam in 
gesprek met dr. Ans van der Ploeg van de Erasmus-Universiteit over het lopende onderzoek 
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naar de ziekte van Pompe bij kinderen. Daar kwam een plaats vrij; Joep dook erin en voltooide 
zijn studie onder leiding van dr. Arnold Reuser.
Joep woont samen met Eleonore in Rotterdam. Hun dochter Luce is nu anderhalf jaar. Op het 
moment van verschijnen van deze dissertatie is Joep in opleiding tot klinisch geneticus. Bezig 
zijn met patiënten én met onderzoek. Altijd iets bijzonders dus…
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List of abbreviations
bAGLU acid α-glucosidase from bovine testis; 
BW body weight 
cAGLU acid α-glucosidase from CHO cells; 
DAB 3’3’diaminobenzidine
EDD end-diastolic diameter
EM Electron microscopy
ERT Enzyme replacement therapy
ESD end-systolic diameter
free M6P exposed (uncapped) M6P groups; 
GMA Glycolmetacrylate
GSDII Glycogen storage disease type II
HW heart weight
KO knock-out
LM Light microscopy
LV left ventricular
LV dP/dtmax maximum rate of rise of left ventricular pressure 
LVW left ventricular weight
M6P mannose 6-phosphate;
mAGLU acid α-glucosidase from mouse milk; 
pAGLU acid α-glucosidase from human placenta; 
PAS Periodic acid Schiff reagent
rhAGLU Recombinant human a-glucosidase
RV right ventricular 
RVW right ventricular weight
τ time constant of early diastolic decay of LV pressure
WT wild-type
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In memoriam
Dr. Johannes Cassianus Pompe
(9 september, 1901 – 15 april, 1945)
Door R. Kamphoven en drs. G.A.M. Bak, arts
De ziekte van Pompe is genoemd naar dr. J.C. Pompe die de oorzaak van deze erfelijke ziekte 
voor het eerst beschreef in zijn proefschrift ‘Cardiomegalia glycogenica’, Amsterdam, 1936.
Jan Pompe werd in Utrecht geboren 09 september 1901 in Utrecht. Na de lagere school gaat 
hij naar het gymnasium, daarna studeert hij medicijnen aan de Universiteit van Utrecht, thans 
Rijksuniversiteit Utrecht. Hij krijgt na zijn afstuderen een baan in het Wilhelminagasthuis 
in Amsterdam waar hij zich gaat specialiseren in de pathologische anatomie. Tijdens die 
specialisatie verdiept hij zich al in de glucose-stofwisseling.
In zijn arikel ‘Over idiopatische hypertrophy van het hart’ (1932) beschrijft hij de sterke 
vergroting van het hart als aangeboren erfelijke aandoening. Onderzoek naar de oorzaak 
daarvan leidt tot zijn proefschrift ‘Cardiomegalia glycogenica’ waarop hij in 1936 promoveert. 
Het gaat hier om het ontbreken van het enzym alfa 1,4-glucosidase, nu bekend als de type 
II-vorm, een van de acht inmiddels bekende typen van deze ziekte.
Dr. Pompe begint na zijn promotie zijn carrière als patholoog-anatoom in het Canisius-
ziekenhuis in Nijmegen maar verruilt dit ziekenhuis in 1939 voor het Onze-Lieve-Vrouwe-
Gasthuis in Amsterdam. Dan krijgen de voorbereidingen op de Tweede Wereldoorlog hem 
in de greep. Hij wordt opgeroepen in militaire dienst als de mobilisatie wordt afgekondigd, 
en krijgt een benoeming als vestinghygiënist bij de Vesting Holland. Maar de capitulatie van 
Nederland laat niet lang op zich wachten: dr. Jan Pompe neemt zijn baan in het Onze-Lieve-
Vrouwe-Gasthuis weer op in mei 1940. In 1942 weigert hij het verplichte lidmaatschap van 
de Nationaal-Socialistische Artsenkamer. Pompe zit dan al in het verzet. Hij biedt in het 
ziekenhuis plaats aan studenten die ook in het verzet zitten, hij neemt later een geheime 
radio-zender over die eind 1944 in zijn laboratorium in het ziekenhuis verborgen wordt. Dat 
kost hem uiteindelijk het leven.
Waarschijnlijk door verraad ‘ontdekken’ de Duitse bezetters in februari 1945 de zender in het 
ziekenhuislaboratorium. Tijdens de inval is dr. Pompe zelf niet aanwezig, maar hij wordt even 
later thuis gearresteerd. Als een Nederlandse verzetsgroep op 15 april 1945 een spoorlijn in 
St.-Pancras opblaast, nemen de Duitsers harde represaillemaatregelen: twintig gevangenen 
worden gefusilleerd. Onder hen dr. Jan Pompe.
Ter herinnering aan hem en aan andere verzetshelden uit het Onze-Lieve-Vrouwe-Gasthuis 
wordt in dit ziekenhuis in 1947 een gebrandschilderd raam onthuld. De naam van Jan Pompe 
wordt verder opgenomen in de Erelijst van Gevallenen die in het gebouw van de Tweede 
Kamer in Den Haag ligt.
Noot:
Het Pompe-instituut in Utrecht en de Pompe-kliniek in Nijmegen zijn vernoemd naar de 
oudere broer van dr. Jan Pompe, mr. Willem Pompe, hoogleraar strafrecht.
Bronnen: 
1  Marten Dooper; ‘Joannes (Jan) Cassianus Pompe’ rubriek ‘Onsterfelijke namen’, bijlage 
Scala, De Limburger 01-05-2002. 
2 Rik Nijland; ‘Pluizige medicijnfabriekjes’, bijlage wetenschap, De Volkskrant 04-07-
1998.
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Dankwoord
Of ‘Mice and men’ zou een ondertitel van dit proefschrift kunnen zijn. Zonder de mus musculus 
zou het zover niet gekomen zijn en dus wil ik van mijn dankwoord gebruik maken om ook 
daar even bij stil te staan.
Binnen het Erasmus MC werken vele mensen die een bijdrage hebben geleverd; van 
medewerkers van het EDC tot aan de collega’s van de Klinische Genetica op de 24e verdieping, 
en in de kliniek. Mijn dank gaat uit naar iedereen die een bijdrage leverde.
Mijn promotor, professor B.A. Oostra, ben ik erkentelijk voor de gelegenheid die hij mij 
geboden heeft om te promoveren aan de vakgroep Klinische Genetica te Rotterdam, voor het 
vertrouwen in het Pompe-onderzoek in het algemeen en de kritische blik op dit proefschrift.
Ik dank de commissieleden prof. dr. H.A. Bűller, prof. dr. J.G.G. Borst en prof. dr. D.J. Duncker 
voor het vlotte lezen van dit werk.
Mijn co-promotor dr. Arnold Reuser wil ik bedanken voor de begeleiding van het gehele 
promotie-traject. Een promotie bestaat uit ‘leermomenten’ en: wat zijn dat er veel geweest. 
Zuivere wetenschap, dankzij jouw inspanning ben ik ermee in aanraking gekomen, op velerlei 
manieren, en vaak ook buiten het Pompe-project om. Het is een andere manier van naar 
de wereld kijken en je verbazen over waarom de dingen zijn, zoals ze zijn; daar dan geen 
genoegen mee nemen, maar willen weten waarom het is, zoals het is.
Mijn tweede co-promotor dr. Ans van der Ploeg representeert de klinische visie binnen dit 
project. Wegens drukte in de kliniek hebben we elkaar te weinig gesproken maar je bijdrage 
was van wezenlijk belang. Je inzet is onbetaalbaar. 
Als duo zijn jullie uniek en in staat tot grote hoogte te komen. In dit project waar kliniek 
en fundament elkaar ontmoeten, wetenswaardigheden uitwisselen en vragen proberen te 
beantwoorden is nog een hoop te doen. Ik hoop dan ook van harte dat jullie daar weer meer 
tijd voor vinden.
Voor de onwetende/ontketende dokter die in het lab strandt, zijn rotsen in de branding bittere 
noodzaak. Discussie over PCR’s, lab-bepalingen, wat er alweer mis is gegaan, waarom en wat 
die grap kostte. SOP’s en protocollen tot je er gek van werd en altijd je troep opruimen!!!! 
Marian, we hebben wel eens ‘gevochten’ maar ik had je o, zo nodig;  bedankt voor de 
vruchtbare samenwerking, je scherpe en brede visie (blijf studeren!!).
De Pompe Club wisselde in zijn aantal deelnemers maar bleef een gebalanceerd geheel. Ik 
ben iedereen (Monique, Dik, Hans, Agnes) dankbaar voor de goede sfeer en samenwerking. 
Jammer dat ik niet bij dat uitje kon zijn.
Laura, je begon als student en liet vele muizen door je handen gaan. We hebben daarna??? 
goed samengewerkt en je hebt bergen werk verzet; dank voor de goede en prettige 
samenwerking.
Maandag-ochtend telefonisch contact met dokter Winkel. Gelukkig zijn we beiden 
rasoptimisten van ‘de copy paste generatie’ tot ‘Is Goed’… ‘Fokke en Sukke ronden het af’; 
beginnen bij versie 13 en direct de ‘nu echt allerlaatste versie’ er achteraan. ‘Het was een 
bloempje van een artikel maar het leest nog niet als een Boek!!’ ‘Wacht maar tot er een nietje 
doorzit’. Hou vol, en goed dat je mijn Paranimf wilt zijn.
Doktor vd Hout, (Hm mooi niet, dr.) soms lijkt het H’tje op z’n baas al is het alleen maar in 
de kordate pas hoewel de wervelwind wel binnenkomt als jij de deur opendoet; dank voor 
je energie, samenwerking en het afronden van jouw boekwerk waardoor ik aan de beurt 
was. Drs. Hagemans, Marloes, met jou komt alles goed, degelijke onderzoekster, het is een 
kwestie van volhouden en….. af en toe met de mannen in de auto zitten (10 uur heen en 12 
uur terug).
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Hollen of stilstaan, het lijkt alsof het niet anders kan. Ventileren bij je mede-Aio’s/
benchgenoten (arts-onderzoekers enz.) is broodnodig, af en toe een Frustootje (cappuccino 
in een gefrustreerde bui), en hop daar gaat-ie weer. (Of course thanks to all from abroad, 
working in the lab.)
Gesprekken over onderwerpen die zeker niet geschikt zijn voor in een proefschrift, maar 
die wel sfeerbepalend zijn. Dank voor vier jaar ‘Lab en Leed’ gaat uit naar Surya, Stefano, 
creative minds behind ‘LAB, the movie; Elly: is dat Perzische bed er nog gekomen?? Rachel: 
schippersverhalen; Miriam: genealogie, of hoeveel gespuis komt er voor in je familie; Ozgur: 
I speak fl uently Turkish now, sorry, it is only three words: Naber and I jijim; en de vele 
studenten in het lab.
Mieke en Leontine: we blijven koffi e ‘doen’, met af en toe een broodje.
Dr. André Hoogeveen: er moet meer gezongen worden op het lab; dr. Frans Verheijen: altijd 
in voor de scherpe opmerking. Kijk uit voor de hiërarchische apoptosis en sla af en toe een 
balletje. Dr. Mark Nellist: je Engelse scheldkanonnades, bescheidenheid en gedrevenheid op 
het lab en in de sport; nog bedankt voor de squashlessen. Violeta, I still practice on your 
christmas song, (Chervenite Boetoeski……).
De medewerkers van de enzymdiagnostiek wil ik bedanken voor hun vele werk in de klinische 
trial en inzichten in de interpretatie van de enzymwaarden die we vonden. Tevens dank voor 
de fl exibiliteit; het lenen van een peukje substraat, even de incubator gebruiken, pipetteren 
op jullie lab; de voorzet van de SOP’s en de gezelligheid. Memorabele momenten in het 
slachthuis en bij het gevecht met de stierentestikels. (Marijke, Joke, Otto, Wim, bedankt voor 
jullie geduld.)
De collega’s van de andere laboratoria: Pre-en Postnataal, DNA-diagnostiek, het metabole lab, 
de beide secretariaten. Dank voor de goede sfeer en het geklets aan de ‘Dorpspomp’ die we 
koffi e-automaat noemen. De praatjes waren nooit slapper dan de koffi e die eruit kwam!!!
Mederwerkers van de experimentele cardiologie onder de bezielende leiding van (toen) prof. 
dr. ir. Pieter Verdouw en (nu) prof. dr. Dirk Duncker, altijd in voor de discussie over sport 
en cardiologie. Het opstarten van de echocardiografi e bij muizen was moeizaam. Van het 
onderwater-echoën via de tube ontharingscrème naar een echt non-invasieve methode. 
René, Mirella dank voor de ontwikkeling en het meten. Rob, zonder jouw computergave was 
de analyse in het waterbad blijven steken.
Het meten van intra-cardiale, en intra-vasculaire drukken in de muis blijft priegelwerk dat 
Monique en Elza tot in de fi nesses beheersen. (Blijf reizen; gitaar spelen enz.) 
Zonder de afdeling pathologie wordt het met die spierbiopten nooit wat. Rob Willemsen 
bedankt voor je adviezen (blijf met twee wielen aan de grond) en Lies-Anne bedankt voor je 
geduld en de hoge kwaliteit van de coupes.
Bij het werken met muizen is niets zo cruciaal als de verzorging van het dier. Gaandeweg dit 
project is er, wat dit betreft, veel veranderd. De overgang naar een nieuwe faciliteit met een 
nieuw drinkwatersysteem ging niet zonder slag of stoot. De verzorging van grote aantallen 
muizen is uiterst complex. Zeker als bepaalde groepen ook nog van verschillende onderzoekers 
(moeilijke mensen) zijn. Toch hebben we in deze periode prettig samengewerkt. Dank aan 
iedereen voor en achter de barrière.
Aan alles komt een eind maar dan steeds is er weer een nieuw begin. Collega’s en bazen 
van ‘de overkant’, bedankt voor jullie geduld. Ik was vast wel eens sjacherijnig of vervelend, 
hopelijk wordt dat minder.
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Dit proefschrift had er niet zo uit gezien zonder de gedrevenheid waarmee Tom de Vries 
Lentsch de Layout voor elkaar gebokst heeft; Tom bedankt en … de deadline gehaald. Ruud 
bedankt voor je ontwerp adviezen, koffi e en fotografi sche visie. Jullie beiden bedankt voor de 
fi losofi sche en politieke debatten tijdens het werk. 
In de turbulentie van het promotie-leven is stabiliteit onontbeerlijk. Verwaarlozing van familie 
en vrienden, het zit me niet lekker. Bedankt voor het blijven vragen: ‘hoe is het met je 
boekje???’ Het boekje is af, dus nu kan het weer…….
Naarmate het einde van een dankwoord nadert blijven er steeds minder mensen over. Je 
ouders en schoonouders, het is toch mooi dat ze onvoorwaardelijk in je blijven geloven. 
Pap & Mam: opvoeden is een vak apart en de dingen die jullie me meegegeven hebben……… 
ik heb ze goed gebruikt. Bedankt voor jullie vertrouwen en ondersteuning. Geen mens kan 
zonder. Pap leuk dat je mijn cv wilde schrijven.
Gijs en Henny, bedankt voor de fi losofi sche momenten over de telefoon, aan tafel, op de bank 
en te voet. Trrriing, en weer een stelling; we hebben het er nog over!!
Eleonore, na alles wat we door of dankzij dit proefschrift hebben meegemaakt, kan ik alleen 
maar héél véél van je houden. Promoveren doe je niet alleen. Eerst waren we met zijn tweeën 
en nu met zijn drieën. Druk op de ketel komt de sfeer niet altijd ten goede maar we hielden 
vol, nog even. Ik heb het wel gemist: samen dingen doen; plannetjes maken en uitvoeren; 
lekker naar buiten. De balans vinden is moeilijk als je iedereen tevreden wilt houden. Ik heb 
wel geleerd dat dat idealistisch is.
Luce, vrolijkheid van binnenuit en dat vleugje temperament, ik ga meer tijd met jou en 
Eleonore doorbrengen. Op naar de bergen en de koeien (Hiiiiiiiiih) en de paardjes (Boehoehoe), 
lekker rommelen met ons ouwe Bakkie.
Groet 
Joep
P.S. Antwoord op de vraag wie is Hoepie (Hoepie = Hub Kamphoven)
